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Apoptosis is a tightly coordinated program to shut down and dismantle a cell, characterized by 
mitochondrial outer membrane permeabilization (MOMP), caspase activation to cleave 
hundreds of proteins, DNA fragmentation, and blocked translation. Little is known about the fate 
of RNA as cells die, even though apoptosis has been intensively studied for decades. Here I 
show that mRNAs, but not noncoding RNAs (ncRNAs), are rapidly and globally degraded during 
apoptosis. The decay occurs in many cell types responding to diverse apoptotic stimuli. mRNA 
decay is triggered early in apoptosis, preceding membrane lipid scrambling, genomic DNA 
fragmentation and modifications to translation initiation factors that might cause translational 
arrest. mRNA decay depends on MOMP and is amplified by effector caspase activity. 3´ 
truncated mRNA decay intermediates with nontemplated uridylate-rich tails are generated 
during apoptosis and degraded by the 3´ to 5´ exonuclease DIS3L2. Knockdown of DIS3L2 
reduces apoptotic mRNA decay and partially rescues cell death. I propose that global mRNA 
decay is a new hallmark of apoptosis caused by the concerted action of several nucleases. 
I also report a new role for RNA and DNA in directing cytotoxic leukocyte proteases to their 
substrates. When cytotoxic lymphocytes recognize and attack infected or cancerous cells, they 
deliver the granzyme (Gzm) serine proteases into the target cell. The Gzms cleave diverse 
protein substrates to orchestrate cell death. RNA binding proteins are highly enriched in 
 iv  
unbiased proteomic screens of Gzm protein substrates. I hypothesized that the Gzms are 
guided to nucleic acid binding protein targets via direct binding to RNA or DNA. Using 
fluorescence polarization, I show that the Gzms and related leukocyte proteases bind to RNA 
and DNA with low nanomolar affinity. Nucleic acid binding by the Gzms facilitates their cleavage 
of RNA and DNA binding proteins, and guides them into target cell nuclei and onto neutrophil 
extracellular traps. Nucleic acid binding provides an elegant mechanism to confer protease 
substrate specificity for cleavage of nucleic acid-binding proteins that play essential roles in 
cellular gene expression and cell proliferation.  
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Chapter 1:  
Introduction 
2 
Effectors of programmed cell death 
Apoptosis is a highly conserved and tightly controlled cell death program used to eliminate 
unwanted cells during development, infection or malignant transformation and to remove cells 
experiencing irreparable stress-related damage [1]. Cell death is crucial for preventing 
carcinogenesis and genes that participate in apoptosis are frequently mutated in human cancers 
[2,3]. Apoptotic cells are rapidly recognized and cleared by professional phagocytes without 
provoking inflammation or harming bystander cells [1]. The best-studied cell death program 
(classical apoptosis) is mediated by the caspase proteases. There are alternate, caspase-
independent programs of cell death triggered in vivo (for example, in response to injury) and by 
killer immune cells [4,5]. In apoptosis, dying cells undergo membrane blebbing, mitochondrial 
damage, DNA degradation, chromatin condensation and nuclear fragmentation. Apoptotic cells 
also secrete soluble signals and display surface lipids to attract phagocytes and stimulate 
immune clearance. Apoptosis is generally triggered in two distinct modes, either by stress 
stimuli (the intrinsic pathway) or death receptor signaling (the extrinsic pathway). The major 
effectors of classical apoptosis are the BCL2 family proteins and the caspases, which form 
intertwined cell death pathways [1].  
Mitochondrial effectors of cell death 
Mitochondria are the site of action of the BCL2 family proteins and a key control center of 
apoptosis. The BCL2 family is divided into three classes: multi-domain anti-apoptotic proteins 
(BCL2, BCL-xL, MCL-1), pro-apoptotic BH3-only proteins (such as BID, NOXA and BIM), and 
pro-apoptotic multi-domain proteins (BAX and BAK) [6–8]. BAX and BAK multimerize to form 
pores in the mitochondrial outer membrane. The pores cause mitochondrial outer membrane 
permeabilization (MOMP), which leads to the release of apoptogenic factors such as 
cytochrome c and SMAC/DIABLO from the intermembrane space to the cytosol. The BH3-only 
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proteins promote, while the anti-apoptotic proteins inhibit, the multimerization of BAX and BAK 
by a variety of mechanisms [7,8]. In the cytosol, cytochrome c orchestrates the formation of the 
apoptosome which activates the initiator caspase 9, while SMAC/DIABLO promotes cell death 
by inactivating caspase inhibitors (the IAP proteins) [9]. Early studies suggested that the 
intermembrane space proteins AIF and ENDOG are also released by MOMP and participate in 
the execution of apoptosis, but this has not been supported by subsequent work [10]. When a 
cell experiences sustained or irreparable stress, MOMP is triggered, setting off the instrinsic 
apoptosis pathway. Stressors generally enhance the activity or expression of BH3-only proteins 
or block the activity of anti-apoptotic BCL2 family proteins [6]. For example, after genotoxic 
stress, TP53 transactivates the expression of the BH3-only proteins NOXA and PUMA to 
promote MOMP [6,11].  
The caspases are major cell death effectors 
The caspases are cysteine proteases that cleave after aspartates. Caspases were originally 
identified as mediators of cell death, but they are now recognized to have non-apoptotic 
functions in inflammation and cell activation [12,13]. To prevent unwanted cell damage or death, 
but enable their rapid activation, the caspases are present in living cells as inactive zymogens. 
The apoptotic caspases are arranged in a pathway with initiator caspases triggering effector 
caspase activation. The initiator caspases are activated by dimerization and recruitment into 
multiprotein complexes, whereupon they activate the effector caspases by cleavage.  
Both the intrinsic and extrinsic death pathways activate initiator and effector caspases, but the 
intrinsic pathway generally begins with MOMP (Figure 1.1). Mitochondrial release of cytochrome 
c triggers formation of the apoptosome – a scaffold that binds to and activates caspase 9 [14]. 
Once activated, caspase 9 cleaves and activates the downstream effector caspase zymogens 
(caspases 3, 6 and 7), which then cleave hundreds of cellular substrates in an accelerating 
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cascade to complete the cell death program [1,15]. Although the caspases have some degree of 
substrate specificity, they cleave hundreds of proteins and not every target is essential for the 
execution of cell death [16,17]. A handful of well-characterized substrates, such as PARP-1, 
ICAD and ROCK1, are likely to be important in apoptosis. Although most stresses are thought to 
first act on the mitochondrial death pathway, some can directly promote caspase activity. For 
example, endoplasmic reticulum (ER) stress promotes the expression and activity of caspase 2, 
another initiator caspase [12,18,19].  
In the extrinsic pathway of cell death, death receptor ligands (such as FASL and TRAIL) engage 
cell surface death receptors to trigger the aggregation of the death induced signaling complex 
(Figure 1.1). This is a platform that activates the initiator caspases 8 and/or 10. Like caspase 9, 
these caspases can cleave and activate the effector caspases, but they also cleave the BH3-
only protein BID to generate truncated BID (tBID). tBID activates BAX and BAK to trigger 
MOMP, thus linking the mitochondrial and extrinsic cell death pathways. Cells differ in their 
requirement for MOMP to initiate death receptor-dependent apoptosis. In type I cells, the 
effector caspases are directly activated by death receptor signaling, whereas type II cells 
require MOMP to amplify the death signal and execute apoptosis downstream of death 
receptors [20]. A balance in expression of proteins that promote and inhibit effector caspase 
activity determines whether cells are type I or type II [21]. Caspase inhibitors can completely 
block apoptosis triggered by death receptors because initiator caspase activity is one of the 
earliest signaling events in the extrinsic pathway and lies upstream of MOMP. 
The prevailing view is that MOMP – as measured by cytochrome c release – is the trigger that 
irreversibly initiates caspase-mediated apoptosis. In single-cell studies of apoptosis triggered by 
death receptor ligands, initiator caspase activity builds slowly before MOMP and switch-like 
effector caspase activation [21,22]. This model posits that the effector caspases are positioned 
downstream of MOMP. However the effector caspases also promote MOMP. For example, the 
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mitochondrial death pathway is severely impaired in mouse cells lacking the effector caspases 3 
and 7 [23]. In apoptosis induced by genotoxic stress, the initial release of a small amount of  
cytochrome c is caspase-independent, but the later release of a much greater amount of 
cytochrome c is blocked by caspase inhibitors [24]. This suggests that cytochrome c release 
may be biphasic. Cells experimentally loaded with exogenous cytochrome c undergo cell death, 
but death is dependent on MOMP (the release of endogenous cytochrome c) and caspase 
activity [25]. The effector caspases promote further MOMP by cleaving and inactivating 
mitochondrial death effectors, including MCL-1. Caspase-uncleavable MCL-1 mutants rescue 
cells from death induced by TRAIL [26]. This feed-forward loop involving MOMP and caspase 
activation may be crucial for the proper execution of apoptosis. 
Hallmarks of apoptosis 
The term apoptosis was coined to describe the characteristic morphology of certain types of 
dying cells in vivo [27]. Cells shrink and break off small membrane-bound bodies (called blebs 
or apoptotic bodies), their chromatin condenses and nuclei fragment, and they are rapidly taken 
up by phagocytic cells. These morphological features have been joined by a few new hallmarks 
of apoptosis over the decades (Figure 1.1). During classical apoptosis, most morphological 
changes are caspase-dependent. Membrane blebbing is caused by caspase 3 cleavage of the 
ROCK1 kinase, which becomes constitutively active and phosphorylates substrates in the actin-
myosin cytoskeletal network to drive membrane contraction [28–30]. Nuclear DNA is cleaved by 
CAD (caspase-activated DNase), which is released from its inhibitor ICAD when ICAD is 
cleaved by caspase 3 [31]. Apoptotic cells signal to professional phagocytes by exposing 
phosphatidylserine (PS) on the outer leaflet of their cell membrane. Because PS is recognized 
by macrophages that phagocytose the apoptotic cell, it is called an “eat me” signal. It was 
hypothesized that a protein that drives bidirectional scrambling of membrane lipids causes PS 
exposure. This putative apoptotic “scramblase” has been sought for some time. A recent report 
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suggests that caspase 3 cleavage of XKR8 is responsible for PS exposure on the outer leaflet 
[32]. However, it is unclear how XKR8 causes phospholipid scrambling, and other studies report 
that PS exposure can occur in a caspase-independent manner [33]. Protein translation also 
ceases during cell death. Although caspase cleavage of translation initiation factors, or proteins 
that modify translation initiation factors, is often cited as responsible for translation arrest [1], 
these alterations may not be necessary or sufficient to block translation [34]. The factors that 
might collude to arrest translation during apoptosis are discussed in more detail below. 
Immune-mediated cell death 
In addition to the intrinsic and extrinsic pathways of apoptosis, cell death can be triggered by 
immune killer cells. Cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells recognize 
infected or transformed cells and eliminate them through cytotoxic attack [5]. In cytotoxic attack, 
the killer cell delivers a lethal dose of proteins into its target cell through an immune synapse. 
The proteins are stored in cytotoxic granules, specialized secretory vesicles stored in the 
cytosol of killer cells [5,35]. The primary cytotoxic effector molecules in these granules are the 
pore forming molecule perforin (Pfn) and the granzyme (Gzm) serine proteases. The granules 
are released into the immune synapse, where Pfn causes a calcium influx in the target cell to 
activate a membrane repair response that culminates in the endocytosis of the granule 
contents. After endocytosis, Pfn forms pores in the endosomal membrane to allow the release 
of the Gzms into the cytosol [36]. The Gzms orchestrate independent programs of cell death by 
cleaving substrates in the cytosol, mitochondria, and nucleus. A single cytotoxic lymphocyte can 
serially recognize and kill several target cells before its supply of cytotoxic granules is 
exhausted [37]. 
The Gzms (five enzymes in humans, ten in mice) activate diverse and redundant pathways of 
programmed cell death by cleaving many cellular proteins to guarantee that infected or 
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transformed cells can’t readily evade immune attack [5]. GzmA and GzmB are the most 
abundant Gzms. GzmB acts like an initiator caspase and triggers mitochondrial and caspase-
dependent death by directly cleaving BID and caspase 3 [38]. GzmA initiates a distinct pathway 
of caspase-independent apoptosis with mostly non-overlapping substrates that damages 
mitochondria without causing MOMP and causes single-stranded, rather than double-stranded, 
DNA damage [5,39]. The death mechanisms activated by the other Gzms are distinct, but not 
well characterized. During cytotoxic attack, the Gzms enter the target cell nucleus and 
concentrate there by an unknown mechanism [40–42]. Once in the nucleus, the Gzms cleave 
many RNA and DNA binding proteins to contribute to cell death [43]. The Gzms can cause 
death across diverse taxa (from human cells to bacteria) by cleaving key components of the 
electron transport chain and generating a lethal oxidative burst, while simultaneously blocking 
the oxidative stress response [44–46]. 
Alterations to pre-mRNA processing during cell death 
Pre-mRNA splicing (hereafter, splicing) occurs co-transcriptionally to remove introns and join 
exon ends to generate a mature mRNA. Splicing is controlled by hundreds of constitutive and 
regulated splicing factors [47]. The splicing reaction is catalyzed by the spliceosome, a complex 
RNA-protein machine [47,48]. Through an ordered assembly process, the spliceosome joins the 
5´ and 3´ splice sites of adjacent exons and excises the intervening intron. Cell stresses can 
alter the splicing of pro- and anti-apopototic mRNAs. Many BCL2 family genes encode multiple 
splice isoforms with opposing effects on cell death. For example, the BCL2L1 locus encodes for 
a pro-apoptotic splice isoform (BCL-xS), and an anti-apoptotic mRNA (BCL-xL) [49,50]. Cell 
stresses alter splicing by a variety of mechanisms, including post-translational modifications to 
splicing factors, alterations to the rate of transcription driven by polymerase II, and 
transactivation of splicing factor expression [34]. Although stresses do alter the expression of 
apoptotic mRNA splice isoforms, the change in the ratio of pro- and anti- apoptotic isoforms 
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occurs slowly. In many cases, it is unclear whether stress-induced changes in alternative 
splicing has a significant effect on apoptosis [34]. 
In contrast to the subtle effects of alternative splicing, we recently found that pre-mRNA splicing 
is profoundly disrupted during apoptosis and GzmA-dependent, caspase-independent cell death 
[43]. We uncovered this connection between the Gzms and splicing with an unbiased proteomic 
screen. Because the Gzm serine proteases accumulate in the nuclei of their target cells, we 
wished to identify their nuclear substrates. The proteomes of intact nuclei that were treated or 
not with GzmA were analyzed for proteins degraded by GzmA. Of 44 nuclear GzmA substrates, 
33 were RNA-binding proteins, including 14 heterogeneous nuclear ribonucleoproteins 
(hnRNPs) [43]. Many hnRNPs were also degraded following caspase activation. Since hnRNPs 
assemble on newly synthesized transcripts to orchestrate post-transcriptional processing, this 
prompted us to look at the fate of newly synthesized RNA in cells undergoing Gzm-mediated 
cell death. Newly synthesized RNA was retained in the nucleus and pre-mRNA splicing was 
severely compromised as measured by intron retention. hnRNP A1 was a robust GzmA target. 
A noncleavable mutant of hnRNP A1 restored splicing and partially rescued cells from death, 
suggesting that the inhibition of pre-mRNA processing was an important component of the cell 
death program. Of note, alterations in mRNA splicing and nuclear export were absent in cells 
experiencing oxidative stress, suggesting that global inhibition of splicing is not a general 
feature of non-apoptotic stress. The splicing defect is likely the reason for nuclear retention of 
newly synthesized mRNAs. Intronless transcripts of immediate early genes (such as Jun) 
transcriptionally activated in response to stress were rapidly exported and translated into 
protein, while stress-activated transcripts that contain introns (such as Fos) were not translated 
into new protein. Based on these findings we hypothesize that disrupted splicing during 
apoptosis blunts an adaptive stress response and tips cells towards death. The profound link 
   10 
between splicing and cell death led us to further explore whether apoptosis also affects the 
stability of pre-existing mRNAs. 
Pathways of mRNA decay 
Human mRNAs have a mean half-life of approximately seven hours [51]. There is a large 
variation in decay rates amongst mRNAs. Much of the variability in half-life is determined by cis 
regulatory elements in the mRNAs, particularly in their 3´ untranslated regions (UTRs) [52]. 
These cis regulatory elements are recognized by RNA binding proteins (RBPs) and other RNAs. 
microRNA (miRNA) recognition elements and AU rich elements are two well-studied examples 
of cis regulatory elements frequently found in 3´UTRs that can alter mRNA translation and 
stability [52,53]. The complex code that underpins the stability and translation of each mRNA is 
only understood at a descriptive level. 
Although decay rates vary widely amongst mRNAs, most mRNAs are thought to be degraded 
by one major decay pathway. In metazoan cells, mRNA degradation initiates with deadenylation 
followed by decapping and exonucleolytic decay from the 5´ and 3´ ends by XRN1 and the 
exosome, respectively (Figure 1.2) [54,55]. There are two major cytosolic deadenylase 
complexes, the CCR4-NOT (CNOT) complex and the PAN complex [55]. CNOT is a multiprotein 
complex that contains two distinct nuclease activities attributable to two pairs of functionally 
redundant paralogs, CNOT7/CNOT8 and CNOT6/CNOT6L. The PAN complex is a heterodimer 
of PAN2 (the nuclease) and PAN3. In human cells, it is thought that PAN2 initiates 
deadenylation and the CNOT complex completes it, but this model is based on limited studies 
using inducible reporter constructs [56], and has not been broadly tested. The triggers of 
deadenylation, and the roles of each cytosolic deadenylase complex in mRNA decay, merit 
further investigation. A deadenylated mRNA can be decapped by DCP2 and degraded by the 5´ 
to 3´ exonuclease XRN1 or degraded from the 3´ end by the exosome. The exosome is a 
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complex consisting of a nine-protein ring plus two subunits with distinct ribonuclease activities: 
DIS3 (RRP44) or its homolog DIS3L1, and EXOSC10 (PM/Scl-100; RRP6). DIS3 and DIS3L1  
possess independent endoribonuclease and 3´ to 5´ exoribonuclease activities, while EXOSC10 
is a 3´ to 5´ exoribonuclease [57].  
Although this canonical mRNA decay pathway is driven by exonucleases, endonucleases also 
contribute to mRNA decay. Endonuclease cleavage can initiate nonsense-mediated decay, a 
pathway that eliminates transcripts with premature termination codons that encode for non-
functional proteins. Another recently-discovered mRNA decay pathway is triggered by ER stress 
[58]. During ER stress, many mRNAs that encode membrane or secreted proteins that are 
localized to the ER are cleaved by the ER-resident endonuclease IRE1 [59–61]. The cleaved 
Figure 1.2: Canonical mRNA decay in human cells
mRNA decay typically initiates with deadenylation followed by decapping and decay from both ends of the 
molecule. In some cases, decay products are still found on polyribosomes, while in others an exit from 
translation is required for decay to occur. 
Capped, translating mRNA
ExosomeDCP2PAN2/PAN3;CNOT complexXRN1
Decay from both ends
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mRNAs are presumably degraded by the exosome and XRN1. Decay of ER-localized mRNAs 
might reduce the load of proteins translated in the ER to alleviate ER stress. 
3´ uridylation acts as a signal for decay of some RNA species [62]. Nontemplated uridylate 
residues, added by terminal uridylyl transferases (TUTases), have been found on histone 
mRNAs [63–66], pre-miRNAs [67], and in mRNAs at miRNA cleavage sites [68]. Human cells 
express a 3´ to 5´ exoribonuclease, DIS3L2, which is homologous to the exosome subunits 
DIS3 and DIS3L1. Unlike its homologs, DIS3L2 does not associate with the exosome, probably 
because it lacks the N-terminal PIN domain responsible for DIS3 and DIS3L1 association with 
the exosome [69]. DIS3L2 preferentially degrades RNAs with 3´ uridylate residues and has 
been implicated in degradation of uridylated pre-miRNAs [70,71] in human cells and mRNAs in 
fission yeast [72]. Knockdown of human DIS3L2 prolongs the half-life of some polyadenylated 
mRNAs [69], suggesting that it contributes to basal mRNA decay.  
In addition to these intrinsic pathways of mRNA decay, some viruses can also instigate global 
mRNA decay. The gammaherpesvirus SOX proteins trigger the decay of host mRNAs while 
sparing viral transcripts [73–75]. This is known as host shutoff. Polymerase I and Polymerase III 
transcripts are not degraded in host shutoff, suggesting that decay is directed toward 
translation-competent mRNAs. Since the discovery of the SOX proteins, unrelated proteins 
encoded by other viruses have been shown to trigger host shutoff, suggesting that this could be 
a common mechanism used by viruses to hijack a host cell [76]. It has been proposed that 3´ 
hyperadenylation of mRNAs is a trigger for SOX-mediated host mRNA decay. The host 
exonuclease XRN1 appears to participate in all of these viral decay pathways [74,76]. However, 
the complete mechanism of host shutoff is not fully understood and likely varies from one virus 
to the next [76].  
There is an intricate relationship between the translation status of an mRNA and its degradation. 
In some cases, translation promotes mRNA decay, while in others, an exit from translation is a 
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prerequisite for mRNA decay [77]. Numerous studies have explored the relationship between 
translation and decay in the context of miRNA target suppression [78]. The most recent studies 
of the miRNA pathway suggest that translation inhibition precedes mRNA decay [79,80]. 
However these findings may not be generalizable to all mRNA decay pathways. Notably, recent 
studies have identified mRNA decay products and enzymes involved in mRNA decay on 
polyribosomes [66,81,82], suggesting that at least some modes of decay can initiate before 
translation ceases (Figure 1.2).  
Translation in cell stress and cell death 
Many non-apoptotic stresses cause a rapid and nearly global shutoff of protein synthesis 
through one of two mechanisms that interfere with translation initiation – phosphorylation of 
eukaryotic translation initiation factor 2α (eIF2α) and inhibition of the eIF4F complex. Translation 
initiation requires a ternary complex composed of eIF2, GTP and the methionine initiator tRNA 
(Met-tRNAiMet). During translation initiation, the GTP is hydrolyzed to GDP, which must be 
recycled by eIF2B to form a new initiation-competent eIF2-GTP-Met-tRNAiMet ternary complex. 
Stresses activate one of four kinases that phosphorylate the eIF2 regulatory subunit (eIF2α) on 
serine 51 [83]. eIF2α phosphorylation leads to a stable, inhibitory association of the eIF2-GDP 
complex with eIF2B, blocking ternary complex recycling. This results in a fast, potent and 
reversible block of translation initiation. eIF2α phosphorylation is the main feature of the 
“integrated stress response,” a common protective program activated by most cellular stresses 
[84]. Although inhibition is nearly global, some transcripts are able to escape this translation 
arrest. 
Stresses also block translation by inhibiting the formation of the eIF4F complex, which is 
composed of the cap binding protein eIF4E, the RNA helicase eIF4A, and the adaptor protein 
eIF4G [85]. eIF4F is required for initiating cap-dependent translation; most mRNAs are 
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translated in this manner and thus dependent on eIF4F. The best-studied regulators of eIF4F 
are the eIF4E binding proteins (4E-BPs), which bind to eIF4E and block its interaction with 
eIF4G. 4E-BP binding to eIF4E is regulated by phosphorylation – hypophosphorylated 4E-BP 
binds eIF4E with high affinity, but phosphorylated 4E-BP doesn’t bind [86]. The 4E-BPs are 
phosphorylated by mTORC1, a kinase complex that integrates signaling from multiple mitogenic 
pathways [86]. In the absence of eIF4F, selected mRNAs can be translated through structured 
elements in their 5´UTRs termed internal ribosomal entry sites (IRES). Numerous apoptosis-
associated transcripts (with both pro- and anti-apoptotic functions) contain IRESs that sustain 
their translation during cell stress. 
Pre-apoptotic alterations of translation complexes 
Many stimuli that trigger cell death cause concomitant cellular stress that arrests translation 
through the aforementioned pathways. MCF-7 cells treated with etoposide have reduced 
translation even when caspase activity is inhibited. Wild-type mouse embryonic fibroblasts 
(MEFs) treated with etoposide have increased eIF2α phosphorylation and association of 4E-
BP1 with eIF4E concurrent with translation inhibition. However MEFs deficient in the eIF2α 
kinase PKR have a comparable block to translation in response to etoposide without any 
increase of eIF2α phosphorylation or 4E-BP1–eIF4E interaction [87]. These results suggest that 
other unknown events besides eIF2α phosphorylation and disruption of eIF4E binding to eIF4G 
may be important for inhibiting translation in cell death triggered by DNA damage. Similarly, 
global translation is reduced by ~50% in MCF-7 cells treated with the death receptor ligand 
TRAIL for a short period, even though there is very little caspase activity or PS externalization 
on the cell membrane. However, at this early time 4E-BP1 hypophosphorylation and reduced 
binding of eIF4G to eIF4E inhibits the eIF4F complex to block cap-dependent translation [88]. 
These alterations to 4E-BP1 are independent of caspase 3, but sensitive to the pan-caspase 
inhibitor zVAD-FMK, suggesting a role for the initiator caspases triggered by death receptor 
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signaling [87]. These pre-apoptotic and caspase-independent signaling events confound any 
straightforward analysis of the steps that cause apoptotic translation arrest. 
Caspase-dependent alterations of translation complexes 
In addition to caspase-independent translation inhibition, the effector caspases directly cleave 
many translation factors. Notably, caspase 3 cleaves eIF4G [89–91]. However it is unclear 
whether eIF4G cleavage products still support translation [92], or to what extent eIF4G cleavage 
contributes to translation inhibition, which is often already well underway by the time eIF4G is 
cleaved. In some studies, eIF4G cleavage correlates well with translation inhibition [89,91], 
while in others, translation inhibition precedes eIF4G cleavage [93,94]. The relative impact of 
eIF4G cleavage on translation may depend on the cell type and death-inducing stimulus. eIF4G 
is not cleaved in caspase 3 deficient MCF-7 cells treated with TRAIL, but translation is still 
effectively inhibited [87]. The eIF2α kinase PKR is cleaved by the caspases during death 
receptor-mediated apoptosis in Jurkat cells, but PKR cleavage and eIF2α phosphorylation are 
late events that occur well after translation inhibition and are probably not major contributors to 
blocked translation in cell death [34,94].  
Although large alterations in translation factors have been cataloged during the initiation and 
execution of apoptosis, it is still unclear whether these modifications are responsible for blocking 
translation. Alterations to translation factors have only been studied in bulk cell populations 
undergoing asynchronous cell death. Even genetically identical sister cells die asynchronously 
in response to apoptotic stimuli [95], making it difficult to dissect which alterations occur in the 
pre-apoptotic phase. For example, it has been argued that many IRES-containing mRNAs are 
up-regulated in apoptotic cells [88], but markers of caspase activity remained low at the time 
IRES-dependent translation was analyzed, raising the possibility that these translation 
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alterations are actually pre-apoptotic. At an even more fundamental level, although widely 
assumed, it has never been proven that translation inhibition contributes to apoptosis.  
Unexplored connections between RNA and cell death 
Given the profound alterations of mRNA splicing in apoptotic cells, I hypothesized that mRNA 
stability might also change during cell death. In contrast to the well-known changes that occur to 
proteins, lipids and DNA during cell death, the fate of RNA in apoptotic cells has not been well 
studied. In some cells, the 28S ribosomal RNA (rRNA) is cleaved during apoptosis by an 
unknown endonuclease to generate distinct fragments [96]. Because this occurs late in the 
death program and is not universally seen, it is unlikely to be essential for apoptosis. In a few 
intriguing studies, individual mRNAs were assayed by Northern blotting and found to decline in 
apoptotic cells [93,97]. However, the kinetics and mechanisms of mRNA decay were not 
investigated in detail in these studies.  
Here I show that global decay of mRNAs, but not noncoding RNAs (ncRNAs), occurs early in 
apoptosis induced by diverse classical apoptotic stimuli. Decay is triggered by MOMP and 
begins around the same time as caspase activation and before DNA degradation. I found that 
apoptotic mRNA decay intermediates are truncated and uridylated at their 3´ ends. The 
uridylated intermediates are further degraded by the 3´ to 5´ exonuclease DIS3L2. Knockdown 
of DIS3L2 or the CNOT7/CNOT8 deadenylases partially rescues apoptotic mRNA decay and 
cell death, suggesting that they participate in apoptotic mRNA decay and that mRNA decay 
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Abbreviations used in this study 
ActD  Actinomycin D 
CFSE  Carboxyfluorescein succinimidyl ester 
cRACE Circular rapid amplification of cDNA ends 
ER  Endoplasmic reticulum 
FISH  Fluorescence in situ hybridization 
Gzm  Granzyme 
hnRNP heterogeneous nuclear ribonucleoprotein 
HR  Hammerhead ribozyme 
MOMP  Mitochondrial outer membrane permeabilization 
NK cell  Natural killer cell 
ORF  Open reading frame 
PAS  Polyadenylation signal sequence 
Pol  Polymerase 
PS  Phosphatidylserine 
RBP  RNA binding protein 
STS  Staurosporine 
TAP  Tobacco acid pyrophosphatase 
TSS  Transcription start site 
UTR  Untranslated region 
zVAD  carbobenzoxy-valyl-alanyl-aspartyl-[O-methyl]-fluoromethylketone 
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Global mRNA decay during apoptosis 
To investigate what happens to mRNAs during apoptosis, we measured housekeeping mRNAs 
and ncRNAs by qRT-PCR and northern blot of total RNA in Jurkat cells treated with a Fas 
receptor-activating antibody (αFas) for 4 hours with or without the pan-caspase inhibitor z-VAD-
fmk (zVAD) (Figure 2.1A-C). We confirmed cell death with Annexin V staining. 85% of αFas-
treated cells stained with annexin V, and death was completely rescued by zVAD (Figure 2.1C). 
qRT-PCR experiments were normalized to U6 snRNA, which remained relatively stable during 
apoptosis. Six normally stable mRNAs, including GAPDH and ACTB (both with reported half-
lives >12 hours [51,98]), declined approximately ten-fold. In contrast, some ncRNAs increased 
(miR-16, miR-21 and 5S rRNA), while others (U2, 7SL, 28S) declined, but much less than the 
mRNAs (Figure 2.1B). When the same cells were treated with Actinomycin D (ActD) for 4 hours 
to block transcription, mRNAs only declined slightly (Figure 2.1C), indicating that mRNA half-life 
was drastically reduced in apoptosis. To test whether mRNA levels change globally during 
apoptosis, we used fluorescence in situ hybridization (FISH) to probe for 18S rRNA and poly(A) 
mRNA (with a dT50 oligonucleotide) in Jurkat cells treated with αFas±zVAD or ActD for 3 hours 
(Figure 2.1D,E). Living cells had strong poly(A) and 18S staining, while apoptotic cells retained 
rRNA staining but lost poly(A) staining, which was rescued by zVAD. ActD had no significant 
effect on the relative strength of the poly(A) and 18S signals. This strongly suggests that mRNA 
is globally degraded, because the poly(A) tail stabilizes mRNA and deadenylated mRNAs are 
rapidly degraded. Controls showed that the FISH assay specifically detected RNA (Figure 2.2). 
The reduction in qPCR and Northern blot signals for several mRNAs, coupled with the global 
loss of poly(A) staining, strongly suggest that global mRNA decay occurs during Fas receptor-
mediated apoptosis. 
To determine whether the reduction in mRNA might be caused by mRNA release into apoptotic 
blebs, αFas was added to Jurkat cells in the presence of blebbistatin, a myosin II inhibitor that 
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Figure 2.1: Rapid and global mRNA decay in apoptosis of Jurkat T cells initiated by αFas 
(A-C) Jurkat cells were treated for 4 hr with αFas±zVAD and ActD. The indicated mRNAs (A) and 
ncRNAs (B) were analyzed by qRT-PCR (UNT – untreated), or northern blot (C). All of the mRNAs 
measured declined drastically, while ncRNAs were more stable. (D,E) Jurkat cells were treated for 3 hr 
with αFas±zVAD and ActD and cytospun onto coverslips. The cells were stained for poly(A) mRNA with 
an oligo(dT) probe or 18S rRNA with a complementary probe, and visualized by bright field fluorescence 
microscopy at 63X (D). The results of 4 independent experiments were automatically quantified and 
normalized to UNT (E). Poly(A) mRNA declined drastically in apoptotic cells, identified by their pyknotic 
nuclei. Scale bar represents 10 µm. Error bars represent SEM of at least 3 independent experiments. 
 
0 0.5 1 1.5 
Poly(A)/18S signal, 










   22 
blocks blebbing [30]. Blebbistatin did not inhibit mRNA disappearance (Figure 2.3), suggesting 
that mRNA is not exported selectively in apoptotic blebs during cell death. Thus, we 
hypothesized that mRNA decays in situ as cells die.  
 
 
Figure 2.2: Controls for RNA FISH 
FISH performed on untreated Jurkat cells confirmed the specificity of poly(A) and 18S FISH. Sodium 
hydroxide treatment, which hydrolyzes RNA but not DNA, abolished mRNA and rRNA staining, but not 
DAPI staining. Scale bar represents 10 µm. 
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Figure 2.3: Reduced cellular mRNA is not due to RNA release in apoptotic blebs 
Jurkat cells were treated with αFas for 3 hr in the presence of blebbistatin, an inhibitor of blebbing, then 
stained by FISH for mRNA and 18S rRNA. Apoptosis was confirmed by annexin V staining (data not 
shown). mRNA still disappeared in non-blebbing αFas-treated cells undergoing apoptosis. The minority of 
cells with persistent poly(A) signal had DAPI staining of non-apoptotic nuclei.  
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Decay is specific to mRNAs 
We tested a series of GFP reporter variants [74,76] to characterize the RNA species targeted 
for decay in cell death. The parental reporter carries GFP driven by a polymerase II (Pol II) 
promoter and terminated by a standard polyadenylation signal sequence (PAS). To terminate 
transcription without polyadenylation, the PAS was replaced with a self-cleaving hammerhead 
ribozyme (HR) sequence. Additionally, 60 adenine or uridine nucleotides were placed before the 
HR sequence to rescue translation (Figure 2.4A). Two additional variants were driven by Pol I 
Figure 2.4: mRNAs are specifically degraded during apoptosis 
(A-D) The indicated reporters (A) were transfected into HeLa cells and GFP protein expression was 
assayed by flow cytometry (B) and immunoblot (C). There was high protein expression from transcripts 
driven by a polymerase II (Pol II) promoter. When the polyadenylation signal sequence (PAS) was 
replaced by a self-cleaving hammerhead ribozyme (HR), protein expression was lost, but rescued by the 
addition of 60 adenine or 60 uridine nucleotides before the HR sequence. Pol I and Pol III transcripts 
expressed no protein. GFP RNA levels were assayed by northern blot of total RNA from HeLa cells 
transfected with the indicated reporter, then treated with STS or left untreated. The northern blot probe 
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and Pol III promoters. When transfected into HeLa cells, GFP-Pol II, HR-A60 and, surprisingly, 
HR-U60 all drove high levels of protein expression (Figure 2.4B,C), while the other reporters 
drove negligible GFP expression. All of the translated mRNAs were decayed in HeLa cells 
treated with STS, while untranslated RNAs were not degraded (Figure 2.4D). This suggests that 
ncRNAs are spared from apoptotic RNA decay. 
Apoptotic mRNA decay occurs in diverse cell types 
We hypothesized that global mRNA decay is a universal feature of cell death that occurs in 
many different cell types responding to diverse cytotoxic stimuli. To test this, we performed 
FISH on HCT116 cells that were treated with TRAIL or ActD for 2.5 hours, and on HeLa cells 
treated with a cytotoxic concentration of ActD for 6 hours (Figure 2.5A,B). In both cases, 
apoptotic cells were almost devoid of poly(A) mRNA signal, but retained strong rRNA staining. 
Figure 2.5: Global mRNA decay is a shared feature of apoptosis in diverse cell types 
(A) HCT116 cells, treated for 2.5 hr with TRAIL or a nontoxic concentration of ActD, and (B) HeLa cells, 
treated for 6 hr with a cytotoxic concentration of ActD, were analyzed by FISH. The percentage of 
annexin V+ cells is shown for each condition. (C) A representative image of CFSE-labeled YT-Indy cells 
mixed with 721.221 cells for 3 hr and stained by FISH. (D) Quantification of the poly(A)/18S ratio in 
nonapoptotic 721.221 cells compared to target cells in conjugates with killer cells in 3 independent 
experiments. Poly(A) mRNA declined drastically, while rRNA was constant in apoptotic cells. Apoptotic 
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These experiments were internally controlled, because living cells lacking apoptotic DNA 
changes by DAPI staining in the same fields retained a strong poly(A) signal, even with 
complete transcription inhibition with ActD. mRNA staining also disappeared in target cells 
undergoing cytotoxic attack. YT-Indy NK cells were labeled with carboxyfluorescein succinimidyl 
ester (CFSE) then incubated with 721.221 B cells for 3 hours at a ratio of 3:1 and stained by  
FISH (Figure 2.5C,D). 60% of 721.221 cells underwent apoptosis as assessed by 51Cr release 
(data not shown). Apoptotic 721.221 cells, identified by their condensed nuclei, but not living 
target cells, lost mRNA signal. The ratio of poly(A) signal to 18S signal declined significantly in 
721.221 cells when they were coincubated with YT-Indy cells (Figure 2.5D). Thus, mRNAs, but 
not ncRNAs, declined drastically during apoptosis in multiple cell types responding to different 
apoptotic stimuli. 
mRNA decay begins early in apoptosis and requires MOMP 
We next determined the kinetics of mRNA decay relative to other hallmarks of apoptosis. Jurkat 
cells treated with ActD±αFas were harvested hourly over a 4 hour time course and analyzed for 
housekeeping gene mRNA stability by qRT-PCR, cleavage of PARP-1 and eiF4G and 
phosphorylation of eiF2α by immunoblot, caspase activation by a luminescent assay, annexin V 
binding, and DNA fragmentation (Figure 2.6A-E). The time course was performed in the 
presence of ActD to assess mRNA stability normalized to U6 in apoptotic cells relative to 
healthy cells. ACTB and GAPDH mRNAs began to decline within 1 hour of adding αFas and 
leveled off by 3 hours, while 7SL ncRNA was stable (Figure 2.6A). Non-apoptotic oxidative 
stress caused by arsenite (+ActD) and caspase-independent programmed cell death induced by 
the killer protease GzmA did not affect mRNA levels (Figure 2.6A and data not shown). Thus, 
the reduction in mRNA was specific for classical apoptosis. Caspase activation and cleavage of 
the caspase substrate PARP-1 began at 1 hour and were complete after 3 hours (Figure 
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2.6B,D). eIF2α phosphorylation and eIF4G cleavage, two alterations associated with translation 
arrest, were first detected after 2 hours of αFas treatment (Figure 2.6D). PS externalization, as 
quantified by annexin V binding, was not detected until 2 hours after αFas was added (Figure 
Figure 2.6: mRNA decay is a very early event in apoptosis 
(A-E) Jurkat cells were treated with ActD±αFas or arsenite for 4 hr and harvested hourly for (A) qRT-
PCR, (B) caspase activity by luminescent assay (AU – arbitrary units), (C) annexin V staining by flow 
cytometry, (D) immunoblot for caspase targets and translation initiation factors and (E) DNA 
fragmentation by electrophoresis. Asterisks indicate caspase cleavage products in panel D. mRNA decay 
was concurrent with caspase activation, but preceded DNA cleavage and phosphatidylserine 
externalization. Notably, mRNA decay initiated before the cleavage of eIF4G or the phosphorylation of 
eIF2α. (F) Jurkat cells were treated for 1 hr with ActD±αFas and stained with DiIC1(5) to measure 
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2.6C). Similarly, genomic DNA fragmentation was only detectable after 2 hours of αFas 
treatment (Figure 2.6E). We stained the cells with DiIC1(5), which only binds to mitochondria 
with an active transmembrane potential. Mitochondrial depolarization began within 1 hour of 
αFas treatment (Figure 2.6F). Thus mRNA decay occurred early in cell death, coincident with 
caspase activation and mitochondrial disruption. 
We next wanted to investigate which effectors of cell death are necessary for apoptotic mRNA 
decay. Because mRNA decay began very early in cell death and MOMP marks an early 
committed step in apoptosis [21], we hypothesized that MOMP is required for mRNA decay. 
Stressors such as STS activate cell death by initiating MOMP upstream of caspase activity, 
whereas αFas activates caspase 8 to trigger MOMP. Thus zVAD blocks MOMP induced by 
αFas but not STS [10,99]. We compared HeLa cells stably expressing BCL2 (HeLa-BCL2) or an 
empty vector (HeLa-puro). In agreement with previous studies [10], BCL2 blocked release of 
cytochrome c and effector caspase activation caused by STS (Figure 2.7A). In contrast, zVAD 
blocked STS-triggered caspase activation, but did not completely block cytochrome c release or 
cell death. mRNA decay was completely rescued by BCL2 expression, but only partially by 
zVAD (Figure 2.7B). BAX and BAK are the BCL2 family proteins that form pores in the 
mitochondrial outer membrane to drive MOMP. Previous work has shown that MOMP is 
severely impaired in BAX/BAK knockout cells [100]. We tested the effect of BAX/BAK 
knockdown on mRNA levels after treatment with STS±zVAD (Figure 2.7C,D). Combined 
BAX/BAK knockdown rescued mRNA levels after treatment with STS to a greater extent than 
effector caspase inhibition by zVAD (Figure 2.7D). Collectively, these results suggest that 
mRNA decay is dependent on MOMP triggered by BAX and BAK. 
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mRNA decay intermediates contain nontemplated 3´ uridylates 
To begin to understand the mechanism of mRNA decay during cell death, we searched for 
decay intermediates using circular RACE (cRACE) [64]. In cRACE, T4 RNA ligase circularizes 
RNA molecules by ligating their 3´ and 5´ ends. The circular mRNA is reverse transcribed with a 
Fraction cytosol total 
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Figure 2.7: mRNA decay requires MOMP 
(A,B) HeLa-BCL2 and HeLa-puro were treated for 6 hr with STS±zVAD. (A) Fractionated cells were 
analyzed by immunoblot (top) for cytochrome c release. STS-dependent cytochrome c release was 
partially inhibited by zVAD, but fully blocked by forced BCL2 expression. Effector caspase activity was 
measured by luminescent reporter assay (bottom). (B) RNAs were assayed by qRT-PCR. Results were 
normalized to untreated cells. BCL2 over-expression inhibited mRNA decay to a greater extent than 
zVAD. Survival, assayed by CytoTox-Glo assay performed after 6 hr STS treatment followed by a 24 hr 
recovery period, was normalized to untreated cells. mRNA decay correlated better with cytochrome c 
release than with effector caspase activation. (C,D) HeLa cells were transfected with control (CTL) 
siRNAs or siRNAs against BAX and BAK, then treated for 4 hr with STS±zVAD. Protein levels were 
quantified by immunoblot (C) and mRNA levels were quantified by qRT-PCR (D). Results were 
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primer targeting the 5´ end of the molecule; this is a template for PCR with primers spanning the 
ligated junction (Figure 2.8A). We treated HeLa cells with STS±zVAD for 6 hours and performed 
cRACE on total RNA with and without tobacco acid pyrophosphatase (TAP) pre-treatment to 
distinguish between capped and decapped decay intermediates (only decapped mRNAs can be 
self-ligated without TAP pre-treatment). We amplified ACTB junctions using a forward primer 
directed to the ACTB 3´UTR near its polyadenylation site and a reverse primer in the ACTB 
5´UTR. Full-length ACTB mRNAs were amplified from both untreated and STS-treated apoptotic 
cells, but only using TAP-treated RNA (Figure 2.8A,B). There were no visible decapped decay 
intermediates (−TAP). When these cRACE products were cloned and sequenced, they 
contained poly(A) tails of similar lengths, independently of treatment (Figure 2.8C). This 
suggests that if deadenylation is a component of apoptotic mRNA decay, it is a rapid step in the 
decay pathway. 
 
Figure 2.8: Full-length mRNAs in apoptotic cells 
(A) Schematic of circularized RACE (cRACE) method used to identify ACTB mRNA decay intermediates 
in HeLa cells treated for 6 hr with STS±zVAD. ACTB decay products were amplified by PCR with a 
forward primer targeting the ACTB 3´UTR, and a reverse primer on the ACTB 5´UTR. (B) Gel 
electrophoresis of amplified ACTB junctions indicates that the full-length ACTB mRNA remained mostly 
capped, even in apoptosis. (C) cRACE clones were sequenced and poly(A) tail lengths of capped, 
polyadenylated ACTB mRNA termini amplified with a primer targeting the ACTB 3´UTR are shown. 
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When the ligated ACTB junctions were amplified using a forward PCR primer located near the 
stop codon in the ACTB open reading frame (ORF) and a reverse primer in the 5´UTR (Figure 
2.9A), novel mRNA decay intermediates were detected in apoptotic cell RNA even in cells 
treated with zVAD (Figure 2.9B). This agrees with our finding that apoptotic mRNA decay is 
partially caspase independent (Figure 2.7). The novel decay intermediates were also amplified 
without TAP pre-treatment, indicating that at least some of the decay intermediates were 
decapped. We cloned and sequenced cRACE products from STS-treated cells to map the 
mRNA termini. The junctions that mapped exactly to the ACTB mRNA had two notable features 
(Figure 2.9C,D). First, their 3´ termini were mostly within 50 nt 3´ of the ACTB stop codon, 
suggesting stalled decay near the ORF. Second, most junctions captured from TAP-treated 
RNA had 5´ termini mapping exactly to the ACTB transcription start site (TSS), while all of the 5´ 
termini captured from TAP-untreated RNA began after the TSS. These results suggest that 
decay proceeds 3´ to 5´ on deadenylated mRNAs before decapping. Surprisingly, some clones 
had non-templated residues between the 3´ and 5´ termini. These added bases were rich in 
uridylates (Figure 2.9E). To confirm that 3´ uridylated ACTB decay intermediates were produced 
during apoptosis, we performed RT-PCR on RNA isolated from cells treated or not with STS 
using an A12-adapter for RT to prime poly(U) sequences and nested primers targeting the ACTB 
ORF and the adapter primer (Figure 2.9F). Novel decay products reproducibly appeared only in 
STS-treated cells (Figure 2.9G). Cloning and sequencing confirmed that these were similar to 
the cRACE products (data not shown). The decay products captured during apoptosis are 
consistent with two possible modes of mRNA decay. Either decay in apoptosis involves 
deadenylation, followed by 3´ directed decay and decapping, or these uridylated decay 
intermediates are generated after internal cleavage by an unknown endonuclease.  
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Figure 2.9: 3´ uridylation of apoptotic decay intermediates 
(A) Schematic of cRACE method used to identify ACTB mRNA decay intermediates in HeLa cells treated 
for 6 hr with STS±zVAD. (B-E) ACTB decay products were amplified using an ORF-targeted primer and 
analyzed by gel electrophoresis (B) and cloning and sequencing of RNA that was treated (C) or not 
treated (D) with tobacco acid pyrophosphatase (TAP) prior to cRACE. Decay intermediates were 
truncated just 3´ of the stop codon. Line diagrams (C, D) depict all ORF-primer amplified cRACE clones, 
excluding clones with nontemplated 3´ extensions. Decapped decay intermediates (−TAP) had shortened 
5´ ends, whereas most clones derived from TAP-treated RNA had a complete 5´ sequence. (E) Some 
apoptotic ACTB mRNA fragments had nontemplated 3´ tails. Shown are nontemplated RNAs obtained for 
TAP-treated RNA. Templated residues matching the ACTB sequence are depicted as a line; uridylate-rich 
nontemplated tails are indicated. (F) Schematic of the RT-PCR method used to amplify 3´ uridylated 
RNAs. (G) Gel electrophoresis of RT-PCR products. Arrow indicates new uridylated ACTB mRNA decay 
fragments in apoptotic cells. Asterisk denotes products primed from oligouridylate tracts elsewhere in the 
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DIS3L2 knockdown inhibits mRNA decay and cell death 
Because DIS3L2 preferentially targets 3´ uridylated pre-miRNAs [70,71], we hypothesized that 
DIS3L2 digests the uridylated mRNA decay products we observed in cell death. To test this 
hypothesis, we knocked down DIS3L1 (as a control) and DIS3L2 in HeLa cells (Figure 2.10A) 
and used RT-PCR with an A12-adapter to amplify 3´ uridylated ACTB mRNA intermediates 
(Figure 2.10B). Novel uridylated ACTB products were detected in nonapoptotic cells transfected 
with DIS3L2 siRNA, but not those transfected with DIS3L1 or control siRNA. The appearance of 
uridylated mRNA decay intermediates in living cells after DIS3L2 knockdown suggests that 
DIS3L2 plays a role in basal mRNA decay. After STS treatment, the uridylated ACTB mRNA 
intermediates greatly increased with DIS3L2 knockdown, and increased somewhat with DIS3L1 
knockdown. DIS3L2, but not DIS3L1, knockdown also significantly reduced STS-mediated 
mRNA decay of three housekeeping genes (ACTB, GAPDH, SDHA) (Figure 2.10C). Thus 
DIS3L2 is a mediator of mRNA decay in apoptosis and may also play a role in basal mRNA 
decay.  
To examine whether mRNA decay contributes to executing apoptosis, we compared caspase 
activation, annexin V staining and cell survival of STS-treated HeLa cells knocked down for 
DIS3L2, DIS3L1 or transfected with a control siRNA. Although caspase 3 cleavage was readily 
apparent by immunoblot after 4 hours of STS treatment in cells treated with DIS3L1 or control 
siRNA, DIS3L2 knockdown rescued caspase 3 cleavage (Figure 2.10D). DIS3L2 knockdown 
also specifically and significantly reduced annexin V staining (Figure 2.10E) and enhanced cell 
viability (Figure 2.10F) in response to both STS and TRAIL.  
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To establish whether these results were broadly applicable and not due to off-target effects of a 
single siRNA, we tested the effect of knocking down DIS3L2 with a different siRNA (Figure 
2.11). We confirmed robust knockdown at the mRNA and protein level (Figure 2.11A,B). As 
before, DIS3L2 knockdown led to the accumulation of 3´ uridylated decay products and partially 
Figure 2.10: DIS3L2 knockdown inhibits cell death and mRNA decay in HeLa cells 
(A) HeLa cells transfected with control (CTL), DIS3L1 or DIS3L2 siRNAs, were harvested 72 hr later for 
immunoblot. (B) Accumulation of uridylated decay intermediates was assessed by RT-PCR with an A12-
adapter primer (as in Fig. 2.9F,G). Uridylated intermediates accumulated in STS-treated cells regardless 
of the siRNA, but accumulated to a greater extent after DIS3L2 knockdown. Arrowhead denotes new 
products; an asterisk denotes products primed from oligouridylate tracts in the ACTB 3´UTR. (C,D) After 
knockdown and STS treatment, mRNA levels were assayed by qRT-PCR (C) and caspase activation was 
assessed by immunoblot for caspase 3 (D). DIS3L2 knockdown partially restored mRNA levels and 
reduced caspase 3 cleavage.  (E,F) Cells, treated for 3 hr with STS or TRAIL, were analyzed for cell 
death by annexin V staining and flow cytometry (E), and for survival assessed after a 24 hr recovery by 
CytoTox-Glo assay (F). DIS3L2 knockdown partially rescued PS externalization and cell survival. Error 
bars represent SEM of at least 3 independent experiments.  
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rescued mRNA decay after treatment with STS (Figure 2.11C-E). To validate the change in 3´ 
uridylation with a more quantitative assay, we performed cRACE on total RNA from cells 
transfected with DIS3L2 or control siRNAs, and treated with STS. Tails with two or more 
uridylates increased significantly in apoptosis after DIS3L2 knockdown as compared to control 
knockdown (p=0.035, Fisher’s exact test) (Figure 2.11D). We also observed an increase in 
ACTB decay intermediates with nontemplated 3´ uridylate tails in living cells after DIS3L2 
knockdown (Figure 2.11C), in agreement with our earlier findings (Figure 2.10B). We confirmed 
that DIS3L2 knockdown reduced effector caspase activation upon STS treatment with a 
luminescent assay (Figure 2.11F) and by immunoblot for caspase 3 (Figure 2.11G). Collectively, 
these results suggest that DIS3L2 targets 3´ uridylated mRNAs in living and dying cells, and that 
DIS3L2 promotes caspase activation and cell death. 
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Figure 2.11: DIS3L2 degrades 3´ uridylated decay intermediates during cell death 
(A,B) qRT-PCR and immunoblot confirmed siRNA knockdown of DIS3L2 in HeLa cells. A different siRNA 
sequence was used in these experiments than in Figure 2.10. (C,D) U-tailed ACTB decay intermediates 
(arrow) accumulated in STS-treated HeLa cells after DIS3L2 knockdown as measured by RT-PCR (C) 
and cRACE (D). Asterisk in (C) denotes products amplified from oligouridylate tracts in the ACTB 3´UTR. 
U-tailed intermediates also accumulated in untreated living cells after DIS3L2 knockdown (C). The 
number of clones exactly matching the genome and with nontemplated 3´ ends is shown (D). There was 
a significant increase in clones with two or more nontemplated uridylates on the 3´ end after DIS3L2 
knockdown (Fisher’s exact test). (E-G) DIS3L2 knockdown partially restored mRNA levels (G) and 
reduced effector caspase activation (F) and caspase 3 cleavage (G) caused by STS. Error bars represent 
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DIS3L2 is a caspase substrate 
Immunoblots of STS and TRAIL treated HeLa cells showed that DIS3L2 protein was cleaved 
inefficiently during apoptosis, generating a persistent fragment (Figure 2.12B). DIS3L2 cleavage 
was blocked by zVAD. We hypothesized that this persistent fragment might retain nuclease 
activity or be more active than the full-length protein. Using N- and C-terminally GFP tagged 
DIS3L2 (NT-GFP DIS3L2 and CT-GFP DIS3L2, respectively), we found that DIS3L2 was 
cleaved near its N-terminus (Figure 2.12C). Using the Cascleave software [101], we identified 
likely caspase cleavage sites in DIS3L2 and mutated the aspartate at the highest-scoring 
predicted site to glutamate (D188E) in NT-GFP DIS3L2. We found that the mutant protein was 
no longer cleaved (Figure 2.12D), suggesting that DIS3L2 is cleaved after this aspartate. We 
generated expression constructs of catalytically inactive DIS3L2 (DIS3L2-D391N) and truncated 
DIS3L2 lacking amino acids 1-188 (DIS3L2-ΔN), which was the same size as cleaved DIS3L2 
(Figure 2.12A,E). We expressed these proteins and wild-type CT-GFP DIS3L2 in HeLa cells 
and performed immunoprecipitation (IP) of the proteins from cytosolic lysates using anti-GFP 
agarose beads. Finally, we incubated a 5´-end-labeled, 3´-uridylated oligoribonucleotide with the 
immunoprecipitated protein and analyzed degradation products by gel electrophoresis and 
autoradiography (Figure 2.12G). Although there was background nuclease activity in all of the 
IPs, there were distinct decay products (arrowhead) generated by DIS3L2 and DIS3L2-ΔN, but 
not DIS3L2-D391N. We tested other substrate RNAs and found that DIS3L2-ΔN was an active 
RNase, but did not differ from DIS3L2 in its substrate specificity (data not shown). These 
experiments indicated that the cleaved DIS3L2 was still an active nuclease. Because only a 
small fraction of the total protein pool was cleaved and caspase cleavage did not alter target 
specificity, we suspect that DIS3L2 cleavage is an epiphenomenon unrelated to the execution of 
apoptosis. 
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Figure 2.12: DIS3L2 is cleaved by caspases during cell death 
(A) DIS3L2 protein is composed of three oligonucleotide binding (OB) domains and an RNase domain. 
The caspase cleavage site (D188) and truncated DIS3L2 (DIS3L2-ΔN) are indicated. (B) HeLa cells were 
treated with STS or TRAIL ±zVAD for 4 hr and lysates were harvested and immunoblotted for 
endogenous DIS3L2 and ACTB. DIS3L2 cleavage was rescued by zVAD. (C) HeLa cells were transfected 
with plasmids encoding DIS3L2 tagged at its N-terminus or C-terminus with GFP (NT-GFP DIS3L2 and 
CT-GFP DIS3L2, respectively). Cells were treated with STS for 4 hr and lysates were blotted for GFP. 
DIS3L2 is cleaved near its N-terminus. (D) A predicted aspartate caspase cleavage residue (D188) was 
mutated in NT-GFP DIS3L2. Mutation of D188 to glutamate (D188E) abolished NT-GFP DIS3L2 
cleavage. (E) Ectopically expressed CT-GFP DIS3L2-ΔN is the same size as the apoptotic fragment of 
CT-GFP DIS3L2. (F,G) Plasmids encoding CT-GFP catalytically inactive DIS3L2 (D391N), DIS3L2 or 
DIS3L2-ΔN were transfected into HeLa cells. Tagged DIS3L2 was purified by GFP IP. Protein loading was 
equalized (F) (WCE − whole cell extract). Beads containing comparable amounts of bound enzyme were 
incubated with a 5´-end labeled oligonucleotide for the indicated times, and reaction products were 
analyzed by gel electrophoresis and autoradiography (G). DIS3L2 activity, as measured by the 
appearance of a specific decay product (arrowhead), was abolished by active site mutation (D391N), but 
not by N-terminal truncation (DIS3L2-ΔN). Background RNase activity reduced the full-length RNA signal 
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Nucleases other than DIS3L2 likely participate in apoptotic mRNA degradation. Paired 
knockdown of the cytosolic deadenylases CNOT7 and CNOT8, but not CNOT6 and CNOT6L, 
also reduced mRNA decay (Figure 2.13A,B). Like DIS3L2 knockdown, CNOT7/CNOT8 
knockdown partially rescued cell death in response to STS and TRAIL (Figure 2.13C,D). (The 
other cytosolic deadenylases (PAN2/PAN3) were not well expressed in HeLa cells.) Collectively, 
these results suggest that multiple exonucleases participate in apoptotic mRNA decay, as in 
basal mRNA decay. 
 
Figure 2.13: CNOT7 and CNOT8 knockdown inhibits mRNA decay and cell death 
(A) Knockdown was verified by qRT-PCR of total RNA harvested 72 hr after HeLa cells were transfected 
with control (CTL), CNOT6 and CNOT6L, or CNOT7 and CNOT8 siRNAs. (p-values are relative to CTL 
siRNA transfection). (B,C) Cells were treated with STS for 4 hr or left untreated, and the indicated mRNAs 
were measured by qRT-PCR (B), and caspase 3 cleavage was assessed by immunoblot (C). Knockdown 
of CNOT7 and CNOT8, but not CNOT6 and CNOT6L, partially rescued apoptotic mRNA decay and 
caspase 3 cleavage in response to STS. (D) Cell survival was measured by a luminescent assay after 3 
hr treatment with STS or TRAIL followed by a 24 hr recovery period and normalized to non-apoptotic 
transfected cells (untreated, UNT). Only knockdown of CNOT7 and CNOT8 partially rescued cell death 
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HeLa, Jurkat, HCT116, 721.221 and YT-Indy were obtained from ATCC. Jurkat, YT-Indy and 
721.221 cells were grown in RPMI with 10% heat-inactivated fetal bovine serum, 100 U/mL 
penicillin G, 100 µg/mL streptomycin sulfate, 6 mM HEPES, 1.6 mM L-glutamine and 50 µM β-
mercaptoethanol. Adherent cells were grown in DMEM with the same supplement. Stable HeLa-
Puro and HeLa-BCL2 cells were generated by retroviral infection and selection with puromycin 
using the pBABE-puro vector as described previously [43].  
Cell treatments  
Jurkat cells were treated with 1:1000 αFas antibody (Millipore, clone CH11). All cells except 
HeLa were treated with 2 µg/mL ActD (Sigma A9415) to inhibit transcription. HeLa cells were 
treated with 10 µg/mL ActD (Figure 2.5B) or 500 nM STS (Cell signaling #9953) for the indicated 
times. HCT116 cells were treated with 100 ng/mL superkiller TRAIL (Enzo Life Sciences ALX-
201-115-C010). To inhibit caspase activity, cells were treated with 100 µM zVAD (BD 550377). 
STS, ActD and zVAD were dissolved in DMSO; an equivalent amount of DMSO (Sigma D2650) 
was added to all control treatments to equalize the final DMSO concentration. For cytotoxic 
attack experiments, YT-Indy cells were mixed with 721.221 cells at an effector:target ratio of 
3:1.  
Assessment of apoptosis  
For cytotoxic attack experiments, death was assessed by 51Cr release assays as previously 
described [43]. In other experiments, cells were stained with annexin V-APC (Life Technologies 
A35110) or DiIC1(5) (Life Technologies M34151) according to the manufacturer’s instructions. 
Both dyes were measured on a FACSCalibur flow cytometer. For measurements of effector 
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caspase activity and cell survival, cells, plated on 96 well tissue culture plates (Corning 3610) 
one day before treatment, were treated for the indicated time, and activity was assessed with 
the Caspase-Glo (Promega G8090) or CytoTox-Glo (Promega G9290) kits, respectively, 
according to the manufacturer’s instructions. Luminescence was measured on a BioTek 
Synergy 2 plate reader. For cell fractionation, cells were washed with PBS and harvested by 
scraping in PBS on ice. Cells were washed once in PBS and resuspended in 5 cell volumes of 
mitochondrial isolation buffer (250 mM sucrose, 10 mM Tris-HCl (pH 7.0), 100 mM KCl, 1 mM 
EDTA, 1X protease inhibitors (Roche 04 693 159 001)). Cells were incubated for 30 min in this 
buffer on ice, then lysed by passage through a 27 gauge needle 30 times. Lysates were spun at 
800 x g for 10 min to remove cell debris. The supernatant was spun again at maximum speed 
for 25 min and this supernatant (cytosolic fraction) was suspended in RIPA buffer for 
immunoblotting. Total protein was harvested in RIPA buffer to control for non-cytosolic proteins. 
For DNA extraction, cells were resuspended and vortexed in lysis buffer (10 mM Tris-HCl, pH 
8.0, 10 mM EDTA pH 8.0, 100 mM NaCl, 0.5% SDS with 40 mg/mL proteinase K (Sigma) and 
incubated for 3 hr at 56oC. Lysate was mixed with an equal volume of TE-buffered phenol, pH 
8.0 (Sigma P4557) and vortexed well before centrifugation for 10 min at 13,000 rpm. The 
aqueous phase was extracted once with an equal volume of chloroform, ethanol precipitated, 
and dissolved in TE. DNA laddering was analyzed by agarose gel electrophoresis.  
qRT-PCR  
RNA was harvested and extracted with TRIzol reagent (Life Technologies 15596018) according 
to the manufacturer’s instructions. 500-1000 ng of total RNA was first treated with the DNA-free 
kit (Life Technologies AM1906) according to the manufacturer’s instructions, and half was 
reverse transcribed in a 20 µl volume with iScript RT reagent (BioRad 1708841) according to 
the manufacturer’s instructions. The other half was used as an RT− control. qRT-PCR was 
performed with SsoFast reagent (BioRad 172-5204) in 20 µl reaction volumes with 1 µl of cDNA 
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and 500 nM primers, using a BioRad CFX96 PCR machine with the recommended cycling 
parameters for the Ssofast reagent. Primers are given in Table 2.1. Taqman miRNA qRT-PCR 
was performed according to the manufacturer’s instructions (Life Technologies N808-0234). The 
following kits from Life Technologies were used for reverse transcription and qPCR. miR-16: 
#000391, miR-21: #000397, U6: #001093. 
Immunoblotting 
Immunoblotting was performed as described previously [43]. All primary antibodies were used at 
1:1000 and secondary antibodies at 1:2500. The following antibodies were used: ACTB (DSHB, 
#JLA20-c); PARP-1 (Santa Cruz, H-250); eIF4G (Cell Signaling, 2498); phospho-eiF2α (Cell 
Signaling, 9721); total eiF2α (Cell Signaling, 9722); VDAC1 (Santa Cruz, sc-8828); cytochrome 
c (Biolegend, 612504); Caspase 3 (Cell Signaling, 9662);  DIS3L1 (Abcam, ab89042); DIS3L2 
(Novus, NBP1-84740); GFP (ABM, G160); Anti-Mouse HRP (GE Healthcare, NA931V); Anti-
Rabbit HRP (GE Healthcare, NA934V); Anti-Chicken HRP (Abcam, ab6753-1500); Anti-Goat 
HRP (Santa Cruz, sc-2020). 
Northern blotting  
2 µg of total RNA was ethanol-precipitated, washed, and dissolved in gel loading buffer (Life 
Technologies AM8547). RNA was denatured and run on a 1.5% denaturing agarose gel in 
MOPS buffer (Life Technologies AM8671). rRNA was visualized with ethidium bromide staining, 
and the RNA was transferred to a Nytran (GE Healthcare 10416296) membrane in SSC (Life 
Technologies AM9763). Probes were prepared by in vitro transcription (AM1314) of PCR 
templates. Samples were hybridized in Ultrahyb buffer (Life Technologies AM8670) and washed 
twice at 65oC for 5 min in 2X SSC, 0.1% SDS, then twice at 65oC for 15 min in 0.1X SSC, 0.1% 
SDS before autoradiography. 
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FISH  
Adherent cells were grown in 24 well plates (Corning 3524) on 12 mm glass coverslips (VWR 
89015-724) pre-treated with poly-L-lysine (Sigma P8920) for 5 min. Jurkat cells were washed, 
resuspended in PBS (Life Technologies 14190-144) with 0.5% BSA (Sigma A9647) and 2 mM 
EDTA (Life Technologies AM9260G), then cytospun (Shandon Cytospin 3) for 4 min onto 
coverslips at 400 rpm before fixation, whereas YT-Indy:721.221 immune conjugates were fixed 
first, then cytospun as above. Cells were fixed for 10 min in 2% formaldehyde (Polysciences 
18814) in 1X PBS, and permeabilized in pure methanol (Fisher BP1105-4) on dry ice for 10 min. 
Slides were washed 3 times for 5 min in 2X SSC. A control for each experiment was treated for 
30 min in 0.1 M NaOH (Fisher SS255-1) in 2X SSC to hydrolyze all RNA. All coverslips were 
inverted onto a drop of hybridization buffer (10% Dextran Sulfate, 35% Formamide, 0.3 M NaCl, 
30 mM sodium citrate, 20 mM DTT) containing 1 µM 18S rRNA probe (Cy5-
ACCAGACTTGCCCTCC) and 333 nM poly(A) (Cy3-dT50) probe. Samples were placed in a 
humidified chamber, and denatured for 5 min at 65oC, followed by 30 min at 45oC and at least 
90 min at 42oC. The samples were washed 3 times for 5 min in 2X SSC at 37oC, and stained 
with DAPI (Sigma D9542) in 2X SSC. Finally, the slides were mounted using polyvinyl alcohol 
(Sigma P-8136) aqueous mounting medium. Cells were imaged using an Axiovert 200M 
microscope (Pan Apochromat, 1.4 NA; Carl Zeiss) at 63X. Images were analyzed with 
SlideBook 4.2 (Intelligent Imaging Innovations). For quantification, cells were automatically 
identified based on rRNA signal, and background intensity was subtracted. All images shown 
are representative of at least 3 independent experiments. 
cRACE  
20 µg of total RNA was treated with the DNA-free kit (Life Technologies) as per the 
manufacturer’s instructions. RNA was ethanol precipitated overnight and washed twice with 
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70% ethanol. RNA was resuspended in 11 µl of 1X TAP buffer (Epicentre T19050). 5 µl was 
treated with 2 units of TAP for 1 hr at 37oC, the other half was treated the same but TAP was 
not added. The reactions were then treated overnight at RT in a 100 µl volume with 10 units of 
T4 RNA ligase (NEB M0204S) with 1 mM ATP in 1X RNA ligase buffer. RNA was ethanol 
precipitated and washed, then resuspended in 20 µl dH2O. 3 µl of this RNA was mixed with 1 µl 
of 10 mM dNTPs, 2 µl of the ACTB RT primer and 7 µl of dH2O. This was heated to 65oC for 5 
min and cooled to 25oC. 7 µl of a master mix containing 4 µl 5X SuperScript III buffer, 1 µl 100 
mM DTT, 1 µl SuperScript III (Life Technologies 18080-093) and 1 µl RNaseOUT (Life 
Technologies 10777-019) was added. The reaction was incubated at 55oC for 60 min and 70oC 
for 15 min before storage at 4oC. 2 µl of this reaction was mixed with 1 µl of each PCR primer 
(at 10 µM), 6 µl dH2O, and 10 µl 2X Phusion polymerase mix (NEB M0531L) and cycled as 
follows: 98oC for 30 s; 35 cycles of 98oC for 10 s, 60oC for 10 s, 72oC for 10 s; and 72oC for 3 
min. PCR products were gel extracted and cloned using the Zero-Blunt PCR kit (Life 
Technologies K2750) according to the manufacturer’s instructions. Primers are given in Table 
2.1. In the figures, line diagrams depict the mapped 5´ and 3´ ends; the sequence between the 
primers is inferred to be full-length ACTB mRNA. 
RT-PCR with adenylated adapter primer to detect uridylated decay products  
1 µg of total RNA was mixed with 3 µl of a 100 µM adapter primer and 1 µl 10 mM dNTPs in a 
final volume of 13 µl. This was heated to 65oC for 5 min and cooled to 25oC. 7 µl of a master 
mix containing 4 µl 5X SuperScript III buffer, 1 µl 100 mM DTT, 1 µl SuperScript III and 1 µl 
RNaseOUT was added. The reaction was incubated at 25oC for 10 min, 50oC for 30 min, and 
70oC for 15 min before storage at 4oC. 2 µl of this reaction was mixed with 1 µl of each outer 
primer, 6 µl dH2O, and 10 µl 2X Phusion polymerase mix and cycled as follows: 98oC for 30 s; 
30 cycles of 98oC for 10 s, 60oC for 10 s, 72oC for 10 s; and 72oC for 3 min. PCR was repeated 
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using identical parameters with the inner primers. Products were cloned as above. Primers are 
given in Table 2.1. 
siRNA knockdown of target genes  
HeLa cells were plated on 6 well plates at a density of 8x104 cells per well 1 day before 
transfection. For transfection, cells were washed twice with PBS and 867 µl of OptiMEM (Life 
Technologies 51985-091) was added to each well. 5 µl OligoFectamine (Life Technologies 
12252-011) was mixed with 24 µl OptiMEM and allowed to rest for 5 min at RT. 100 µl OptiMEM 
pre-mixed with 2.5 µl of a 20 µM siRNA (or siRNA pool) was added to the OligoFectamine 
complexes, mixed well, and incubated for 20 min at RT. The entire reaction mixture was added 
to 1 well of cells. After 6 hr, the cells were washed in PBS and returned to growth medium. 
Unless otherwise indicated, all assays were performed 72 hr after transfection. The following 
siRNAs were from Dharmacon: CTL (D-001210-05-05); CNOT7 (M-012897-02-0005); CNOT8 
(M-018791-00-0005); CNOT6 (M-019101-01-0005); CNOT6L (M-016411-01-0005); DIS3L1 (M-
015333-00-0005); DIS3L2 (M-018715-01-0005). In Figure 2.11, the following siRNAs were used 
(from Ambion): CTL (4390843); DIS3L2 (4392420). 
Cloning  
The GFP reporter constructs shown in Figure 2.4 were kindly provided by Dr. Britt Glaunsinger 
[74,76]. GFP-DIS3L2 constructs were kindly provided by Dr. Andrzej Dziembowski [69] and 
used as a template for PCR mutagenesis. Briefly, primer pairs were mixed with 100 ng of 
plasmid at a final concentration of 500 nM in 1X Phusion PCR mix, and subjected to 24 cycles 
of PCR. Products were cleaned up with a column kit (Qiagen 28106) and brought to a 18.5 µl 
volume in 1X T4 DNA ligase buffer (NEB). This was treated with 0.5 µl T4 PNK (NEB M0201S) 
for 30 min at 37oC, 0.5 µl T4 DNA ligase (NEB M0202S) for 1 hr at RT and 0.5 µl DpnI (NEB 
R0176S) for 30 min at 37oC, followed by chemical transformation into high efficiency E. coli. The 
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BCL2 expression vector was generated by PCR amplification of BCL2 and subcloning into the 
EcoRI and SalI sites of pBABE-puro. In all cases, multiple clones were picked and correct 
insertions/mutations were verified by sequencing. Primer sequences are provided in Table 2.1.  
GFP immunoprecipitation (IP) and in vitro activity of DIS3L2  
One day before transfection, 1.1x106 HeLa cells were plated on 10 cm dishes in antibiotic-free 
medium. The following day, each plate was transfected by mixing 600 µl of OptiMEM and 6 µl 
Lipofectamine 2000 (Life Technologies 11668-027) with 600 µl of OptiMEM and 3 µg of plasmid. 
After 20 min incubation, lipoplexes were added to cells in 4.8 ml of antibiotic-free medium. The 
medium was changed after 6 hrs of transfection. The following day, cells were washed in cold 
PBS, scraped and washed again in a 15 mL conical tube in PBS. The cells were then 
resuspended in lysis buffer (50 mM Tris-HCl, pH 8.0, 200 mM NaCl, 2.5 mM MgCl2, 0.5% v/v 
Triton-X with 1X protease inhibitors (Roche)), mixed well by pipetting and tumbled for 30 min at 
4oC. Lysates were centrifuged for 10 min at 10,000 rpm and supernatants were transferred to a 
new tube. GFP-Trap agarose beads (ChromoTek gta-20) were washed three times in lysis 
buffer without Triton-X, the lysates were added directly to the beads and tumbled for 2 hr at 4oC. 
The beads were washed once in lysis buffer and then three times in lysis buffer without Triton-X, 
and finally resuspended in RNase activity buffer (10 mM Tris-HCl, pH 8.0, 75 mM NaCl, 1 mM 
DTT, 0.2 mM MgCl2). A small fraction of each IP was used for immunoblot to equalize protein 
loading. For end labeling, 5 µl of RNA oligo (1 µM) was mixed with 1 µl T4 PNK and 4 µl γ32P-
ATP (3000 µCi/mmol) in a 25 µl volume in 1X T4 PNK buffer, and incubated for 30 min at 37oC, 
then cleaned up with a G-25 column (GE Healthcare 27-5325-01). Equal amounts of protein 
were incubated with the end-labeled oligomer (sequence shown in Figure 2.12) for the indicated 
times at 37oC, the reactions were stopped by adding 2 volumes of 2X gel loading buffer (Life 
Technologies AM8547) and analyzed by denaturing PAGE and autoradiography. 
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Statistical analysis  
Pooled data from 3 independent cytotoxic attack FISH experiments were compared using a 
Mann-Whitney test. cRACE results after DIS3L2 knockdown were compared by Fisher’s exact 









Chapter 3: Conclusions  
Rapid and global mRNA decay during apoptosis with 3´ uridylated 
intermediates degraded by DIS3L2 
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Summary 
Although much is known about the changes to genomic DNA, proteins and lipid membranes that 
occur during cell death, little is known about what happens to RNA. Here we show that early, 
global mRNA decay is a new hallmark of classical apoptotic cell death. Global mRNA 
degradation, which did not occur in ncRNAs, was instigated by a variety of proapoptotic signals 
(death receptor ligation, STS, high dose ActD and NK cell attack) in several different cell types. 
It was specific to classical apoptosis and did not occur during non-apoptotic oxidative stress or 
caspase-independent programmed cell death triggered by GzmA. We are unaware of any other 
physiological setting in which mRNA is degraded so rapidly and globally. Global mRNA decay 
was completely inhibited by blocking MOMP using BCL2 over-expression and BAX/BAK 
knockdown, but only partially attenuated by caspase inhibition. In this study we began to define 
the mRNA decay pathway activated during apoptosis. mRNA decay products appear during cell 
death that are absent in living cells. ACTB mRNA decay intermediates were truncated at their 3´ 
ends just downstream of the stop codon. Some of the 3´ truncated decay products had 
nontemplated, uridylate-rich tails. The 3´ uridylated intermediates increased after DIS3L2 
knockdown, which also inhibited global mRNA decay. These findings suggest that DIS3L2 is 
one of the RNases responsible for apoptotic mRNA decay. DIS3L2 knockdown also led to 
similar decay intermediates in non-apoptotic cells, adding to growing evidence suggesting that 
DIS3L2 is also involved in normal mRNA turnover [69]. Knockdown of CNOT7 and CNOT8 also 
implicates these deadenylases in apoptotic mRNA digestion. 
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Our data are consistent with a model (Figure 3.1) in which apoptotic mRNA decay mimics 
normal mRNA decay and begins at the 3´ end with (1) deadenylation by CNOT7 and/or CNOT8; 
(2) 3´ to 5´ digestion by the exosome or other 3´ to 5´ exonucleases, which might stall at 
ribosomes or secondary structure; (3) oligouridylation of the 3´ ends of stalled decay products 
by an unidentified TUTase; (4) digestion of oligouridylated decay intermediates by DIS3L2; (5) 
decapping followed by complete decay from both ends of the mRNA. It is unlikely that this  
sequence proceeds in a strictly linear manner. For example, decapping likely follows 
deadenylation, but could precede 3´ to 5´ exonucleolytic decay. Detailed kinetic and mechanistic 
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studies will be necessary to fully characterize the sequence of events. Even in living cells it can 
be unclear what signal marks mRNAs for destruction. Because decay during apoptosis is rapid 
and synchronous, it may be a useful system to probe general mechanisms of mRNA decay.  
Broader implications and future directions 
Although this study identified some components of the apoptotic mRNA decay pathway, there 
are still many open questions (Figure 3.1). Our results suggest that a mitochondrial product 
released during MOMP initiates global mRNA decay. Future studies will be needed to define the 
mechanism that instigates mRNA destabilization. The mechanism of caspase activation 
downstream of MOMP was discovered through careful biochemical characterization of cytosolic 
extracts that could recapitulate caspase 3 cleavage and activation [14]. This approach identified 
the release of cytochrome c from the mitochondrial intermembrane space as the trigger for 
apoptosome formation and caspase 9 activation. It is possible to recapitulate some aspects of 
mRNA decay in vitro. Similar biochemical systems combining fractionation of mitochondrial 
extracts with an mRNA decay assay could be used to identify the factor(s) that trigger apoptotic 
mRNA decay. Type I cells, which do not require MOMP to execute apoptosis triggered by death 
receptors, have delayed cytochrome c release relative to type II cells [21]. It would be 
informative to determine whether there is a difference in the rate of mRNA decay between type I 
and type II cells. Based on our observation that decay is dependent on MOMP, we hypothesize 
that mRNA decay is slightly delayed in type I cells. 
Biochemical studies should be complemented by further genetic studies of the nucleases that 
participate in apoptotic mRNA decay. Systematic knockdown or knockout of known 
ribonucleases and their cofactors in human cells, paired with functional phenotyping, such as 
deep sequencing, uridylation assays, and quantification of mRNA decay rates and poly(A) tail 
lengths could be a powerful approach to better understand mRNA decay in dying cells. Studies 
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that have characterized the nucleases that participate in human cell mRNA decay usually 
focused on reporter mRNAs and used siRNAs for loss-of-function [56,102]. mRNA decay has 
been well-characterized in yeast with detailed genetic, functional and biochemical studies [103]. 
A systematic study of human cells with loss-of-function of specific decay factors could provide 
valuable insight into the role of these enzymes in living and dying cells. 
Although CNOT7 and CNOT8 knockdown rescued mRNA decay and cell death, we did not 
observe an increase in partially deadenylated decay intermediates in apoptotic cell RNA, 
probably because deadenylated mRNAs are rapidly eliminated. We suspect that another 3´ to 5´ 
exoribonuclease digests the deadenylated mRNA. The most likely candidate is the exosome, 
which is responsible for basal digestion of deadenylated mRNAs [54]. DIS3L2 or the cytosolic 3´ 
to 5´ exonuclease ERI1 [104] could also participate in these early stages of decay. Exosomes in 
the cytosol can contain three different exoribonucleases, DIS3, DIS3L1 and EXOSC10. 
Knockdown of DIS3L1 had little impact on mRNA decay or apoptosis. In our preliminary 
experiments, knockdown of EXOSC10 appears to reduce mRNA decay and cell death triggered 
by STS (data not shown). We intend to investigate this promising lead in more detail. If the 
exosome is involved, it would further support our current working model (Figure 3.1). 
It remains to be determined what role DIS3L2 might play in regulating the stability of different 
classes of RNAs. Here we found that DIS3L2 targets 3´ uridylated mRNA decay products in a 
manner analogous to the degradation of uridylated pre-miRNAs [70]. However DIS3L2 might not 
target all 3´ uridylated RNAs in every setting. Although uridylation is thought to be an important 
signal in histone mRNA degradation, in a recent study knockdown of EXOSC10 extended 
histone mRNA half-life, but DIS3L2 knockdown had no effect on histone mRNA levels [66]. 
mRNA decay can occur on translating polyribosomes [66,69,81,82]. Uridylation of stalled 
transcripts and DIS3L2 digestion of uridylated mRNAs may serve to reinitiate degradation 
caused by stalling at ribosomes. Future studies using 3´ end-directed deep sequencing 
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protocols [105], paired with knockdown or knockout of DIS3L2, could lead to powerful insights 
into its substrates and sequence specificity.  
Next generation sequencing will also be a powerful approach to uncover more about the biology 
of RNA decay during cell death. Future studies should include deep sequencing of ribosomal 
RNA-depleted total RNA from apoptotic cells, which might provide new information about the 
patterns and kinetics of mRNA decay. For example, it may be that mRNAs with a large amount 
of secondary structure are resistant to decay, or that ribosomes protect RNA from decay. This 
could be tested by comparing the regions of mRNAs that are resistant to apoptotic decay to the 
profile of ribosome protected sequence fragments [106]. It may be that certain cis regulatory 
elements in mRNAs (primary sequence, secondary structure, or both) protect them from 
apoptotic mRNA decay. Such a cis regulatory element was found to protect the IL6 mRNA from 
decay driven by the viral SOX proteins [107].  
Newer sequencing approaches might also be revealing. Notably, 3´ end sequencing should 
reveal whether the global distribution of mRNA poly(A) tail lengths changes during cell death 
and whether many decay products have nontemplated 3´ uridylation or if this is a more isolated 
phenomenon. Apoptotic mRNA decay may have been overlooked for decades in part because 
apoptosis has been studied in bulk populations of asynchronously dying cells. It is challenging 
to assess the disappearance of mRNA when only a fraction of cells in a bulk population are 
apoptotic at any given time point. Indeed, the FISH approach taken in this study was critical for 
showing that mRNA decay was truly global. An approach was recently developed to perform 
RNA deep sequencing in situ on fixed cells [108]. If paired with immunofluorescence staining for 
markers of cell death, this method could provide greater insight into the kinetics of mRNA 
decay. 
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We have not yet identified the putative TUTase that is responsible for adding uridylate-rich tails 
to the 3´ end of ACTB decay intermediates. Our preliminary studies have identified a candidate 
TUTase, but this work requires further validation (data not shown). It will be interesting to see 
whether knocking down TUTases reduces apoptotic mRNA decay or cell death. 
Although our data are consistent with 3´ to 5´ exonucleolytic decay of mRNAs, we cannot rule 
out the possibility that an endonuclease is involved. Endonuclease cleavage occurs in some 
mRNA decay pathways, such as nonsense-mediated decay [58]. During ER stress, many 
mRNAs that encode membrane or secreted proteins that are localized to the ER are 
endonucleolytically cleaved by the the ER-resident endonuclease IRE1 [59–61]. Decay of ER-
localized mRNAs is thought to reduce the translation of ER proteins to alleviate ER stress. In 
our experiments, IRE1 knockdown, unlike knockdown of CNOT7, CNOT8 and DIS3L2, 
promoted cell death, even in untreated cells (data not shown), probably because cells lacking 
IRE1 have a blunted stress response. It thus seems unlikely that this ER-specific exonuclease, 
which probably protects against cell death, is responsible for global mRNA decay during 
apoptosis, which enhances cell death 
Why is mRNA eliminated in apoptosis? 
It is unclear how mRNA decay contributes to the execution of programmed cell death. We 
previously found that mRNA splicing and RNA export were disabled during both classical 
apoptosis and caspase-independent programmed cell death [43]. This prevented the expression 
of mRNAs that were transcribed in response to the death-inducing stimuli and thus promoted 
apoptosis by blocking new protein synthesis needed for cellular repair. Now we find that 
preexisting mRNAs are rapidly degraded during classical apoptosis, which should interfere with 
the expression of repair proteins as well as housekeeping and other cellular proteins.  
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Global mRNA decay seems important to cell death execution, since interfering with it by 
knocking down enzymes responsible for apoptotic mRNA degradation reduced apoptosis and 
promoted cell survival. Unexpectedly, knockdown of DIS3L2 also reduced caspase 3 cleavage 
during apoptosis. How this happens remains to be defined. It may be that mRNA decay blocks 
the translation of antiapoptotic proteins. For example, the BCL2 family member MCL-1 has a 
very short protein half-life [109]. It could be that mRNA decay prevents new MCL-1 protein from 
being translated. The pool of pre-existing MCL-1 declines rapidly when it is not replenished by 
translation, thus activating a feed-forward loop that promotes further release of mitochondrial 
effectors. If this is true, it may be that the release of a small amount of cytochrome c is only the 
prelude to commitment to apoptosis and a second wave of cytochrome c release is required for 
cell death. 
Global mRNA decay during cell death could also be useful for eliminating viral mRNAs to 
contain the spread of infection. However, some viruses encode proteins that trigger host cell 
mRNA degradation [73,74,76]. It might be informative to compare and contrast the modes of 
RNA decay induced by viral infection and cell death. Apoptotic cells are also recognized and 
cleared by professional phagocytes. It has been speculated that genomic DNA is fragmented 
during apoptosis to expedite immune clearance of dead cells. It could be that mRNA decay 
plays a similar role. 
We favor a simple hypothesis that, by degrading all of their mRNA, apoptotic cells block new 
protein synthesis. Cells that cannot synthesize new proteins are unable to survive. However, it 
is challenging to tease apart the relationship between translation and mRNA decay. It is well 
known that most cellular stresses arrest protein translation [34]. The stimuli that trigger 
apoptosis also induce stress and stress-associated alterations to translation initiation factors 
[34]. We found that changes to translation initiation factors during apoptosis occur after most of 
the cellular mRNA has already been degraded. Thus inhibiting translation initiation could 
 56  
contribute to blocking de novo protein synthesis during apoptosis, but likely has less of an 
impact than global mRNA decay. In stress-induced translation arrest, mRNAs remain stable. In 
contrast, the translation arrest in cell death is coupled with global RNA decay. Future studies 
should assess, in parallel, the translation status of cells treated with apoptotic stimuli and the 
rate of decay of their mRNAs. Careful kinetic analyses, similar to those used to study miRNA-
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Abbreviations used in this study 
AF488  AlexaFluor 488 
CATG  Cathepsin G 
CTL   Cytotoxic T lymphocyte 
dsDNA  Double-stranded DNA 
FAM  Fluorescein amidite 
FP  Fluorescence polarization 
GO  Gene ontology 
Gzm  Granzyme 
H1  Histone H1 
hnRNP Heterogeneous nuclear ribonucleoprotein 
MOMP  Mitochondrial outer membrane permeabilization 
NE  Neutrophil elastase 
NET  Neutrophil extracellular trap 
NK cell  Natural killer cell 
PE  Pancreatic elastase 
Pfn  Perforin 
PMA  Phorbol 12-myristate 13-acetate 
RBP  RNA binding protein 
ssDNA  Single-stranded DNA 
ssRNA  Single-stranded RNA  
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Introduction 
CTLs and NK cells eliminate virus-infected cells and tumor cells by releasing the Gzm serine 
proteases and Pfn from cytotoxic granules into the immune synapse formed with the cell 
destined for elimination [5]. GzmA and GzmB, the most abundant and best studied Gzms, are 
delivered to the target cell cytosol by Pfn and rapidly concentrate in the target cell nucleus by an 
unknown mechanism and induce independent programs of cell death [41,42]. To orchestrate 
cell death in diverse types of target cells, the Gzms cleave multiple substrates, likely numbering 
in the hundreds, within the cytosol, nucleus, and mitochondria [5,43].  
Although all of the Gzms can cause target cell death, the killing mechanisms of GzmA and 
GzmB are best understood. GzmB acts like an initiator caspase – it triggers MOMP and effector 
caspase activity in parallel. GzmB cleaves BID to generate tBID, which triggers MOMP through 
the formation of BAX/BAK oligomers [111]. GzmB also directly cleaves and activates caspase 3. 
GzmA triggers a distinct cell death pathway. It cleaves numerous substrates in the nucleus, 
cytosol and mitochondria [40,43–45,112,113] to initiate a unique program of cell death 
characterized by mitochondrial damage and single-stranded DNA nicks without MOMP or 
caspase activation [5,39]. The multiple death programs initiated by the different Gzms make it 
very difficult for a cell to resist cytotoxic attack. 
DNA and RNA binding proteins are highly represented in the set of Gzm substrates. A recent 
proteomics study that profiled GzmA substrates in isolated nuclei identified 44 candidate 
substrates, of which 33 were RBPs, including 12 hnRNPs [43]. The remaining 11 candidate 
substrates were mostly DNA binding proteins. In some cases, the nucleic acid appears to play 
an important role in the Gzm/target interaction. GzmA cleavage of histone H1 and binding to 
PARP-1 depends on the presence of DNA [112,113]. All five human Gzms cleave hnRNP K in 
an RNA-dependent manner [114]. Gzm cleavage of viral and host nucleic acid binding proteins 
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also plays an important role in controlling viral infection [115,116]. Thus many of the substrates 
of GzmA and GzmB are nucleic acid binding proteins that are physiologically important for 
cytotoxicity or the control of viral infections.  
Although serine proteases have a high degree of sequence similarity, the Gzms are most 
closely related to a group of myeloid cell granule proteases involved in microbial defense. These 
immune proteases include the neutrophil proteases neutrophil elastase (NE) and cathepsin G 
(CATG) [117]. When neutrophils are activated, they can ensnare and kill microbes in neutrophil 
extracellular traps (NETs), which are formed by nuclear DNA in a unique non-apoptotic cell 
death mechanism called NETosis [118]. NE participates in NETosis by translocating to the 
neutrophil nucleus where it cleaves histones [119]. Histone cleavage promotes chromatin 
decondensation, which precipitates the extrusion of nuclear DNA through the cell membrane. 
The extruded DNA is coated with histones, antimicrobial peptides, NE and CATG [120].  
The aim of this study was to explore further the role of nucleic acids in mediating Gzm/substrate 
interactions and trafficking. We find that RNA enhances in vitro cleavage of RBP substrates, but 
not non-RBP substrates. We show that Gzms directly bind RNA and DNA with nanomolar 
affinity. NE and CATG also bind nucleic acids with high affinity, while digestive serine proteases 
do not. In the presence of competitor DNA, the leukocyte serine proteases do not localize to 
nuclei and NETs. Together, our findings indicate that nucleic acid binding is a conserved and 
functionally important property of leukocyte serine proteases that directs them to and enhances 
their cleavage of nucleic acid binding protein targets.  
Gzm targets are enriched for nucleic acid binding proteins 
Because the Gzms concentrate in the nucleus of target cells, we hypothesized that proteins that 
function in the nucleus might be over-represented amongst Gzm substrates. Two proteomics 
studies identified candidate GzmA and GzmB substrates without bias by analyzing Gzm-
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incubated cell lysates for novel cleavage products [121,122]. We analyzed these target lists 
using the FuncAssociate gene ontology (GO) tool [123] for over-represented GO terms in both 
GzmA and GzmB datasets (Figure 4.1A and Appendix 1 – Supplemental Table 1). Proteins with 
nucleic acid-related GO terms were the most highly enriched categories, when analyzed for 
each Gzm individually or together. The top 7 GO terms for both Gzms (mRNA metabolic 
process, nucleic acid metabolic process, gene expression, RNA metabolic process, nuclear 
part, nucleotide metabolic process, RNA binding) were highly significantly over-represented (P-
values of ~10-50 for each Gzm). This analysis suggested that Gzms might have a special 
preference for nucleic acid binding, especially RBP, substrates. 
RNA promotes GzmA and GzmB cleavage of RNA-binding proteins 
We first asked whether RNA enhances Gzm RBP cleavage by comparing Gzm cleavage of 
RBPs in whole cell lysates depleted of RNA. HeLa cell lysates were pretreated or not with a 
mixture of RNase A and T1 before a 15 minute incubation with varying concentrations of 
recombinant human GzmA or GzmB. The samples were then immunoblotted for known GzmA 
and GzmB targets. All three GzmA RBP targets analyzed (hnRNP U, DDX5, hnRNP A1) were 
cleaved less efficiently in RNase-treated samples (Figure 4.1B). Similarly, cleavage of RBP 
targets of GzmB (hnRNP U, G3BP1, hnRNP C1/C2) was reduced by removing RNA (Figure 
4.1C). In contrast, non-RBP targets (LMNB1, HMGB2, TUBA, ICAD) were cleaved equally or 
more efficiently in RNase-treated lysates, suggesting that Gzm target preference is altered to 
favor non-RBPs in the absence of RNA (Figure 4.1B,C). This effect is not universal to cytotoxic 
proteases as RNase treatment did not affect caspase 3 cleavage of its RBP substrates hnRNP 
C1/C2 and G3BP1 (Figure 4.1D). We next tested whether adding HeLa cell total RNA would 
alter in vitro GzmB cleavage of recombinant hnRNP C1 and LNMB1. The RBP hnRNP C1 was 
more efficiently cleaved in the presence of added RNA, while cleavage of the non-RBP LMNB1 
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Figure 4.1: RBP target cleavage by Gzms is enhanced by RNA
(A) GO analysis of GzmA and GzmB targets. Nucleic acid binding proteins were highly enriched. (B,C) 
Cell lysates were incubated with RNase or left untreated, then incubated with  the indicated concentration 
of GzmA (B) or GzmB (C). The reactions were analyzed by immunoblot. RNase treatment of HeLa cell 
lysates reduced GzmA and GzmB cleavage of RBP targets, but not non-RBP targets. Results in (B) and 
(C) are representative of at least three independent experiments. (D) HeLa cell lysates were treated with 
RNase or left untreated, then treated with recombinant caspase 3. RNase treatment of HeLa cell lysates 
did not affect cleavage of RBP targets by active caspase 3. (E) GST-tagged recombinant proteins were 
pre-incubated with RNase or the indicated concentration of HeLa cell total RNA, then incubated with 
GzmB. Cleavage of recombinant hnRNP C1, but not recombinant LMNB1, was enhanced by exogenous 
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was unaffected (Figure 4.1E). These results indicate that RNA enhances Gzm cleavage of RBP 
targets. Of note, although the highest concentration of RNA still enhanced cleavage, GzmB 
cleavage of hnRNP C1 was more efficient when less RNA was added.  
Gzms bind RNA with nanomolar affinity 
Because RNA enhanced Gzm activity against RBPs, we hypothesized that the Gzms are 
directed to RBP targets by binding to RNA. We tested RNA binding by fluorescence polarization 
(FP), a technique widely used to measure protein-nucleic acid interactions [124], using a 3´ 
fluorescein amidite (FAM)-labeled oligouridylate homopolymer (rU30). As a positive control, we 
measured RNA binding of human antigen R (HuR), a GzmB substrate that binds to AU-rich 
RNA sequences [125]. GzmA, GzmB and HuR all bound to rU30 with high affinity, while the 
negative control protein BSA did not bind (Figure 4.2A). The apparent equilibrium dissociation 
constants (Kd) between all three purified proteins and the rU30 oligo determined by FP were in 
the nanomolar range (Table 4.1).  
GzmB cleavage of HuR is enhanced by HuR binding to RNA 
Because HuR preferentially binds AU-rich sequences, we used its specificity to assess the 
effect of substrate binding to RNA on GzmB cleavage. We compared GzmB cleavage of HuR in 
the presence of an AU-rich target sequence (AU RNA) [126] that both HuR and GzmB bound 
with similar affinity (Figure 4.2B and Table 4.1) and in the presence of a control sequence 
(BB94) that bound well only to GzmB (Figure 4.2C and Table 4.1). Formation of the cleavage 
product was enhanced by AU RNA, but only minimally increased by BB94 RNA (Figure 4.2D). 
These results suggest that RBP targets are optimally cleaved by Gzms when both the target 
and Gzm interact with RNA. 
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Gzms bind DNA with nanomolar affinity 
Because the Gzms bind to RNA and cleave many DNA binding proteins, we asked whether they 




















Figure 4.2: Gzms directly bind RNA
(A-C) FP assays were peformed with Gzms and the indicated RNAs. (A) GzmA, GzmB and the positive 
control HuR all bound to a FAM-labeled 30-nt uridylate homopolymer, but BSA did not bind. (B) GzmB and 
HuR bound a 30-nt RNA containing an AU-rich sequence (AU RNA). (C) GzmB, but not HuR, bound a 
length-matched control RNA (BB94 RNA). The mean polarization values and SEM are plotted. The appar-
ent Kd is shown in Table 4.1. Results are representative of at least 3 independent experiments. (D) The 
GzmB target HuR was most efficiently cleaved when it was bound to RNA. GST-tagged HuR protein was 
incubated with the indicated molar ratio of AU RNA or BB94 RNA, and GzmB was then added for 30 min. 
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stranded DNA (ssDNA) oligonucleotide of the same sequence as BB94 RNA (Figure 4.3A). 
Both GzmA and GzmB bound ssDNA with nanomolar apparent Kd (Table 4.1). GzmB (Kd = 35 
nM, 95% CI [31,40]) bound ssDNA almost as strongly as histone H1 (H1) (Kd = 10 nM, 95% CI 
[8, 12]), similar to reported values [127]). GzmA binding was somewhat weaker (Kd = 122 nM, 
95% CI [95, 158]). Both Gzms also bound to a double-stranded DNA (dsDNA) oligonucleotide 
containing the same BB94 sequence with nanomolar affinities (Figure 4.3B and Table 4.1). To 
determine if Gzm binding might have a sequence preference, we performed FP assays with 
ssDNA homopolymers (dA30, dT30 and dC30). Oligo(dG) was not tested because it tends to form 
Table 4.1: Protein – nucleic acid interactions measured by FP in this study  
The apparent dissociation constant (Kd) with 95% confidence interval (CI) in brackets is given for each 
binding interaction. 
 
Oligo Protein Kd (nM) [95% CI] 
rU(30) GzmA 232 [194-277] 
 
GzmB 159 [125-202] 
  HuR 121 [113-129] 
AU RNA GzmA 401 [35 nM-4.5 mM] 
 
GzmB 651 [157 nM-2.7 mM] 
 
NE 602 [304 nM-1.2 mM] 
 
CATG 165 [139-197] 
  HuR 492 [255-952] 
BB94 ssRNA GzmA 1.6 mM [188 nM-15.2 mM] 
 
GzmB 480 [337-685] 
  HuR 4.8 mM [16 nM-1465.9 mM] 
BB94 ssDNA GzmA 122 [95-158] 
 
GzmB 35 [31-40] 
 
NE 272 [219-339] 
 
CATG 22 [17-29] 
  Histone H1 10 [8-12] 
BB94 dsDNA GzmA 120 [106-136] 
 
GzmB 161 [112-231] 
 
NE 607 [516-712] 
 
CATG 35 [24-52] 
  Histone H1 9 [7-13] 
dC(30) GzmA 91 [65-127] 
  GzmB 175 [140-219] 
dT(30) GzmA 48 [42-55] 
  GzmB 45 [26-78] 
    



































































































Figure 4.3: GzmA and GzmB bind DNA with nanomolar affinity
(A,B) The binding of a FAM-labelled ssDNA (A) or dsDNA (B) oligonucleotide to GzmA, GzmB, H1, and 
BSA was measured by FP. (C,D) To determine whether binding was sequence-dependent, interactions of 
GzmA (C) and GzmB (D) with FAM-labeled homo-oligomers was measured by FP. Both Gzms bound to 
pyrimidine tracts (dT30 and dC30) more strongly than the purine tract dA30. The mean polarization values are 
plotted with SEM. Results are representative of at least 3 independent experiments. The apparent Kd for 
each interaction is given in Table 4.1.
 68  
higher order structures and aggregate. Both Gzms bound dT30 > dC30 with nanomolar affinity, 
but only weakly bound to dA30 (Figure 4.3C,D). This suggests that the Gzms bind preferentially 
to pyrimidines. These assays were performed in buffer containing 100 mM NaCl. Since many 
protein-DNA complexes are sensitive to salt concentration, we performed FP assays over a 
range of NaCl and KCl concentrations, while holding the GzmB and nucleic acid concentration 
constant. Although binding decreased at higher salt concentrations, binding of GzmB to DNA 
and RNA remained strong at physiological concentrations (150 mM NaCl or KCl) (Appendix 1 - 
Supplemental Figure 1).  
Myeloid granule serine proteases bind nucleic acids 
Next we asked whether nucleic acid binding is a general property of serine proteases or limited 
to a subset. To visualize the evolutionary relationships between the Gzms and other serine 
proteases, we performed a phylogenetic analysis of all annotated human serine proteases. The 
Gzms form a monophyletic group with other leukocyte serine proteases (Figure 4.4A). This 
group includes five neutrophil proteases (NE, CATG, NSP4, PRTN3, AZU1) [128] and the mast 
cell protease CMA1. The Gzms are more distantly related to digestive enzymes, such as 
pancreatic elastase (PE) and trypsin. We used FP to assess the affinity of native human CATG 
and NE, porcine PE, and bovine trypsinogen (the proenzyme of trypsin) for RNA, ssDNA and 
dsDNA (Figure 4.4B and Table 4.1). Both neutrophil proteases bound these nucleic acids with 
nanomolar affinity like the Gzms, but neither digestive protease bound. This agrees with an 
earlier study showing that NE binds to DNA [129]. To validate DNA binding with an independent 
assay, we used oligo(dT)-conjugated beads to pull down the Gzms, neutrophil proteases and 
PE (Figure 4.4C). Consistent with the FP results, the leukocyte proteases (GzmA, GzmB, NE 
and CATG), but not the digestive protease, bound to oligo(dT) beads. Binding was specific to 
DNA since it was decreased by pretreating the beads with DNase. The proteases also did not 
bind to protein G-conjugated beads. We hypothesized that DNA binding would enhance 


























































































































































Figure 4.4: Leukocyte serine proteases bind to DNA and RNA with nanomolar affinity
(A) Phylogenetic analysis of all human serine proteases. The leukocyte proteases form a monophyletic 
group. (B) Binding of CATG and NE (neutrophil proteases) and PE and Trypsinogen (digestive proteases) 
to ssRNA, ssDNA and dsDNA was measured by FP. The leukocyte proteases bound and digestive proteas-
es did not. (C) Binding was assayed by affinity pulldown with oligo(dT)-conjugated beads. The leukocyte 
proteases bound oligo(dT) beads while the digestive protease PE did not. DNase pre-treatment reduced 
binding, and none of the proteases bound the same beads conjugated to protein G instead of oligo(dT). (D) 
H1 was pre-incubated with the indicated amount of salmon sperm DNA, then treated with GzmA or NE. The 
proteins were separated by SDS-PAGE and visualized by silver staining. DNA enhanced H1 cleavage by 
GzmA and NE.
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leukocyte protease cleavage of DNA binding protein substrates, as shown above for RNA and 
previously shown for GzmA cleavage of histone H1 [113]. We treated purified histone H1, a 
target of both GzmA and NE with each protease in the presence of increasing concentrations of 
salmon sperm DNA. H1 cleavage by NE was greatly increased by adding even a small amount 
of DNA (Figure 4.4D). H1 cleavage by GzmA was first promoted, then inhibited, by increasing 
amounts of salmon sperm DNA. Inhibition by high concentrations of exogenous RNA was also 
seen when we analyzed GzmB cleavage of hnRNP C1 (Figure 4.1E). These results suggest 
that an excess of nucleic acids interferes with formation of a substrate-nucleic acid-protease 
complex. Collectively, these results demonstrate that nucleic acid binding is a conserved and 
functionally important property of leukocyte serine proteases. 
DNA binding mediates localization of Gzms to the nucleus 
During killer cell attack, the Gzms rapidly concentrate in the nucleus of target cells by an 
unknown mechanism. A previous study suggested that nuclear localization is mediated by 
affinity of the Gzms for insoluble nuclear factors [42]. We hypothesized that the nuclear 
accumulation of Gzms is driven by direct binding to nuclear DNA. To test this idea, we 
incubated fixed and permeabilized HeLa cells with AlexaFluor488 (AF488) labeled serine 
proteases and visualized their localization with fluorescence microscopy (Figure 4.5). As 
expected, the Gzms stained the cytosol and nucleus, but concentrated in the nucleus. To test 
whether nuclear accumulation was mediated by DNA binding, we co-incubated the Gzms with 
salmon sperm DNA before adding them to the fixed cells. Incubation with exogenous DNA 
abolished both cytosolic and nuclear staining of the Gzms (Figure 4.5). We treated fixed cells 
with DNase and RNase, which modestly reduced nuclear and cytosolic GzmB staining, 
respectively (Appendix 1 – Supplemental Figure 2). DNase treatment did not remove all nuclear 
DNA, so it may be that GzmB binds to residual nucleic acids after nuclease treatment. Labeled 
NE also accumulated in the nuclei of fixed cells, in agreement with the known nuclear 
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translocation of this enzyme during NETosis [119]. PE did not localize to fixed cell nuclei and its 
staining intensity and pattern were not impacted by pre-incubation with salmon sperm DNA 
(Figure 4.5). Thus, DNA binding by the Gzms and NE likely mediates their nuclear trafficking 
during cytotoxic attack and NETosis, respectively. 
 
Localization of NE and CATG to NETs is mediated by DNA binding 
CATG and NE both concentrate on NETs [120]. We asked whether DNA binding facilitates 
localization of these enzymes to NETs. Neutrophils isolated from human peripheral blood were 
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treated with phorbol 12-myristate 13-acetate (PMA) for 3 hours to induce NET formation in the 
presence of AF488-labeled NE, CATG or PE. Competitor DNA was added to some samples 
during NET formation. Both neutrophil enzymes, but not PE, spontaneously concentrated on the 
NETs, and binding to the NETs was inhibited by adding salmon sperm DNA (Figure 4.6). 
Exogenous DNA added during NETosis also reduced the association of endogenous NE to 
NETs (Appendix 1 - Supplemental Figure 3). Thus, CATG and NE specifically localize to NETs 
by binding to DNA. 
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Methods 
Antibodies 
The following antibodies were used at the indicated final concentration or dilution: mouse 
monoclonal antibodies to hnRNP U (Santa Cruz; 3G6; 0.2 mg/ml), hnRNP A1 (Sigma; 4B10; 2 
mg/ml), lamin B1 (Calbiochem; 101-B7; 1/1,000), α-tubulin (Sigma; B-5-1-2; 1/1,000), G3BP1 
(BD; 23/G3BP; 0.25 mg/ml), hnRNP C1/C2 (Sigma; 4F4; 0.4 mg/ml), β-actin (Developmental 
Studies Hybridoma Bank; 1/1,000), HuR (Santa Cruz; 3A2; 0.2 mg/ml); rabbit antisera to 
HMGB2 (Abcam; 1/1,000), ICAD (Abcam; 0.5 mg/ml), NE (Abcam; 1 mg/ml); DDX5 (Abcam; 0.5 
mg/ml). Secondary antibodies were sheep anti-mouse-HRP (GE; 1/2,500), donkey anti-rabbit-
HRP (GE; 1/2,500), donkey anti-goat-HRP (GE, 1/2,500), goat anti-rabbit AF488 (Invitrogen; 
1/200), donkey anti-mouse Cy3 (Jackson ImmunoResearch 715-165-150; 1:200). Normal rabbit 
IgG (Cell Signaling 2729; 1 mg/ml) was used as an isotype control for immunofluorescence.  
Proteins 
Human GzmA and GzmB expression plasmids [43] were transfected into HEK 293T cells by 
calcium phosphate precipitation. The transfected cells were grown in serum-free ExCell 293 
medium (Sigma) for 4 days. Recombinant granzymes were purified from the culture 
supernatants by immobilized metal affinity chromatography using Nickel-NTA (Qiagen) following 
the manufacturer’s instructions. Eluted granzymes were treated with enterokinase (0.05 IU/mL 
supernatant; Sigma) for 16 hours at room temperature. Active Gzms were finally purified on an 
S column, concentrated, and quality tested as previously described [130]. GST-tagged HuR, 
hnRNPC1, and LMNB1 were expressed and purified as described [43]. H1 (NEB M2501S) and 
caspase 3 (Enzo – ALX-201-059-U025) were purchased. Other serine proteases were NE 
(Athens Research and Technology, Athens, GA 16-14-051200), PE (Millipore 324682), CATG 
(Athens Research and Technology 16-14-030107) and trypsinogen (Sigma T1143). Proteins 
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were fluorescently labeled with AF488 according to the manufacturer’s instructions (Invitrogen 
A30006). 
In vitro cleavage in cell lysates 
Whole cell lysates were made from 106 HeLa cells suspended in 1 mL of lysis buffer (50 mM 
Tris-HCl, pH 8.0, 100 mM NaCl) by alternating freezing in an ethanol/dry ice bath and thawing at 
37oC three times. Cell debris was pelleted by centrifugation (16,000 x g for 10 min at 4oC). The 
supernatant was divided, and half was treated with RNase A/T1 (Thermo) at a concentration of 
325 U/mL for 30 min at 37oC. RNaseOUT (Invitrogen) was added at a concentration of 1000 
U/mL to the remaining half. The lysates were then treated with the indicated amounts of Gzms 
in a volume of 60 µL for 15 min at 37oC. In some cases, GzmB was incubated with varying 
amounts of salmon sperm DNA on ice for 30 min before addition to lysates. The cleavage 
reaction was stopped by adding 5x SDS loading buffer and boiling at 95°C for 5 min. For 
caspase 3 experiments, lysates were incubated with or without 1 unit of recombinant capsase 3 
for 1 hour before stopping the reaction. Samples were analyzed by SDS-PAGE and 
immunoblot. 
In vitro cleavage of recombinant proteins 
In vitro cleavage was performed in 100 mM NaCl, 50 mM Tris-HCl (pH 7.5). Each protein was 
first incubated in the indicated concentration of HeLa cell total RNA or salmon sperm DNA for 
20 min and then incubated with 50 nM GzmB for 15 min (hnRNP C), 50 nM GzmB for 30 min 
(LMNB1), 200 nM GzmA for 20 min (H1) or 5 nM NE for 10 min (H1). Total HeLa cell RNA was 
purified with Trizol (Invitrogen) according to the manufacturer’s instructions. The final 
concentrations of hnRNP C, LMNB1 and H1 were 333 nM, 1 nM and 400 nM respectively. For 
HuR cleavage, RNA oligos were diluted to 10 µM, heated at 70°C for 10 min and cooled on ice. 
400 nM recombinant GST-tagged HuR was incubated with or without 200 nM recombinant 
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GzmB. The cleavage reactions were performed in the presence of 3 ng/µL total HeLa RNA, AU 
RNA or BB94 RNA at the indicated molar ratios and incubated in a total volume of 40 µL at 
37°C for 30 min. Cleavage reactions were stopped by adding 5X SDS loading buffer and boiling 
for 5 min. Cleavage was assayed by immunoblot or silver staining (Invitrogen SilverQuest kit). 
Protease localization in permeabilized HeLa cells 
HeLa cells were obtained from ATCC and maintained in DMEM supplemented with 10% heat-
inactivated fetal bovine serum, 100 U/mL penicillin G, 100 µg/mL streptomycin sulfate, 6 mM 
HEPES, 1.6 mM L-glutamine and 50 µM β-mercaptoethanol. HeLa cells were grown overnight 
on 12 mm coverslips, then fixed for 10 min at RT in 2% formaldehyde, then permeabilized for 10 
min in methanol on dry ice. In some experiments the cells were treated with DNase I (NEB) or 
RNase A/T1 (Thermo) at a 1:50 dilution for 4 hours at RT before blocking. The cells were 
blocked with 1% bovine serum albumin (BSA) in PBS for 1 hour at RT, coverslips were 
incubated with blocking buffer containing salmon sperm DNA or no DNA for 30 min on ice and 
then incubated at RT for 1 hour with 100 nM AF488-labeled serine proteases. The cover slips 
were then washed and stained with 4 µg/mL DAPI in PBS and mounted on slides (VWR 48311-
703) using polyvinyl alcohol (Sigma P-8136) aqueous mounting medium. Cells were imaged 
using an Axiovert 200M microscope (Pan Apochromat, 1.4 NA; Carl Zeiss). Images were 
analyzed with SlideBook 4.2 (Intelligent Imaging Innovations Inc.).  
Neutrophil isolation and activation 
Human studies were reviewed and approved by the Harvard Committee on the Use of Human 
Subjects (IRB-P00005698). Neutrophils were isolated from the blood of de-identified healthy 
donors by density gradient centrifugation as described [131]. The neutrophil layer was washed 
with HBSS and resuspended at 106 cells/mL in RPMI. Neutrophils (2.5x105) were incubated at 
37°C for 15 min on 12 mm coverslips in 24-well flat-bottom cell culture plates and then treated in 
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500 ml RPMI for 3 hours with 100 nM PMA (phorbol 12-myristate 13-acetate, Sigma P1585). In 
some experiments, 100 nM AlexaFluor-488 (AF488)-labeled protease and/or salmon sperm 
DNA (Sigma D7656) were added just prior to adding PMA. Treated cells were fixed in PBS 
containing 4% formaldehyde. For immunofluorescence staining of endogenous NE, the fixed 
cells were incubated with primary antibody or rabbit antiserum control for 1 hour at RT, washed 
three times in PBS, and then incubated in secondary antibody (AF488-labeled goat α-rabbit 
IgG) for 1 hour at RT. The cells were washed, stained with DAPI, and mounted as above.  
Gene Ontology and phylogenetic analysis of serine proteases 
We analyzed the candidate targets of human GzmA [122] and GzmB [121] identified by 
proteomics using the FuncAssociate tool [123] on default settings. Top gene ontology (GO) 
terms were ranked by the sum of the –log10(p) values for enrichment of targets of each enzyme. 
All human proteins having the GO term “serine-type peptidase activity” (GO:0008236) were 
identified with AmiGO [132]. Of these proteins, the manually annotated and reviewed Swiss-Prot 
sequences were downloaded using the UniProt retrieve tool [133]. The sequences were 
trimmed to focus on their protease domains and exclude spurious alignment of other protein 
domains in multidomain proteins. The ClustalW2 [134] multiple sequence alignment and 
phylogeny tools were used with default parameters to construct a phylogenetic tree. Phylogeny 
was visualized with the EvolView web tool [135]. 
Fluorescence polarization oligonucleotides 
The following FAM-labeled oligonucleotides were used for FP, all from Integrated DNA 
Technologies: 
BB94 DNA: 5’TCTGTGAGTTGAACGCACACATCACAAAGGAG-FAM-3’ 
dA(30): 5’AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA-FAM-3’ 




BB94 RNA: 5’UCUGUGAGUUGAACGCACACAUCACAAAGGA-FAM-3’ 
AU RNA: 5’CCCAAGCUUAUUUAUUUAUUUAUUGCAGGUC-FAM-3’ 
Fluorescence polarization assays 
FAM-labeled oligonucleotides were used at 10 nM, and binding reactions were performed in a 
total volume of 20 µL. Proteins and oligos were diluted in 10 mM Tris-HCl, pH 7.5, 100 mM NaCl 
and 2.5 mM MgCl2. For RNA oligos, RNAseOUT was added to a final concentration of 1 U/µL. 
Diluted RNA oligos were heated to 70°C for 10 min prior to use. In the salt concentration assay, 
protein concentration was fixed (100 nM) and either NaCl or KCl was added to the assay buffer 
at the indicated final concentrations. Samples were equilibrated in 384-well black polystyrene 
assay plates (Corning 3575) for 20 min at room temperature, and polarization was determined 
using a Synergy 2 Microplate Reader and Gen5 Data Analysis Software (BioTek).  
Fluorescence polarization data analysis 
The apparent equilibrium Kd was determined from fitting the data to a sigmoidal dose-response 
function using JMP Pro 10 (JMP Statistical Discovery Software from SAS). The apparent Kd was 
determined for each protein/nucleic acid interaction using the equation f=c+{(d-c)/(1+10^(-
a(log10([P]-b))))}, where f is the fraction bound or the polarization value, [P] is the protein 
concentration, b is the equilibrium Kd, a is the Hill coefficient, d is the maximum polarization and 
c is the minimum polarization [136]. Each experiment was performed at least in duplicate. The 
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average and standard error of the polarization value for each protein concentration was 
calculated from at least 10 independent samples. 
Oligo(dT) pulldown 
120 µl Oligo(dT)25 Dynabeads (Invitrogen 61002) and 10 µl Protein G Dynabeads (Invitrogen 
10004D) were washed three times in 50 mM Tris-HCl, pH 7.5, 100 nM NaCl. The beads were 
blocked for 30 min at RT in the same buffer containing 0.5% bovine serum albumin (BSA) 
(Sigma A9647). Following blocking, half of the Oligo(dT)25 Dynabeads were treated at RT for 30 
min with 25 U Benzonase® Nuclease (Sigma E1014), the other half was left untreated. After this 
incubation, the beads were incubated with 120 µl of protein (final concentration 1 µM) in 
blocking buffer for 30 min at room temperature. The beads were washed three times and protein 
was eluted by boiling samples for 3 min in 30 µl SDS loading buffer. Samples were 








Chapter 5: Conclusions 
Cytotoxic leukocyte protease binding to nucleic acids promotes 




This work demonstrates that the Gzms and related leukocyte proteases are bona fide nucleic 
acid binding proteins with nanomolar affinities. The basis for substrate specificity of the Gzms, 
which are highly specific proteases, remains largely unknown. Although each Gzm has a strong 
preference for specific P1 residues in its substrates, primary amino acid sequence around the 
cleavage site does not predict Gzm cleavage. Structural features likely play a key role in Gzm 
substrate recognition. We find that the high affinity of the Gzms for nucleic acids may be an 
important determinant of substrate specificity. Nucleic acid binding is a simple and elegant 
mechanism to direct leukocyte serine proteases to DNA and RNA binding protein targets and 
probably explains why nucleic acid binding proteins are highly over-represented amongst Gzm 
substrates. Gzms and their substrates may be brought together by binding to nearby sites on 
the same nucleic acid strand. The Gzms form a monophyletic group with other leukocyte serine 
proteases, which also bind nucleic acids with high affinity. Importantly, nucleic acid binding 
regulates the sub-cellular localization of Gzms and neutrophil proteases. Leukocyte protease 
concentration in cell nuclei was prevented by exogenous DNA. Our results support the “affinity” 
model for Gzm nuclear concentration posited over a decade ago and identify DNA as the 
unknown factor mediating this phenomenon [42]. Similarly, the localization of NE and CATG to 
NETs and the antimicrobial activity of NETs likely depend in part upon the affinity of these 
proteases for DNA. 
Is nucleic acid binding specific? 
The leukocyte serine proteases rank amongst the most cationic proteins in the cell, with very 
high predicted isoelectric points (pIs): GzmA – 9.22, GzmB – 9.69, CATG – 11.37, NE – 9.89 
[133]. The empirical pIs of NE and CATG are ~11 and >11, respectively [137]. This raises the 
question of whether nucleic acid binding is specific or simply a consequence of charge-
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balancing electrostatic interactions. For several reasons, we believe binding is specific and 
physiologically relevant. First, the digestive serine proteases, which do not bind nucleic acids, 
are also cationic with similar pIs as the Gzms. Porcine PE has a reported pI of 9.5 to >11, while 
the pI of trypsinogen is ~9.3, but neither binds nucleic acids [138–140]. Second, Gzm binding to 
DNA is sequence-specific, favoring pyrimidine-rich sequences. Third, these proteases directly 
bind DNA under physiologic conditions. Finally, charge alone does not preclude specificity; RNA 
and DNA binding proteins are characterized by cationic patches that mediate binding to nucleic 
acids by electrostatic interactions [141]. In fact, many nucleic acid binding proteins (such as the 
histones) have a highly cationic net charge. The crystal structures of the Gzms show that they 
have positively charged surfaces that could be nucleic acid binding sites [142,143].  
Broader implications and functional significance 
Negatively charged sugars play a significant role in granule packaging and target cell uptake of 
cationic Gzms. In cytotoxic granules, the Gzms bind serglycin, a small negatively charged 
proteoglycan containing chondroitin 4-sulfate [144]. Serglycin-null T cells are defective in 
packaging GzmB into granules. Upon degranulation, GzmB is released from serglycin and binds 
to cell membrane proteoglycans, notably heparan sulfate. Purified GzmB has higher affinity for 
heparan sulfate than serglycin [145]. Our results suggest that when Gzms enter target cells they 
bind to another class of negatively charged molecule, nucleic acids. Gzm binding to different 
anionic biomolecules as they move from the granules to the target cell nucleus may form a 
physical ‘chain of custody’ to ensure proper Gzm trafficking and targeting.  
Nucleic acid binding enhances the activity and function of leukocyte serine proteases, which 
may be critical to Gzm induction of cell death and neutrophil protease-mediated NET formation 
and function. Exogenous DNA transformed purified H1 from a very weak substrate to a robust 
target. However excess DNA and RNA inhibited cleavage of H1 and hnRNP C1, respectively. A 
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previous study also found that DNA inhibited NE and CATG proteolysis of the non-nucleic acid 
binding protein elastin [146]. An excess of nucleic acid, which has high affinity for both the 
protease and its substrate, likely interferes with formation of the ternary protease-nucleic acid-
substrate complex. 
Preferential targeting of DNA and RNA binding proteins by Gzms is an underappreciated 
property critical for executing cell death. Nucleic acid binding is a simple mechanism to guide 
Gzms to targets that are essential for survival. Cleavage of nucleic acid binding substrates 
should enhance Gzm execution of death, independently of caspase activation. During Gzm-
mediated cell death, targeting of RBPs disrupts pre-mRNA processing and nuclear export [43]. 
In the extracellular environment, DNA binding may sequester leukocyte serine proteases to 
focus their activity on pathogens, which get caught in NETs, and minimize tissue injury.  
Future directions 
Many important questions raised by this work could be answered with further biochemical and 
structural characterization of the interaction between the Gzms and nucleic acids. The leukocyte 
serine proteases share a common structural fold with digestive proteases such as trypsin [147], 
but only the leukocyte proteases bind nucleic acids. Computational modeling, comparing the 
leukocyte serine proteases with digestive serine proteases, might generate some predictions 
about the critical residues that interact with RNA and DNA. A more direct approach would be to 
obtain a crystal structure of a Gzm in complex with DNA or RNA. There are numerous crystal 
structures of the Gzms and other serine proteases [142,143]. It might be relatively 
straightforward to use similar experimental conditions to crystallize a Gzm in complex with RNA 
or DNA. Such a structure would probably aid in identifying the key residues that interact with 
nucleic acid, and might provide hints about the sequence specificity of Gzm-nucleic acid 
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interaction. Targeted mutagenesis, or domain-swapping with other serine proteases, could be 
used to test the contribution of specific residues to nucleic acid binding. 
Structural insights into Gzm-target interactions would permit further characterization of the 
biological significance of nucleic acid binding. It might be possible to identify Gzm mutations that 
abolish nucleic acid binding, but not protease activity. These mutant Gzms could be tested in 
vitro for their substrate specificity and their cytotoxicity towards human cells and pathogens. 
They should no longer concentrate in the nucleus of target cells or fixed and permeabilized 
cells, as we showed in this study. It might even be possible to generate mutant mice expressing 
Gzms deficient in nucleic acid binding and test their ability to control infections and tumors. 
GzmA/GzmB double knockout mice are relatively healthy, but are highly susceptible to poxvirus 
infections [148]. Furthermore, GzmB cleaves nucleic acid binding proteins to control latent HSV 
infections and block poxvirus replication in cell culture [115,116]. We hypothesize that nucleic 
acid binding directs the Gzms towards proteins that are essential for viral replication and host 
cell survival, thus suppressing viral infection. If this hypothesis is correct, these mutant mice 
should be immunodeficient (but perhaps less immunodeficient than knockout mice). However, 
the mutations might cause immunodeficiency for reasons other than nucleic acid binding, for 
example if the residues that bind nucleic acids are also important for the interaction of Gzms 
with serglycins or the surface of their target cells. It would therefore be important to test whether 
the CTLs and NK cells of these mice have normal cytotoxic granules, and whether Gzm delivery 
into target cells is impaired.  
This study reports a novel mechanism for proteases to target their substrates. It explains the 
localization of the Gzms during cytotoxic attack and their preference for targeting DNA and RNA 
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Supplemental Figure 1: Dependence on salt concentration of GzmB binding to nucleic acids
Binding of GzmB to BB94 RNA and BB94 ssDNA was assayed by FP in the presence of the indicated 
concentration of KCl or NaCl. Error bars represent SEM of at least 6 independent wells from 2 experi-
ments.
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Supplemental Figure 2: RNase and DNase impact subcellular localization of GzmB in fixed cells
HeLa cells were fixed and permeabilized, then treated with RNase or DNase or both, then incubated with 
AF488-labeled GzmB and stained for DAPI. As an internal control for staining intensity and to visualize 
the nuclei, the cells were stained with an antibody against hnRNP A1. RNase modestly reduced cytoso-
lic GzmB staining, while DNase modestly reduced nuclear GzmB staining. Scale bar is 10 µm.
































Supplemental Figure 3: DNA affinity mediates binding of endogenous NE to NETs
Primary neutrophils were treated with PMA to induce NETs and coincubated with the indicated concentra-
tion of salmon sperm DNA, then fixed and stained for endogenous NE (green) and for DNA with DAPI 
(red). Endogenous NE localized to NETs, and exogenous salmon sperm DNA reduced its localization to 
NETs. Scale bar is 10 µm.
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Supplemental Table 1: GO analysis of GzmA and GzmB targets from proteomics studies  
GO terms with a summed –log10(P) of 50 or greater are presented. Many of the top terms relate to 












mRNA metabolic process 50.1 67.6 117.7 
nucleic acid metabolic process 58.8 54.9 113.7 
gene expression 46.1 64.5 110.7 
RNA metabolic process 49.6 57.4 107.0 
nuclear part 61.9 44.5 106.4 
nucleobase, nucleoside, nucleotide and nucleic acid metabolic process 54.6 46.9 101.5 
RNA binding 36.9 61.4 98.3 
intracellular organelle part 48.6 47.0 95.7 
organelle part 49.2 46.1 95.3 
ribonucleoprotein complex 39.0 51.9 90.9 
cellular nitrogen compound metabolic process 47.7 41.4 89.1 
nitrogen compound metabolic process 45.9 40.8 86.7 
intracellular part 48.1 37.6 85.8 
cellular macromolecule metabolic process 50.2 35.5 85.7 
nucleus 45.5 34.4 79.8 
intracellular organelle 40.8 38.5 79.3 
organelle 40.6 38.4 79.0 
viral transcription 21.8 53.6 75.4 
macromolecular complex 43.8 30.7 74.4 
translational elongation 24.7 49.7 74.4 
viral infectious cycle 21.0 52.0 73.0 
non-membrane-bounded organelle 24.9 48.1 73.0 
intracellular non-membrane-bounded organelle 24.9 48.1 73.0 
translational termination 20.8 51.4 72.2 
cellular component disassembly at cellular level 23.0 48.7 71.7 
cellular component disassembly 23.0 48.6 71.5 
cellular macromolecular complex disassembly 21.2 48.2 69.4 
macromolecular complex disassembly 21.1 48.1 69.2 
cellular protein complex disassembly 19.7 49.2 68.9 
protein complex disassembly 19.6 49.1 68.7 
macromolecule metabolic process 40.1 27.5 67.6 
RNA processing 30.3 35.5 65.8 
cellular macromolecular complex subunit organization 20.3 44.6 64.9 
endocrine pancreas development 18.1 46.0 64.2 
protein binding 44.2 18.1 62.2 
viral reproductive process 16.4 44.4 60.9 
cellular macromolecule biosynthetic process 27.2 31.8 59.0 
nucleic acid binding 24.4 34.0 58.4 
intracellular membrane-bounded organelle 35.3 22.6 57.9 
cellular metabolic process 35.8 22.1 57.9 
membrane-bounded organelle 35.3 22.5 57.8 
RNA biosynthetic process 20.8 37.0 57.8 
macromolecule biosynthetic process 26.6 31.1 57.7 
nucleoplasm 35.1 22.4 57.5 
cellular component organization or biogenesis at cellular level 26.7 30.5 57.2 
macromolecular complex subunit organization 18.7 36.5 55.2 
cellular component organization at cellular level 26.4 27.6 54.0 
cellular component organization or biogenesis 25.4 28.6 53.9 
cytosol 28.6 23.4 52.0 
cytoplasm 39.4 12.6 52.0 
viral reproduction 14.8 36.5 51.3 
primary metabolic process 31.8 19.4 51.2 
mRNA processing 25.0 26.0 51.1 
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The Journal of Immunology
Leukocyte Protease Binding to Nucleic Acids Promotes
Nuclear Localization and Cleavage of Nucleic Acid Binding
Proteins
Marshall P. Thomas,1 Jennifer Whangbo,1 Geoffrey McCrossan, Aaron J. Deutsch,
Kimberly Martinod, Michael Walch,2 and Judy Lieberman
Killer lymphocyte granzyme (Gzm) serine proteases induce apoptosis of pathogen-infected cells and tumor cells. Many known Gzm
substrates are nucleic acid binding proteins, and the Gzms accumulate in the target cell nucleus by an unknown mechanism. In this
study, we show that human Gzms bind to DNA and RNAwith nanomolar affinity. Gzms cleave their substrates most efficiently when
both are bound to nucleic acids. RNase treatment of cell lysates reduces Gzm cleavage of RNA binding protein targets, whereas
adding RNA to recombinant RNA binding protein substrates increases in vitro cleavage. Binding to nucleic acids also influences
Gzm trafficking within target cells. Preincubation with competitor DNA and DNase treatment both reduce Gzm nuclear locali-
zation. The Gzms are closely related to neutrophil proteases, including neutrophil elastase (NE) and cathepsin G. During neutrophil
activation, NE translocates to the nucleus to initiate DNA extrusion into neutrophil extracellular traps, which bind NE and cathepsin
G. These myeloid cell proteases, but not digestive serine proteases, also bind DNA strongly and localize to nuclei and neutrophil
extracellular traps in a DNA-dependent manner. Thus, high-affinity nucleic acid binding is a conserved and functionally important
property specific to leukocyte serine proteases. Furthermore, nucleic acid binding provides an elegant and simple mechanism to
confer specificity of these proteases for cleavage of nucleic acid binding protein substrates that play essential roles in cellular gene
expression and cell proliferation. The Journal of Immunology, 2014, 192: 5390–5397.
C ytotoxic T lymphocytes and NK cells eliminate virus-infected cells and tumor cells by releasing the gran-zyme (Gzm) serine proteases and perforin from cytotoxic
granules into the immunologic synapse formed with the cell
destined for elimination (1). GzmA and GzmB, the most abundant
and best-studied Gzms, are delivered to the target cell cytosol by
perforin, rapidly concentrate in the target cell nucleus by an un-
known mechanism, and induce independent programs of cell death
(2, 3). To orchestrate cell death in diverse types of target cells, the
Gzms cleave multiple substrates, likely numbering in the hun-
dreds, within the cytosol, nucleus, and mitochondria (1, 4). DNA
and RNA binding proteins are highly represented in the set of
Gzm substrates. All but 1 of the 17 substrates of GzmA that have
been carefully validated bind to DNA, RNA, or chromatin (1, 4).
A recent proteomics study that profiled GzmA substrates in iso-
lated nuclei identified 44 candidate substrates, of which 33 were
RNA binding proteins (RBPs), including 12 heterogeneous nu-
clear ribonucleoproteins (hnRNP) (4). The remaining 11 candidate
substrates were mostly DNA-binding proteins. In some cases, the
nucleic acid appears to play an important role in the Gzm–target
interaction. GzmA cleavage of histone H1 (H1) and binding to
poly [ADP-ribose] polymerase 1 depends on the presence of DNA
(5, 6). All five of the human Gzms cleave hnRNP K in an RNA-
dependent manner (7). Gzm cleavage of viral and host nucleic
acid binding proteins also plays an important role in controlling
viral infection (8, 9). Thus many of the substrates of GzmA and
GzmB are nucleic acid binding proteins that are physiologically
important for cytotoxicity or the control of viral infections.
Although serine proteases have a high degree of sequence sim-
ilarity, the Gzms are most closely related to a group of myeloid cell
granule proteases involved in microbial defense. These immune
proteases include the neutrophil proteases neutrophil elastase (NE)
and cathepsin G (CATG) (10). When neutrophils are activated,
they can ensnare and kill microbes in neutrophil extracellular traps
(NETs), which are formed by nuclear DNA in a unique, non-
apoptotic cell death mechanism called NETosis (11). NE partic-
ipates in NETosis by translocating to the neutrophil nucleus,
where it cleaves histones (12). Histone cleavage promotes chro-
matin decondensation, which precipitates the extrusion of nuclear
DNA through the cell membrane. The extruded DNA is coated
with histones, antimicrobial peptides, NE, and CATG (13).
The aim of this study was to explore further the role of nucleic
acids in mediating Gzm–substrate interactions and trafficking. We
Program in Cellular and Molecular Medicine, Boston Children’s Hospital, Boston,
MA 02115; Division of Hematology-Oncology, Boston Children’s Hospital, Boston,
MA 02215; and Department of Pediatrics, Harvard Medical School, Boston, MA
02115
1M.P.T. and J.W. contributed equally to this work.
2Current address: Department of Medicine, Anatomy Unit, University of Fribourg,
Fribourg, Switzerland.
Received for publication December 9, 2013. Accepted for publication March 24,
2014.
This work was supported by a National Science Foundation graduate research fel-
lowship (to M.P.T.), National Institutes of Health K08 Grant HL094460 (to J.W.),
a Boston Children’s Hospital Career Development Fellowship (to J.W.), and National
Institutes of Health Grant AI45587 (to J.L.).
Address correspondence and reprint requests to Dr. Judy Lieberman or Dr. Jennifer
Whangbo, Harvard Medical School, WAB 255, 200 Longwood Avenue, Boston,
MA 02115 (J.L.) or Boston Children’s Hospital/Dana-Farber Cancer Institute,
450 Brookline Avenue, Boston, MA 02215 (J.W.). E-mail addresses: judy.
lieberman@childrens.harvard.edu (J.L.) or jennifer.whangbo@childrens.harvard.edu
(J.W.)
The online version of this article contains supplemental material.
Abbreviations used in this article: AF488, Alexa Fluor 488; CATG, cathepsin G; CI,
confidence interval; FP, fluorescence polarization; GO, gene ontology; Gzm, gran-
zyme; H1, histone H1; hnRNP, heterogeneous nuclear ribonucleoprotein; NE, neu-
trophil elastase; NET, neutrophil extracellular trap; pI, isoelectric point; RBP, RNA
binding protein; RT, room temperature.
Copyright! 2014 by TheAmericanAssociation of Immunologists, Inc. 0022-1767/14/$16.00
www.jimmunol.org/cgi/doi/10.4049/jimmunol.1303296
 at Francis A Countway Library of M




find that RNA enhances in vitro cleavage of RBP substrates, but
not non-RBP substrates. We show that Gzms directly bind RNA
and DNAwith nanomolar affinity. NE and CATG also bind nucleic
acids with high affinity, whereas digestive serine proteases do not.
In the presence of competitor DNA, the leukocyte serine proteases
do not localize to nuclei and NETs. Together, our findings indicate
that nucleic acid binding is a conserved and functionally important
property of leukocyte serine proteases that directs them to and
enhances their cleavage of nucleic acid binding protein targets.
Materials and Methods
Abs
The following Abs were used at the indicated final concentration or dilution:
mouse mAbs to hnRNP U (3G6; Santa Cruz Biotechnology; 0.2 mg/ml),
hnRNP A1 (4B10; Sigma-Aldrich; 2 mg/ml), lamin B1 (101-B7; Calbio-
chem; 1/1,000), a-tubulin (B-5-1-2; Sigma-Aldrich; 1/1000), G3BP1
(23/G3BP; BD Biosciences; 0.25 mg/ml), hnRNP C1/C2 (4F4; Sigma-
Aldrich; 0.4 mg/ml), b-actin (Developmental Studies Hybridoma Bank;
1/1000), HuR (3A2; Santa Cruz Biotechnology; 0.2 mg/ml); rabbit antisera
to HMGB2 (Abcam; 1/1000), ICAD (Abcam; 0.5 mg/ml), and NE (Abcam;
1 mg/ml); and DDX5 (Abcam; 0.5 mg/ml). Secondary Abs were sheep anti-
mouse HRP (GE Healthcare; 1/2500), donkey anti-rabbit HRP (GE;
1/2500), donkey anti-goat HRP (GE Healthcare; 1/2500), goat anti-rabbit
Alexa Fluor 488 (AF488; Invitrogen; 1/200), and donkey anti-mouse Cy3
(715-165-150; Jackson ImmunoResearch Laboratories; 1:200). Normal
rabbit IgG (2729; Cell Signaling Technology; 1 mg/ml) was used as an
isotype control for immunofluorescence.
Proteins
Human GzmA and GzmB expression plasmids (4) were transfected into
HEK 293T cells by calcium phosphate precipitation. The transfected cells
were grown in serum-free ExCell 293 medium (Sigma-Aldrich) for 4 d.
Recombinant Gzms were purified from the culture supernatants by immo-
bilized metal affinity chromatography using Nickel-NTA (Qiagen) following
the manufacturer’s instructions. Eluted Gzms were treated with enterokinase
(0.05 IU/ml supernatant; Sigma-Aldrich) for 16 h at room temperature (RT).
Active Gzms were finally purified on an S column, concentrated, and quality
tested as previously described (14). GST-tagged HuR, hnRNPC1, and
LMNB1 were expressed and purified as described (4). H1 (M2501S; New
England Biolabs) and caspase-3 (ALX-201-059-U025; Enzo Life Scien-
ces) were purchased. Other serine proteases were NE (16-14-051200;
Athens Research and Technology, Athens, GA), pancreatic elastase (324682;
Millipore), CATG (16-14-030107; Athens Research and Technology), and
trypsinogen (T1143; Sigma-Aldrich). Proteins were fluorescently labeled
with AF488 according to the manufacturer’s instructions (A30006; Invitrogen).
In vitro cleavage in cell lysates
Whole-cell lysates were made from 106 HeLa cells suspended in 1 ml lysis
buffer (50 mM Tris-HCl [pH 8] and 100 mM NaCl) by alternating freezing
in an ethanol/dry ice bath and thawing at 37˚C three times. Cell debris was
pelleted by centrifugation (16,000 3 g for 10 min at 4˚C). The supernatant
was divided, and half was treated with RNase A/T1 (Thermo Scientific) at a
concentration of 325 U/ml for 30 min at 37˚C. RNaseOUT (Invitrogen) was
added at a concentration of 1000 U/ml to the remaining half. The lysates
were then treated with the indicated amounts of Gzms in a volume of 60 ml
for 15 min at 37˚C. In some cases, GzmB was incubated with varying
amounts of salmon sperm DNA on ice for 30 min before addition to lysates.
The cleavage reaction was stopped by adding 53 SDS loading buffer and
boiling at 95˚C for 5 min. For caspase-3 experiments, lysates were incubated
with or without 1 U recombinant capsase-3 for 1 h before stopping the
reaction. Samples were analyzed by SDS-PAGE and immunoblot.
In vitro cleavage of recombinant proteins
In vitro cleavage was performed in 100 mM NaCl and 50 mM Tris-HCl
(pH 7.5). Each protein was first incubated in the indicated concentration of
HeLa cell total RNA or salmon sperm DNA for 20 min and then incubated
with 50 nM GzmB for 15 min (hnRNP C), 50 nM GzmB for 30 min
(LMNB1), 200 nM GzmA for 20 min (H1), or 5 nM NE for 10 min (H1).
Total HeLa cell RNAwas purified with TRIzol (Invitrogen) according to the
manufacturer’s instructions. The final concentrations of hnRNP C, LMNB1,
and H1 were 333, 1, and 400 nM, respectively. For HuR cleavage, RNA
oligonucleotides were diluted to 10 mM, heated at 70˚C for 10 min, and
cooled on ice. A total of 400 nM recombinant GST-tagged HuR was
incubated with or without 200 nM recombinant GzmB. The cleavage reac-
tions were performed in the presence of 3 ng/ml total HeLa RNA, AU RNA,
or BB94 RNA at the indicated molar ratios and incubated in a total volume
of 40 ml at 37˚C for 30 min. Cleavage reactions were stopped by adding
53 SDS loading buffer and boiling for 5 min. Cleavage was assayed by
immunoblot or silver staining (Invitrogen SilverQuest kit; Invitrogen).
Protease localization in permeabilized HeLa cells
HeLa cells were obtained from American Type Culture Collection and
maintained in DMEM supplemented with 10% heat-inactivated FBS, 100
U/ml penicillin G, 100 mg/ml streptomycin sulfate, 6 mM HEPES, 1.6 mM
L-glutamine, and 50 mM 2-ME. HeLa cells were grown overnight on 12-
mm coverslips, then fixed for 10 min at RT in 2% formaldehyde, and
permeabilized for 10 min in methanol on dry ice. In some experiments, the
cells were treated with DNase I (New England Biolabs) or RNase A/T1
(Thermo Scientific) at a 1:50 dilution for 4 h at RT before blocking. The
cells were blocked with 1% BSA in PBS for 1 h at RT, and coverslips were
incubated with blocking buffer containing salmon sperm DNA or no DNA
for 30 min on ice and then incubated at RT for 1 h with 100 nM AF488-
labeled serine proteases. The coverslips were then washed and stained with
4 mg/ml DAPI in PBS and mounted on slides (48311-703; VWR Inter-
national) using polyvinyl alcohol (P-8136; Sigma-Aldrich) aqueous mount-
ing medium. Cells were imaged using an Axiovert 200M microscope (Pan
Apochromat, 1.4 numerical aperture; Carl Zeiss). Images were analyzed
with SlideBook 4.2 (Intelligent Imaging Innovations).
Neutrophil isolation and activation
Human studies were reviewed and approved by the Harvard Committee on
the Use of Human Subjects (IRB-P00005698). Neutrophils were isolated
from the blood of deidentified healthy donors by density-gradient centri-
fugation as described (15). The neutrophil layer was washed with HBSS
and resuspended at 106 cells/ml in RPMI 1640. Neutrophils (2.5 3 105)
were incubated at 37˚C for 15 min on 12-mm coverslips in 24-well flat-
bottom cell-culture plates and then treated in 500 ml RPMI 1640 for 3 h
with 100 nM PMA (P1585; Sigma-Aldrich). In some experiments, 100 nM
AF488-labeled protease and/or salmon sperm DNA (D7656; Sigma-
Aldrich) was added just prior to adding PMA. Treated cells were fixed
in PBS containing 4% formaldehyde. For immunofluorescence staining of
endogenous NE, the fixed cells were incubated with primary Ab or rabbit
antiserum control for 1 h at RT, washed three times in PBS, and then in-
cubated in secondary Ab (AF488-labeled goat anti-rabbit IgG) for 1 h at
RT. The cells were washed, stained with DAPI, and mounted as above.
Gene ontology and phylogenetic analysis of serine proteases
We analyzed the candidate targets of human GzmA (16) and GzmB (17)
identified by proteomics using the FuncAssociate tool (18) on default settings.
Top gene ontology (GO) terms were ranked by the sum of the2log10(p) values
for enrichment of targets of each enzyme. All human proteins having the GO
term “serine-type peptidase activity” (GO:0008236) were identified with
AmiGO (19). Of these proteins, the manually annotated and reviewed
Swiss-Prot sequences were downloaded using the UniProt retrieve tool
(20). The sequences were trimmed to focus on their protease domains
and exclude spurious alignment of other protein domains in multidomain
proteins. The ClustalW2 (21) multiple sequence alignment and phylogeny
tools were used with default parameters to construct a phylogenetic tree.
Phylogeny was visualized with the EvolView Web tool (22).
Fluorescence polarization oligonucleotides
The following FAM-labeled oligonucleotides were used for fluorescence





UUUUUUUUUUUUUUUUUUUUUUU-FAM-39; BB94 RNA, 59-UCU-
GUGAGUUGAACGCACACAUCACAAAGGA-FAM-39; and AU RNA, 59-
CCCAAGCUUAUUUAUUUAUUUAUUGCAGGUC-FAM-39.
FP assays
FAM-labeled oligonucleotides were used at 10 nM, and binding reactions
were performed in a total volume of 20 ml. Proteins and oligonucleotides
were diluted in 10 mM Tris-HCl (pH 7.5), 100 mM NaCl, and 2.5 mM
MgCl2. For RNA oligonucleotides, RNAseOUT was added to a final
concentration of 1 U/ml. Diluted RNA oligonucleotides were heated to 70˚
C for 10 min prior to use. In the salt concentration assay, protein con-
centration was fixed (100 nM), and either NaCl or KCl was added to the
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assay buffer at the indicated final concentrations. Samples were equili-
brated in 384-well black polystyrene assay plates (3575; Corning) for 20
min at RT, and polarization was determined using a Synergy 2 Microplate
Reader and Gen5 Data Analysis Software (BioTek).
FP data analysis
The apparent equilibrium Kd was determined from fitting the data to a
sigmoidal dose-response function using JMP Pro 10 (JMP Statistical
Discovery Software from SAS Institute). The apparent Kd was determined
for each protein–nucleic acid interaction using the equation f = c + {[d2 c]/
[1 + 10^ (2a[log10([P] 2 b)])]}, where f is the fraction bound or the po-
larization value, [P] is the protein concentration, b is the equilibrium Kd, a is
the Hill coefficient, d is the maximum polarization, and c is the minimum
polarization (23). Each experiment was performed at least in duplicate. The
average and SE of the polarization value for each protein concentration was
calculated from at least 10 independent samples.
Oligo(dT) pulldown
A total of 120 ml Oligo(dT)25 Dynabeads (61002; Invitrogen) and 10 ml
Protein G Dynabeads (10004D; Invitrogen) was washed three times in 50
mM Tris-HCl (pH 7.5) and 100 nM NaCl. The beads were blocked for 30
min at RT in the same buffer containing 0.5% BSA (A9647; Sigma-
Aldrich). Following blocking, half of the Oligo(dT)25 Dynabeads were
treated at RT for 30 min with 25 U Benzonase Nuclease (E1014; Sigma-
Aldrich), and the other half was left untreated. After this incubation, the
beads were incubated with 120 ml protein (final concentration 1 mM) in
blocking buffer for 30 min at RT. The beads were washed three times, and
protein was eluted by boiling samples for 3 min in 30 ml SDS loading
buffer. Samples were electrophoresed through a 12% polyacrylamide de-
naturing gel and visualized by Coomassie staining.
Results
Predicted targets of GzmA and GzmB are enriched for nucleic
acid binding proteins
Because the Gzms concentrate in the nucleus of target cells, we
hypothesized that proteins that function in the nucleus might be
overrepresented among Gzm substrates. Two proteomics studies
identified candidate GzmA and GzmB substrates without bias by
analyzing Gzm-incubated cell lysates for novel cleavage products
FIGURE 1. RBP target cleavage by Gzms is enhanced by RNA. (A) GO analysis of GzmA and GzmB targets. Nucleic acid binding proteins are highly
enriched. (B–E) Cell lysates or recombinant proteins were incubated with RNase or the indicated concentration of total RNA followed by incubation with
Gzms or caspase 3. The reactions were analyzed by immunoblot. RNase treatment of HeLa cell lysates reduced cleavage by GzmA (B) and GzmB (C) of
RBP targets, but not non-RBP targets. Results in (B) and (C) are representative of at least three independent experiments. (D) RNase treatment of HeLa cell
lysates did not affect cleavage of RBP targets by active caspase-3. (E) GzmB cleavage of recombinant hnRNP C1, but not recombinant LMNB1, was
enhanced by exogenous total RNA. Results in (D) and (E) are representative of two independent experiments.
5392 GRANZYMES BIND NUCLEIC ACIDS WITH NANOMOLAR AFFINITY
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(16, 17). We analyzed these target lists using the FuncAssociate GO
tool (18) for overrepresented GO terms in both GzmA and GzmB
datasets (Fig. 1A, Supplemental Table I). Proteins with nucleic
acid–related GO terms were the most highly enriched categories,
when analyzed for each Gzm individually or together. The top
seven GO terms for both Gzms (mRNA metabolic process, nucleic
acid metabolic process, gene expression, RNA metabolic process,
nuclear part, nucleotide metabolic process, and RNA binding)
were highly significantly overrepresented (p values of ∼10250 for
each Gzm). This analysis suggested that Gzms might have a special
preference for nucleic acid binding, especially RBP, substrates.
RNA promotes GzmA and GzmB cleavage of RNA-binding
proteins
We first asked whether RNA enhances Gzm RBP cleavage by
comparing Gzm cleavage of RBPs in whole-cell lysates depleted of
RNA. HeLa cell lysates were pretreated or not with a mixture of
RNase A and T1 before a 15-min incubation with varying con-
centrations of recombinant human GzmA or GzmB. The samples
were then immunoblotted for known GzmA and GzmB targets.
All three GzmA RBP targets analyzed (hnRNP U, DDX5, and
hnRNPA1) were cleaved less efficiently in RNase-treated samples
(Fig. 1B). Similarly, cleavage of RBP targets of GzmB (hnRNP U,
G3BP1, and hnRNP C1/C2) was reduced by removing RNA
(Fig. 1C). In contrast, non-RBP targets (LMNB1, HMGB2, TUBA,
and ICAD) were cleaved equally or more efficiently in RNase-
treated lysates, suggesting that Gzm target preference is altered to
favor non-RBPs in the absence of RNA. This effect is not universal
to cytotoxic proteases, as RNase treatment did not affect caspase-3
cleavage of hnRNP C1/C2 and G3BP1 RBP substrates (Fig. 1D).
We next tested whether adding HeLa cell RNAwould alter in vitro
GzmB cleavage of recombinant hnRNP C1 and LNMB1. The RBP
hnRNP C1 was more efficiently cleaved in the presence of added
RNA, whereas cleavage of the non-RBP LMNB1 was unaffected
(Fig. 1E). These results indicate that RNA enhances Gzm cleavage
of RBP targets. Of note, although the highest concentration of RNA
still enhanced cleavage, GzmB cleavage of hnRNP C1 was more
efficient when less RNA was added.
The Gzms bind to RNA with nanomolar affinity
Because RNA enhanced Gzm activity against RBPs, we hypoth-
esized that the Gzms might bind to RNA to direct them to RBP
targets. We tested RNA binding by FP, a technique widely used to
measure protein–nucleic acid interactions (24), using a 39 FAM-
labeled oligouridylate homopolymer (rU30). As a positive control,
we measured RNA binding of human Ag R (HuR), a GzmB sub-
strate that binds to AU-rich RNA sequences (25). GzmA, GzmB,
and HuR all bound to rU30 with high affinity, whereas the negative
control protein BSA did not bind (Fig. 2A). The apparent equi-
librium Kd of all three purified proteins with the rU30 oligonucle-
otide determined by FP was in the nanomolar range (Table I).
GzmB cleavage of HuR is enhanced by HuR binding to RNA
Because HuR preferentially binds AU-rich sequences, we used its
specificity to assess the effect of substrate binding to RNA on
GzmB cleavage. We compared GzmB cleavage of HuR in the
presence of an AU-rich target sequence (AU RNA) (26) that both
HuR and GzmB bind with similar affinity (Fig. 2B, Table I) and in
the presence of a control sequence (BB94) that binds well only to
GzmB (Fig. 2C, Table I). Formation of the cleavage product was
enhanced by AU RNA, but only minimally increased by BB94
RNA (Fig. 2D). These results suggest that RBP targets are opti-
mally cleaved by Gzms when both the target and Gzm interact
with RNA.
FIGURE 2. Gzms directly bind RNA. FP assays with purified Gzms and
RNA. (A) GzmA and GzmB bound to a FAM-labeled 30-nt RNA [rU(30)].
(B) GzmB and HuR bind a 30-nt RNA containing an AU-rich sequence
(AU RNA). (C) GzmB, but not HuR, binds a length-matched control RNA
(BB94 RNA). The mean polarization values 6 SEM are plotted, and the
apparent Kd with 95% CI in brackets is shown. Results are representative
of at least three independent experiments. (D) GzmB cleaves HuR, an RBP
target, most efficiently when it is bound to RNA. GST-tagged HuR protein
was incubated with indicated molar ratios of AU RNA or BB94 RNA, and
GzmB was then added for 30 min. HuR cleavage was detected by im-
munoblot probed for GST.
The Journal of Immunology 5393
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Gzms bind DNA with nanomolar affinity
Because the Gzms bind to RNA and cleave many DNA binding
proteins, we asked whether they could also bind DNA. We used FP
to measure the binding of GzmA and GzmB to an ssDNA oligo-
nucleotide of the same sequence as BB94 RNA (Fig. 3A). Both
GzmA and GzmB bound ssDNA with nanomolar Kd (Table I).
GzmB {Kd 35 nM [95% confidence interval (CI) 31–40]} bound
ssDNA almost as strongly as H1 (Kd 10 nM [95% CI 8–12]),
similar to reported values (27). GzmA binding was somewhat
weaker (Kd 122 nM [95% CI 95–158]). Both Gzms also bound to a
dsDNA oligonucleotide containing the same BB94 sequence with
nanomolar affinities (Fig. 3B). To determine if Gzm binding might
have a sequence preference, we performed FP assays with ssDNA
homopolymers (dA30, dT30, and dC30). Oligo(dG) was not tested
because it tends to form higher order structures and aggregate.
Both Gzms bound dT30 . dC30 with nanomolar affinity, but only
weakly bound to dA30 (Fig. 3C, 3D). This suggests that the Gzms
bind preferentially to pyrimidines. These assays were performed
in buffer containing 100 mM NaCl. Because many protein–DNA
complexes are sensitive to salt concentration, we performed FP
assays over a range of NaCl and KCl concentrations, while holding
the GzmB and nucleic acid concentration constant. Although
binding decreased at higher salt concentrations, binding of GzmB to
DNA and RNA remained strong at physiological concentrations
(150 mM NaCl or KCl) (Supplemental Fig. 1).
Myeloid granule serine proteases bind nucleic acids
Next we asked whether nucleic acid binding is a general property
of serine proteases or limited to a subset. To visualize the evolutio-
nary relationships between the Gzms and other serine proteases, we
performed a phylogenetic analysis of all annotated human serine
proteases. The Gzms form a monophyletic group with other leu-
kocyte serine proteases (Fig. 4A). This group includes five neu-
trophil proteases (NE, CATG, NSP4, PRTN3, and AZU1) (28) and
the mast cell protease CMA1. The Gzms are more distantly related
to digestive enzymes, such as pancreatic elastase and trypsin. We
used FP to assess the affinity of native human CATG and NE,
porcine pancreatic elastase, and bovine trypsinogen (the proen-
zyme of trypsin) for RNA, ssDNA, and dsDNA (Fig. 4B). Both
neutrophil proteases bound these nucleic acids with nanomolar
affinity like the Gzms, but neither digestive protease bound. This
agrees with an earlier study showing that NE binds to DNA (29).
To validate DNA binding with an independent assay, we used
oligo(dT)-conjugated beads to pull down the Gzms, neutrophil
proteases, and pancreatic elastase (Fig. 4C). Consistent with the
FP results, the leukocyte proteases (GzmA, GzmB, NE, and
CATG), but not the digestive protease, bound to oligo(dT) beads.
Binding was specific to DNA because it was decreased by pre-
treating the beads with DNase. The proteases also did not bind to
protein G–conjugated beads. We hypothesized that DNA binding
FIGURE 3. GzmA and GzmB bind DNA with nanomolar affinity. The
binding of a FAM-labeled ssDNA (A) or dsDNA (B) oligonucleotide
(BB94) to GzmA, GzmB, H1, and BSAwas measured by FP. To determine
whether binding was sequence dependent, interactions of GzmA (C) and
GzmB (D) with 39 FAM-labeled homo-oligomers [dA(30), dC(30), and
dT(30)] were measured by FP. Both Gzms bound pyrimidine tracts [dT(30)
and dC(30)] more strongly than the purine tract dA(30). The mean polari-
zation values 6 SEM are plotted, and the apparent Kd with 95% CI in
brackets is shown. Results are representative of at least three independent
experiments.
Table I. Protein–nucleic acid interactions measured by FP in this study
Oligonucleotide Protein Kd (nM)
rU(30) GzmA 232 (194–277)
GzmB 159 (125–202)
HuR 121 (113–129)
AU RNA GzmA 401 (35 nM–4.5 mM)
GzmB 651 (157 nM–2.7 mM)
NE 602 (304 nM–1.2 mM)
CATG 165 (139–197)
HuR 492 (255–952)
BB94 ssRNA GzmA 1.6 mM (188 nM–15.2 mM)
GzmB 480 (337–685)
HuR 4.8 mM (16 nM–1465.9 mM)










dC(30) GzmA 91 (65–127)
GzmB 175 (140–219)
dT(30) GzmA 48 (42–55)
GzmB 45 (26–78)
The apparent Kd with 95% CI in parentheses is given for each binding interaction.
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would enhance leukocyte protease cleavage of DNA binding pro-
tein substrates, as shown above for RNA and previously shown for
GzmA cleavage of H1 (5). We treated purified H1, a target of both
GzmA and NE with each protease in the presence of increasing
concentrations of salmon sperm DNA. H1 cleavage by NE was
greatly increased by adding even a small amount of DNA (Fig. 4D).
H1 cleavage by GzmA was first promoted, then inhibited, by in-
creasing amounts of salmon sperm DNA. Inhibition by high con-
centrations of exogenous RNA was also seen when we analyzed
GzmB cleavage of hnRNP C1 (Fig. 1E). These results suggest that
an excess of nucleic acids interferes with formation of a substrate–
nucleic acid–protease complex. Collectively, these results demon-
strate that nucleic acid binding is a conserved and functionally
important property of leukocyte serine proteases.
DNA binding mediates localization of Gzms to the nucleus
During killer cell attack, the Gzms rapidly concentrate in the nu-
cleus of target cells by an unknown mechanism. A previous study
suggested that nuclear localization is mediated by affinity of the
Gzms to insoluble NFs (3). We hypothesized that the nuclear ac-
cumulation of Gzms is driven by direct binding to nuclear DNA.
To test this idea, we incubated fixed and permeabilized HeLa cells
with AF488-labeled serine proteases and visualized their locali-
zation with fluorescence microscopy (Fig. 5A). As expected, the
Gzms stained the cytosol and nucleus, but concentrated in the
nucleus. To test whether nuclear accumulation was mediated by
DNA binding, we coincubated the Gzms with salmon sperm DNA
before adding them to the fixed cells. Incubation with exogenous
DNA abolished both cytosolic and nuclear staining of the Gzms
(Fig. 5A). We treated fixed cells with DNase and RNase, which
modestly reduced nuclear and cytosolic GzmB staining, respec-
tively (Supplemental Fig. 2). DNase treatment did not remove all
nuclear DNA, so it may be that GzmB binds to residual nucleic
acids after nuclease treatment. Labeled NE also accumulated in
the nuclei of fixed cells, in agreement with the known nuclear
translocation of this enzyme during NETosis (12). Pancreatic
FIGURE 4. Leukocyte serine proteases bind to RNA and DNA with nanomolar affinity. (A) Phylogenetic analysis of all human serine proteases shows
that leukocyte serine proteases form a monophyletic group. (B) Interactions of two neutrophil serine proteases (NE and CATG) and digestive serine
proteases (trypsinogen and pancreatic elastase [PE]) with RNA, ssDNA, and dsDNAwere measured by FP. NE and CATG bound with nanomolar affinity,
but the digestive proteases did not. The mean polarization values 6 SEM and the apparent Kd with 95% CI in brackets are shown. (C) Direct binding of
GzmA, GzmB, NE, CATG, and PE to ssDNAwas assessed by affinity pulldown with oligo(dT)25-conjugated beads. The leukocyte proteases bound, but the
digestive enzyme did not. Binding was reduced by DNase treatment. None of the proteases bound to protein G beads. (D) Purified H1 was not cleaved in the
absence of added DNA. Cleavage of H1 by GzmA and NE was assessed in the presence of increasing amounts of salmon sperm DNA. Addition of small
amounts of DNA enhanced cleavage by both GzmA and NE. At higher concentrations, DNA inhibited GzmA cleavage. Results are representative of at least
three independent experiments.
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elastase did not localize to fixed cell nuclei, and its staining in-
tensity and pattern were not impacted by preincubation with
salmon sperm DNA (Fig. 5A). Thus, DNA binding by the Gzms
and NE likely mediates their nuclear trafficking during cytotoxic
attack and NETosis, respectively.
Localization of NE and CATG to NETs is mediated by DNA
binding
CATG and NE both concentrate on NETs (13). We asked whether
DNA binding facilitates localization of these enzymes to NETs.
Neutrophils isolated from human peripheral blood were treated
with PMA for 3 h to induce NET formation in the presence of
AF488-labeled NE, CATG, or pancreatic elastase. Competitor
DNA was added to some samples during NET formation. Both
neutrophil enzymes, but not pancreatic elastase, spontaneously
concentrated on the NETs, and binding to the NETs was inhibited
by adding salmon sperm DNA (Fig. 5B). Exogenous DNA added
during NETosis also reduced the association of endogenous NE to
NETs (Supplemental Fig. 3). Thus, CATG and NE specifically
localize to NETs by binding to DNA.
Discussion
This work demonstrates that the Gzms and related leukocyte
proteases are bona fide nucleic acid binding proteins with nano-
molar affinities. The basis for substrate specificity of the Gzms,
which are highly specific proteases, remains largely unknown.
Although each Gzm has a strong preference for specific P1 residues
in its substrates, primary amino acid sequence around the cleavage
site does not predict Gzm cleavage. Structural features likely play
a key role in Gzm substrate recognition. This study suggests that
the high affinity of the Gzms for nucleic acids may be an important
determinant of substrate specificity. Nucleic acid binding is a
simple and elegant mechanism to direct leukocyte serine proteases
to DNA and RNA binding protein targets and probably explains
why nucleic acid binding proteins are highly overrepresented
among Gzm substrates. Gzms and their substrates may be brought
together by binding to nearby sites on the same nucleic acid strand.
The Gzms form a monophyletic group with other leukocyte ser-
ine proteases, which also bind to nucleic acids with high affinity.
Importantly, nucleic acid binding regulates the subcellular local-
ization of Gzms and neutrophil proteases. Leukocyte protease
concentration in cell nuclei was prevented by exogenous DNA. Our
results support the affinity model for Gzm nuclear concentration
posited over a decade ago and identify DNA as the unknown insoluble
factor mediating this phenomenon (3). Similarly, the localization
of NE and CATG to NETs and the antimicrobial activity of NETs
likely depend in part upon the affinity of these proteases for DNA.
The leukocyte serine proteases rank among the most cationic
proteins in the cell, with very high predicted isoelectric points
(pIs): GzmA, 9.22; GzmB, 9.69; CATG, 11.37; and NE, 9.89 (20).
The empirical pIs of NE and CATG are ∼11 and.11, respectively
(30). This raises the question of whether nucleic acid binding is
specific or simply a consequence of charge-balancing electrostatic
interactions. For several reasons, we believe binding is specific
and physiologically relevant. First, the digestive serine proteases,
which do not bind nucleic acids, are also cationic with similar pIs
as the Gzms. Porcine pancreatic elastase has a reported pI of 9.5
to .11, whereas the pI of trypsinogen is ∼9.3, but neither binds
nucleic acids (31–33). Secondly, Gzm binding to DNA is sequence
specific, favoring pyrimidine oligomers. Third, these proteases
directly bind DNA under physiologic conditions. Finally, charge
alone does not preclude specificity; RNA and DNA binding pro-
teins are characterized by cationic patches that mediate binding to
nucleic acids by electrostatic interactions (34). The Gzm struc-
tures predict positively charged surfaces that could be nucleic acid
binding sites (35, 36). Further biochemical and structural studies
FIGURE 5. DNA binding regulates nuclear localization of leukocyte
serine proteases and binding to NETs. The effect of DNA on localization
of exogenously added serine proteases to permeabilized cells was assessed
by fluorescence microscopy. (A) Permeabilized HeLa cells were incubated
with AF488-labeled serine proteases (green) that had been preincubated
with buffer or DNA and then stained with DAPI (red). GzmA, GzmB, and
NE were visualized in the cytoplasm, but concentrated in the nucleus.
Preincubation with salmon sperm DNA blocked cellular retention. Pan-
creatic elastase (PE) did not localize to the nucleus, and its staining pattern
was not affected by preincubation with DNA. (B) AF488-labeled NE,
CATG, and PE (green) were added with or without salmon sperm DNA to
neutrophils during NET formation. Cells were fixed and stained for DAPI
(red). NE and CATG localized to NETs, but pancreatic elastase did not.
Salmon sperm DNA blocked binding of NE and CATG to NETs. Images
are representative of three independent experiments. Scale bars, 10 mm.
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that look at the interactions of these leukocyte proteases with
nucleic acids and specific protein substrates are needed.
Negatively charged sugars play a significant role in granule
packaging and target cell uptake of cationic Gzms. In cytotoxic
granules, the Gzms bind serglycin, a small negatively charged
proteoglycan containing chondroitin 4-sulfate (37). Serglycin-null
T cells are defective in packaging GzmB into granules. Upon
degranulation, GzmB is released from serglycin and binds to cell
membrane proteoglycans, most notably heparan sulfate. Purified
GzmB has higher affinity for heparan sulfate than serglycin (38).
Our results suggest that when Gzms enter target cells they bind to
another class of negatively charged molecules, nucleic acids. Gzm
binding to different anionic biomolecules as they move from the
granules to the target cell nucleus may form a physical chain of
custody to ensure proper Gzm trafficking and targeting.
Nucleic acid binding enhances the activity and function of
leukocyte serine proteases, which may be critical to Gzm induction
of cell death and neutrophil protease-mediated NET formation and
function. Exogenous DNA transformed purified H1 from a very
weak substrate to a robust target. However, excess DNA and RNA
inhibited cleavage of H1 and hnRNP C1, respectively. A previous
study also found that DNA inhibited NE and CATG proteolysis of
the nonnucleic acid binding protein elastin (39). An excess of
nucleic acid, which has high affinity for both the protease and its
substrate, likely interferes with formation of the ternary protease–
nucleic acid–substrate complex.
Preferential targeting of DNA and RNA binding proteins by
Gzms is an underappreciated property critical for executing cell
death. Nucleic acid binding is a simple mechanism to guide Gzms
to targets that are essential for survival. Cleavage of nucleic acid
binding substrates should enhance Gzm execution of death, in-
dependently of caspase activation. During Gzm-mediated cell
death, targeting of RBPs disrupts pre-mRNA processing and nu-
clear export (4). In the extracellular environment, DNA binding
may sequester leukocyte serine proteases to focus their activity on
pathogens, which get caught in NETs, and minimize tissue injury.
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mRNA metabolic process 50.1 67.6 117.7 
nucleic acid metabolic process 58.8 54.9 113.7 
gene expression 46.1 64.5 110.7 
RNA metabolic process 49.6 57.4 107.0 
nuclear part 61.9 44.5 106.4 
nucleobase, nucleoside, nucleotide and nucleic acid metabolic process 54.6 46.9 101.5 
RNA binding 36.9 61.4 98.3 
intracellular organelle part 48.6 47.0 95.7 
organelle part 49.2 46.1 95.3 
ribonucleoprotein complex 39.0 51.9 90.9 
cellular nitrogen compound metabolic process 47.7 41.4 89.1 
nitrogen compound metabolic process 45.9 40.8 86.7 
intracellular part 48.1 37.6 85.8 
cellular macromolecule metabolic process 50.2 35.5 85.7 
nucleus 45.5 34.4 79.8 
intracellular organelle 40.8 38.5 79.3 
organelle 40.6 38.4 79.0 
viral transcription 21.8 53.6 75.4 
macromolecular complex 43.8 30.7 74.4 
translational elongation 24.7 49.7 74.4 
viral infectious cycle 21.0 52.0 73.0 
non-membrane-bounded organelle 24.9 48.1 73.0 
intracellular non-membrane-bounded organelle 24.9 48.1 73.0 
translational termination 20.8 51.4 72.2 
cellular component disassembly at cellular level 23.0 48.7 71.7 
cellular component disassembly 23.0 48.6 71.5 
cellular macromolecular complex disassembly 21.2 48.2 69.4 
macromolecular complex disassembly 21.1 48.1 69.2 
cellular protein complex disassembly 19.7 49.2 68.9 
protein complex disassembly 19.6 49.1 68.7 
macromolecule metabolic process 40.1 27.5 67.6 
RNA processing 30.3 35.5 65.8 
cellular macromolecular complex subunit organization 20.3 44.6 64.9 
endocrine pancreas development 18.1 46.0 64.2 
protein binding 44.2 18.1 62.2 
viral reproductive process 16.4 44.4 60.9 
cellular macromolecule biosynthetic process 27.2 31.8 59.0 
nucleic acid binding 24.4 34.0 58.4 
intracellular membrane-bounded organelle 35.3 22.6 57.9 
cellular metabolic process 35.8 22.1 57.9 
membrane-bounded organelle 35.3 22.5 57.8 
RNA biosynthetic process 20.8 37.0 57.8 
macromolecule biosynthetic process 26.6 31.1 57.7 
nucleoplasm 35.1 22.4 57.5 
cellular component organization or biogenesis at cellular level 26.7 30.5 57.2 
macromolecular complex subunit organization 18.7 36.5 55.2 
cellular component organization at cellular level 26.4 27.6 54.0 
cellular component organization or biogenesis 25.4 28.6 53.9 
cytosol 28.6 23.4 52.0 
cytoplasm 39.4 12.6 52.0 
viral reproduction 14.8 36.5 51.3 
primary metabolic process 31.8 19.4 51.2 
mRNA processing 25.0 26.0 51.1 
cellular component organization 25.0 25.8 50.9 
 
Supplemental Table I: GO analysis of GzmA and GzmB targets from proteomics studies. GO 
terms with a summed –log10(P) of 50 or greater are presented. Many of the top terms relate to 





































Supplemental Figure 1: Dependence on salt concentration of GzmB binding to nucleic acids.
Binding of GzmB to BB94 RNA and BB94 ssDNA was assayed by FP in the presence of varying concentrations of KCl and NaCl. 
Error bars represent the SEM of at least 6 independent wells from 2 experiments.
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Supplemental Figure 2: DNase and RNase treatment of permeabilized HeLa cells alters GzmB subcellular localization.
Permeabilized HeLa cells were pretreated with RNase, DNase, or both, then incubated with AF488-labeled GzmB (green) 
and stained for hnRNP A1 (red) to visualize cell nuclei and DAPI (blue) to visualize nuclear DNA. RNase and DNase modestly 
reduced cytosolic and nuclear GzmB staining, respectively. Treatment with both RNase and DNase reduced GzmB staining 


























Supplemental Figure 3: Excess DNA blocks binding of 
endogenous neutrophil elastase to NETs. 
Cells were stained with a neutrophil elastase antibody (green) 
and DAPI (red). Images are representative of three independent 
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Summary: Studies of the regulation of gene expression historically
focused on transcription. However, during stress and apoptosis, pro-
found gene expression changes occur more rapidly and globally than is
possible by regulating transcription. Posttranscriptional changes in
mRNA processing and translation in response to diverse stresses shut
down most protein translation to conserve energy and lead to rapid
remodeling of the proteome to promote repair. Pre-mRNA splicing and
mRNA stability are fundamentally altered under some stress conditions.
Stress pathways coordinate a cytoprotective repair response, while
simultaneously initiating signaling that can ultimately trigger cell death.
How the cell mediates the decision between repair and apoptosis is lar-
gely not understood. In some stresses, microRNAs may tip the balance.
Here, we review what is known about posttranscriptional gene regula-
tion during stress, focusing on what is still unknown and how new
technologies might be used to understand what changes are most phys-
iologically important in different forms of stress and death.
Keywords: stress, apoptosis, pre-mRNA splicing, translation, miRNA
Introduction
The cell responds to stress rapidly by remodeling protein
expression within minutes. Transcriptional changes are too
slow to accomplish this task. Most mRNAs have half-lives
on the scale of hours [on average 6.9 h in human cells,
more than 50-fold longer than in E. coli (1, 2)]. Hence,
posttranscriptional events play a pivotal role in regulating
the initial rapid response to cell stress. A swift, almost glo-
bal, shutoff of translation occurs in response to diverse cel-
lular insults. This ‘integrated stress response’ is generally an
adaptive program that helps a cell endure stress and renor-
malize when the stress abates. Concurrent with this rapid
response, stresses trigger many slower-acting alterations in
gene expression, including changes in transcription, many
of which provide protection against potential future insults.
However, persistent stresses favor changes in expression that
will ultimately tip a cell toward apoptosis. The expression of
proapoptotic effectors can be regulated at multiple check-
points, with each checkpoint requiring continued stress.
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One example of this is upregulation of the proapoptotic
CHOP transcription factor during endoplasmic reticulum
(ER) stress, as discussed later. How cells respond to stress
ultimately depends on the type, severity, and duration of
the stress. Although most research on the stress response has
focused on inhibition of translation, strong and in some
cases very rapid alterations in pre-mRNA splicing and mRNA
stability occur in response to some stresses. These events
need to be better characterized. Changes in posttranscrip-
tional regulation occur both before and after cells that fail to
repair become committed to apoptosis. The best-studied
apoptotic change in gene expression is a global translational
arrest, but the mechanistic underpinnings of this phenome-
non remain poorly understood. Even less is known about
changes in mRNA stability and splicing in apoptosis,
although recent work from our laboratory suggests that dra-
matic changes in pre-mRNA splicing occur during pro-
grammed cell death that promote the cell’s demise.
The basics of cell stress and apoptosis
Eukaryotes have evolved a comprehensive portfolio of mech-
anisms to cope with cell stress. In this review, we focus on
the response to a few stresses in which posttranscriptional
regulation has been best studied. The heat shock (HS)
response is one of the best characterized. The master regula-
tor of many aspects of the HS response is the transcription
factor HSF1, which does not respond to HS per se but senses
misfolded proteins in the cytoplasm that accumulate during
HS and other stresses (3). When activated, HSF1 translocates
to the nucleus and transactivates a repair program, most
notably inducing the heat shock proteins (HSPs), molecular
chaperones that promote proper protein folding. Genotoxic
stress (4, 5), which is important in the etiology and treat-
ment of cancer, activates expression of the tumor suppressor
TP53, a key transcription factor that induces the expression
of genes to promote cell cycle arrest and apoptosis. Unlike
other stresses, genotoxic stress does not necessarily directly
induce translational arrest, but can trigger profound TP53-
dependent and -independent alterations in splicing. TP53
also enhances the transcription of microRNA primary tran-
scripts that play a potentially important role in the genotoxic
stress response. ER stress rapidly triggers a translation block
through the unfolded protein response (UPR). Excessive
protein load in the ER, malfunctioning ER protein-folding
chaperones, or genetic protein-folding disorders can all
induce the UPR. Three major ER sensors of unfolded pro-
teins are ATF6, PERK, and IRE1 (6). The transcription factor
ATF6 migrates from the ER to the Golgi during stress,
where it is released by proteolytic cleavage and then traffics
to the nucleus to transactivate genes that remediate ER stress.
PERK and IRE1 are both kinases, which become activated by
homo-oligomerization and autophosphorylation in response
to ER stress to mediate profound alterations in translation
and mRNA stability. Collectively, these proteins both reduce
the protein load in the ER by reducing protein synthesis and
activate a slower adaptive response that requires de novo tran-
scription and translation to improve ER protein folding
(7, 8). If ER stress is irremediable, a back-up program pre-
pares the cell for apoptosis.
Apoptosis is a tightly controlled cell death program used
to eliminate unwanted cells during development, infection,
or malignant transformation and to eliminate cells experi-
encing irreparable stress-related damage. Apoptotic cells are
rapidly recognized and cleared by macrophages and other
scavenger cells without causing inflammation or harm to
bystander cells. The best-studied cell death program (classi-
cal apoptosis) is mediated by the caspases, but alternate cas-
pase-independent programs of cell death are also triggered
by immune killer cells. In all these pathways, dying cells
undergo membrane blebbing, mitochondrial damage, DNA
degradation, chromatin condensation, and nuclear fragmen-
tation. Executing programmed cell death requires that the
cell membrane remain intact maintaining enough ATP to
execute the program; apoptosis takes several hours to com-
plete. The major effectors of classical apoptosis are the BCL-
2 family proteins and the caspases, which form intertwined
cell death pathways (9). The mitochondria are the site of
action of the BCL-2 family and a key control point in cell
death. The BCL-2 family is divided into three classes: multi-
domain anti-apoptotic proteins (BCL-2, BCL-XL, MCL-1),
the proapoptotic BH3-only proteins (such as BID and BAD),
and the proapoptotic multidomain proteins (BAX and BAK)
(10, 11). BAX and BAK form pores in the mitochondrial
outer membrane to cause mitochondrial outer membrane
permeabilization (MOMP) and the release of apoptogenic
factors, including cytochrome c and SMAC/DIABLO, from
the intermembrane space to the cytosol. The BH3-only pro-
teins promote BAX and BAK multimerization, while the
anti-apoptotic members inhibit it (11). The caspases are cys-
teine proteases that orchestrate cell death by cleaving a large
number of substrates. The initiator caspases are activated by
dimerization and autoproteolysis in response to death recep-
tor ligation (caspases 8 and 10), MOMP (caspase 9), or
stress signaling (caspase 2). Mitochondrial release of cyto-
chrome c triggers formation of the apoptosome – a scaffold
that binds and activates caspase 9. Once activated, caspase 9
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and the other initiator caspases cleave and activate the
downstream effector caspase zymogens (caspase 3, 6, and
7), which then cleave hundreds of cellular substrates in an
accelerating cascade to complete the cell death program (9,
12). In the extrinsic pathway of cell death, death receptor
signaling induces activation of caspase 8 or 10. In addition
to activating the effector caspases by direct cleavage, the ini-
tiator caspases cleave the BH3-only protein BID to truncated
BID (tBID), which activates BAX and BAK. Cell stresses can
lead to apoptosis, generally through the intrinsic pathway of
apoptosis by enhancing the activity or expression of BH3-
only proteins (10). For example, in genotoxic stress, TP53
transactivates the BH3-only proteins NOXA and PUMA (4,
10). Some stresses activate caspase 2 by an unknown mecha-
nism to cleave BID and initiate the mitochondrial pathway
(13).
The granzymes (Gzms) are killer lymphocyte serine prote-
ases, stored with other cytotoxic molecules (notably perfo-
rin, the pore-forming protein that delivers Gzms into cells
targeted for immune elimination) in cytotoxic granules
(14). The Gzms (5 distinct enzymes in humans, 10 in mice)
activate diverse and redundant pathways of programmed cell
death by cleaving many cellular proteins, to guarantee that
it will be difficult for infected or transformed cells to evade
immune attack. GzmB acts like an initiator caspase by
directly cleaving BID and caspase 3. GzmA initiates a distinct
pathway of caspase-independent apoptosis with mostly
non-overlapping substrates that damages mitochondria with-
out causing MOMP and causes single-stranded, rather than
double-stranded, DNA damage (15, 16). The death mecha-
nisms activated by the other Gzms are distinct from these
two but not well characterized. The Gzms translocate into
the target cell nucleus by an unknown mechanism (17, 18),
where they have recently been shown to disrupt pre-mRNA
splicing and nuclear export profoundly.
A very robust bistable switch controls the balance between
life and apoptosis. A recent single-cell study of apoptotic cells
indicates that initiator caspase activity can build slowly before
triggering suicide through irreversible MOMP and effector
caspase activation (19). Stress pathways simultaneously pro-
mote repair and activate molecules that can eventually trigger
an irreversible commitment to apoptosis. The distinction
between the preapoptotic and commitment phases is not triv-
ial, and conflating the two can be misleading. For example,
although it is clear that translation is strongly inhibited after
the commitment to apoptosis, preapoptotic signaling events
can inhibit translation even without cell death (20). In this
review, we seek to draw a clear distinction between events
that occur in response to preapoptotic stresses and those
restricted to the commitment phase of cell death.
Effects of stress and death on splicing
Pre-mRNA splicing (hereafter referred to simply as splicing)
occurs cotranscriptionally to excise introns and join exon
ends to generate a mature mRNA (Fig. 1). Splicing is
controlled by hundreds of constitutive and regulated splicing
A
B
Fig. 1. pre-mRNA splicing and alternative splicing. (A) The cis-regulatory elements recognized by the spliceosome are the 5′ and 3′ splice sites
and the branch point. Other elements in the mRNA are recognized by splicing regulators to ensure the fidelity of splicing. (B) Four major types
of alternative splicing. First and last exons can also vary. Alternative transcription start sites and cleavage and polyadenylation sites also contribute
to isoform diversity. Global splicing inhibition is manifested as intron retention, as occurs in apoptosis and HS. Other forms of alternative splicing
are more common in genotoxic stress. Note that the 5′ and 3′ splice sites refer to the ends of the intron that is spliced out, not the retained exon.
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factors (21). The basic splicing reaction is catalyzed by the
spliceosome, a complex and well-studied RNA-protein
machine (21, 22). The splicing reaction involves the recog-
nition of three cis-regulatory elements on pre-mRNA – the
5′ splice site, the branch point, and the 3′ splice site (22)
(Fig. 1A). Through an ordered assembly process, the spliceo-
some brings together the 5′ and 3′ splice sites and excises
the intervening intron. However, the information contained
in these three cis-regulatory elements is not sufficient to
define exon boundaries; most transcripts contain many cryp-
tic splice sites that are rarely or never used (23). The body
of the transcript bears other cis-regulatory elements bound
by splicing accessory factors that provide additional specific-
ity to ensure the fidelity of splicing. In addition, chromatin
signatures and nucleosome positioning affect exon recogni-
tion (24). The information conferred by these different fac-
tors is integrated by the spliceosome to generate mature
mRNA. Two classes of abundant splicing regulators are the
hnRNPs (heterogeneous nuclear ribonucleoproteins) and SR
proteins, which are historically viewed as splicing repressors
and enhancers, respectively (25, 26). In agreement with this
view, in vitro assays on model templates have demonstrated
that hnRNP A1 antagonizes exon inclusion promoted by the
SR protein SRSF1 (SF2/ASF) (27, 28). These results are sup-
ported by recent genome-wide surveys showing that hnRNP
C1/C2 binding is depleted around splice sites (29). How-
ever, other studies suggest that hnRNPs can either repress or
activate splicing in a sequence-dependent manner (30, 31).
The complexity of the splicing code allows for variations
in splicing, such that the same genomic locus can generate
many different transcripts. Alternative splicing generates
considerable transcriptome diversity. In fact, >95% of multi-
exon genes generate more than one splice isoform (25).
Alternative splicing variants include exon skipping, intron
retention, and the use of alternative 5′ and 3′ splice sites
(Fig. 1B). Transcriptome-wide sequencing and microarray
studies have focused on the large variation in alternative
splicing found across tissues, and the corresponding varia-
tions in expression of splicing regulators, such as the hnRNP
and SR proteins (25, 32, 33). In contrast with tissue-specific
splicing, stress causes transient splicing alterations through
rapid, often reversible, changes in trans-acting factors. There-
fore, cell stress presents an opportunity to understand what
factors regulate alternative and constitutive splicing in a
physiological setting.
The best-characterized stress-induced alterations in splic-
ing occur in heat shock. In HS, but not other stresses, there
is potent, yet transient, global inhibition of splicing (26),
leading to intron retention (Fig. 1B). Splicing of model tem-
plates treated with a nuclear extract from heat-shocked cells
is completely inhibited (34). The SR protein SRSF10
(SRp38) is the master splicing inhibitor in HS (35). SRSF10
is normally abundantly phosphorylated, but, when hypo-
phosphorylated during HS, strongly inhibits splicing in vitro
(35). The HS-mediated block of splicing is independent of
the HS master transcriptional regulator HSF1 (36). The
SRSF10-mediated block on splicing is transient because
SRSF10 is completely rephosphorylated within 1 h of recov-
ery from HS (35). Although splicing inhibition by HS is well
characterized in nuclear extracts, much less is known about
what happens inside intact cells. As transcription is also
strongly inhibited during HS (37), the relative importance of
blocking transcription versus splicing is unknown. Further-
more, as most splicing occurs cotranscriptionally (38), in vitro
studies using pretranscribed model splicing templates could
lead to erroneous conclusions (35). One recent study utilized
splicing-sensitive microarrays to analyze the transcriptome of
HS-treated cells, and found an increase in the usage of
downstream ‘latent’ 5′ splice sites (39) (Fig. 1B). However,
this analysis filtered out cases of intron retention, which
should be ubiquitous in HS. Many HS-induced isoforms con-
tain premature termination codons, which mark transcripts
for nonsense-mediated decay in the cytoplasm (40).
Not much is known about alterations in splicing during
cell death. Our laboratory recently found that pre-mRNA
nuclear export and splicing are profoundly disrupted in cell
death mediated by GzmA and GzmB and likely during cas-
pase-mediated apoptosis more generally. Because the Gzm
serine proteases accumulate in the nucleus of target cells,
we wished to identify their nuclear substrates. The proteo-
mes of intact nuclei that were treated or not with GzmA
were analyzed for proteins degraded by GzmA. Of 44
nuclear substrates, 33 were RNA-binding proteins, including
14 hnRNPs (41). Many hnRNPs were also degraded follow-
ing caspase activation. As hnRNPs assemble on newly syn-
thesized transcripts to orchestrate posttranscriptional
processing, this prompted us to look at the fate of newly
synthesized RNA in cells undergoing Gzm-mediated apopto-
sis. Newly synthesized RNA globally was retained in the
nucleus and pre-mRNA splicing was severely compromised
as assessed by measuring intron retention. Notably, GzmA
cleaved hnRNP A1, causing it to mislocalize to the cyto-
plasm. A non-cleavable mutant of hnRNP A1 restored splic-
ing and partially rescued cells from death, suggesting that
the inhibition of pre-mRNA processing is an important
component of the cell death program (Fig. 2A). Of note,
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alterations in mRNA splicing and nuclear export were absent
in cells undergoing oxidative stress, suggesting that global
inhibition of splicing is not a general feature of non-
apoptotic stress. The splicing defect was likely the reason for
nuclear retention of newly synthesized mRNAs. Intronless
transcripts of immediate early genes (such as Jun) transcrip-
tionally activated in response to stress were rapidly exported
and translated into protein, whereas stress-activated tran-
scripts that contain introns (such as Fos) were not translated
into new protein. On the basis of these findings, we
hypothesize that disrupted splicing during apoptosis blunts
an adaptive stress response and tips the cell toward death.
The great increase in intron retention observed during
programmed cell death, which we interpreted as global
inhibition of splicing, may seem surprising given that
hnRNP proteins are generally considered splicing silencers
(25, 27). However, a view of hnRNPs as only splicing
silencers is an oversimplification. Most human introns are
long, with a mean length of approximately 3.2 kb (42),
and hnRNP A1 promotes the excision of long introns
(! 1 kb). When hnRNP A1-binding activity is inhibited in
vitro, long introns are almost completely retained (31). In a
recent genome-wide study of hnRNP function and targets,
intron retention significantly increased when any of six
hnRNPs were knocked down (30). Four of these hnRNPs
are GzmA targets and several are validated caspase substrates
as well (41). GzmA also potentially cleaves other splicing
factors, which became undetectable after GzmA treatment.
These included U5S1, a component of the spliceosome, and
SRSF1, which aids the spliceosome in recognizing the 5′
splice site, and is required for the splicing of at least some
transcripts in vitro (43). GzmA cleavage of some SR proteins
could collaborate with hnRNP cleavage to enhance intron
retention. Future studies should characterize what happens
to the spliceosome and how splicing changes during differ-
ent forms of stress and apoptosis. It is not clear whether the
Gzms simply inhibit splicing (as evidenced by intron reten-
tion) or also activate alternative splicing (Fig. 1B).
Alternative splicing in stress and death
In contrast with the broad inhibition of splicing caused by
HS and GzmA, other stresses appear to bring about more
targeted alterations in splicing. Apoptotic genes in both the
mitochondrial and caspase cell death pathways have pro-
and anti-apoptotic splice isoforms, whose relative expression
is modulated during stress. Genotoxic stress alters splicing
by several distinct mechanisms. These include altering the
rate of transcription, sequestration of splicing factors, and
transactivation of certain splicing factors. Splice site selection
is modulated by the transcription rate of RNA polymerase II
(PolII), further supporting the idea that transcription and
splicing are intimately coupled (44–46). The ‘kinetic cou-
pling’ model posits that PolII pausing downstream of alter-
native exons with weak splice sites promotes their inclusion
(47) (Fig. 2B). The putative mechanism is simple – when
PolII is slowed, downstream constitutive splice sites are less
available, providing more time for exons with weak splice
sites to be included. Stresses that reduce the transcription
rate of specific genes should disproportionately alter their
splicing. Low-dose ultraviolet (UV) irradiation induces mod-
est phosphorylation of PolII in the heptad repeats of its
C-terminal domain (CTD), which reduces the rate of tran-
scription and alters splicing of model transcripts and splicing
reporter minigenes (48). Expression of PolII phosphomimet-
ic mutants, which transcribe more slowly, recapitulates
some of the UV-induced changes in splicing (48). A recent
transcriptomic analysis supports the kinetic splicing model.
In Jurkat cells treated with drugs to reduce the PolII elonga-
tion rate, downregulated transcripts have more alternative
splicing, favoring inclusion of exons with weaker splice sites
(49). However, PolII interacts during transcription with
many pre-mRNA processing factors (50) in a manner that
may also depend on CTD phosphorylation (45). Thus PolII
phosphorylation may modulate splicing both by altering the
rate of transcription and through changes in its interactions
with splicing factors. However, altered cassette exon splicing
in response to various genotoxic stresses is usually modest.
The functional significance of altered splicing in response to
altered PolII elongation rates remains unclear (47–49).
Stress also modulates the expression, localization, and
activity of splicing factors. Osmotic shock and high doses of
UV drive the phosphorylation and cytoplasmic relocalization
of hnRNP A1 in a p38 MAPK-dependent manner (51).
Other hnRNPs and SR proteins remain in the nucleus.
Osmotic stress or constitutive p38 MAPK activation also
alters splicing of a reporter minigene. However, it remains
unclear whether altered splicing during these stresses is due
to changes in hnRNP A1 localization.
Alternative splicing during cell stress can play a pivotal
role in tuning the cellular response to stress. During geno-
toxic stress, TP53 is upregulated and transcriptionally acti-
vates many targets, including MDM2. MDM2 ubiquitinates
TP53 and targets it for destruction, thus completing a nega-
tive feedback loop that limits TP53 activity. However, as
long as the stress persists, despite the increase in MDM2
transcription, exon skipping during the processing of the
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MDM2 pre-mRNA increases and consequently MDM2 mature
mRNA and protein levels do not increase. At the same time,
other mRNAs are normally processed (52). MDM2 splicing is
restored when the genotoxic stress is removed, producing
MDM2 protein, which shuts down the stress response by
degrading TP53. MDM2 exon inclusion is promoted during
transcription by an interaction between YB-1 and EWS
proteins; this interaction declines during genotoxic damage.
YB-1 and EWS also promote proper exon inclusion of other
genes that undergo exon skipping in genotoxic stress (52).
How stress signaling diminishes the EWS–YB-1 interaction
remains unknown. As YB-1 promotes the recognition of
weak 3′ splice signals and the inclusion of the associated ex-
ons (53), reduced YB-1 activity could explain how certain
MDM2 exons (those with weak splice signals) are skipped
during genotoxic stress.
The transcriptional regulation of splicing factors can also
affect cell fate in response to stress. E2F1, which is induced
by genotoxic stress, transcriptionally activates SRSF2 (SC35),
which promotes the expression of the proapoptotic splice
variants of CASP9, CASP8, and BCL2L1 (BCL-xL/-xS) (54).
Knockdown of SRSF2 inhibits the upregulation of all proa-
poptotic splice variants and consequently inhibits apoptosis.
The E2F-driven change in splice isoform ratios and the proa-
poptotic increase in the ratio of BCL-xS/BCL-xL appears to be
much greater than that due to PolII phosphorylation (48) or
TP53 signaling (55).
Unanswered questions concerning splicing in stress
and cell death
There is no unified understanding of what happens to splic-
ing during cellular stress. Although splicing is strongly
inhibited by SRSF10 hypophosphorylation in vitro, some
transcripts must still be correctly spliced to respond ade-
quately to HS. While some heat shock proteins are encoded
by intronless transcripts (HSP70), others are not (HSP27,
HSP90). How are these still processed in the context of a
potent block on splicing? Most studies in intact cells have
assayed a mixture of stable prestress mRNAs and new mRNA
produced after the stress (39, 49). This may miss many
events because mature mRNAs are relatively stable and many
stress-induced alterations to splicing are transient, such as
the SRSF10-driven block to splicing in HS. Most studies of
splicing and stress have relied on a handful of model
transcripts or transfected splicing reporters to draw general
conclusions about alternative splicing in stress and cell death
A
B
Fig. 2. Some mechanisms that regulate splicing in cell death and stress. (A) In living cells, the hnRNPs help to define intron boundaries.
During killer cell attack, GzmA enters the nucleus, cleaving hnRNP A1, which relocalizes to the cytoplasm. A potent block on splicing leads to
nuclear retention of nascent RNA and intron retention. Expression of a GzmA-uncleavable form of hnRNP A1 partially rescues both splicing and
cell death. (B) The kinetic model of splicing posits that the rate of PolII transcription dictates exon choice. When PolII transcription is fast, strong
splice sites are rapidly made available and those sites are preferred. Because splicing occurs cotranscriptionally, when transcription is slow, the
spliceosome has time to utilize weak splice sites, permitting the inclusion of exons surrounded by weak sites. During some forms of stress PolII is
phosphorylated in its C-terminal domain, which reduces the rate of transcription.
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(41, 48, 52, 54, 55). However, splicing is sensitive to
sequence context and is regulated by a complex milieu of
cis- and trans-acting factors (23). New experimental tech-
niques to metabolically label and capture nascent mRNAs
(1, 56, 57), when combined with splicing-sensitive micro-
arrays (30) or RNA-seq (32), can now be leveraged to
assess the transcriptome-wide impact of HS on splicing and
capture transient changes in pre-mRNA processing. These
methodologies should be very powerful tools for under-
standing the global change in splicing that occurs in
response to various stresses and apoptosis.
The alterations in alternative splicing observed during
stress and cell death provide opportunities to improve our
understanding of how splicing is regulated and to under-
stand how changes in splicing contribute to a cell’s survival
or death. The same stress can manipulate splicing by multi-
ple mechanisms. For example, genotoxic stresses alter the
phosphorylation and localization of hnRNP A1 (51), slow
PolII elongation (48), disrupt the interaction of YB-1 and
EWS with the spliceosome (52), and transcriptionally upre-
gulate splicing factors (54). The best studies have systemati-
cally addressed each of these possible mechanisms to assess
their relative contributions to observed splicing defects (48,
52). As evidenced by vast differences in splicing driven by
HS and genotoxic stress, the type, duration, and severity of
the stress will determine the nature and extent of the splic-
ing changes. Crucially, in almost every case, it remains
unclear whether altered splicing in stress has functional con-
sequences. Many apoptosis-associated genes undergo altered
splicing in response to stress, generating transcript isoforms
that produce proteins with significant functional differences
(58). However, most stresses induce only modest changes
in the ratio of the different splice isoforms (48, 55, 59). In
limited cases, manipulating the trans-acting factors that con-
trol altered splicing after stress substantially alters cell sur-
vival (54). Very few studies have shown that a single
alternative splicing event in the cell stress response is signifi-
cant. Antisense oligonucleotides can be used to interfere
with individual splice sites to modulate the expression of
specific splice isoforms (60). This tool might be useful to
manipulate specific splice isoforms during cell stress to
assess their importance. Finally, altered splicing in stress
cannot be viewed in a vacuum – virtually all stresses induce
profound alterations to translation, and some factors (such
as hnRNP A1 and SRSF1) regulate both splicing and transla-
tion initiation.
Regulation of translation in cell stress
Translational control has been extensively studied in stress
and apoptosis (61, 62). Here, we focus on the interplay
between stress and cell death, in particular how altered
translation during stress protects cells from or predisposes
them toward apoptosis. Most stresses cause a rapid and
nearly global shutoff of protein synthesis through one of
two mechanisms that interfere with translation initiation –
phosphorylation of eIF2a and inhibition of the eIF4F com-
plex (Table 1). Modifications of these factors are common in
almost all stresses, and their effects can be assessed by global
snapshots of translation, captured by 35S labeling of newly
synthesized proteins and separation of polyribosomes on
density gradients. Inhibiting translation serves to conserve
cell resources, as translation consumes >50% of cellular
energy (61), and to remodel the proteome by selective
translation of individual transcripts (63, 64). Recent work
suggests that the balance between repair and cell death is
regulated by translation.
Table 1. Effects of stress on translation





Caspase cleavage of eIF4G
Unknown PKR activation occurs after translation shutoff.
Mechanism of 4E-BP phosphorylation unknown
Heat shock Yes
PKR and HRI,
depending on cell type
HSP27 blocks eIF4G interaction
with eIF4E





HRI in erythroid cells)
Hypophosphorylation of 4E-BPs Yes Mild stress only alters 4E-BPs and eIF4F complex.




4E-BP1 expression induced by
ATF4, which enhances
translation inhibition
Yes Some transcripts are translated to balance repair
and stress, notably ATF4 and CHOP
eIF2a phosphorylation occurs during all of these stresses and other stresses including nutrient starvation, UV irradiation, and oxidative stress. Cap-
dependent translation is inhibited by disrupting the eIF4F complex, but this is achieved by diverse mechanisms.
© 2013 John Wiley & Sons A/S. Published by Blackwell Publishing Ltd
Immunological Reviews 253/2013 243
Thomas & Lieberman ! mRNA regulation in stress and death
123
Translation initiation requires a ternary complex com-
posed of the translation initiation factor eIF2, GTP, and the
methionine initiator tRNA (Met-tRNAi
Met). During transla-
tion initiation, GTP is hydrolyzed to GDP, which must be
recycled by eIF2B to form a new initiation-competent eIF2-
GTP-Met-tRNAi
Met ternary complex. Stresses can activate one
of four kinases that phosphorylate the eIF2 regulatory sub-
unit (eIF2a) on serine 51. The kinases and their respective
stress activators are PKR (viral infection), PERK (ER stress),
GCN2 (nutrient starvation), and HRI (oxidative stress) (64).
S51 phosphorylation of eIF2a leads to stable, inhibitory
association of the eIF2-GDP complex with eIF2B, blocking
recycling of the ternary complex. This results in a fast,
potent, and reversible block of translation initiation. eIF2a
phosphorylation is the main feature of the integrated stress
response, a common protective program activated by most
cellular stresses (65) (Table 1). A fraction of the proteome
escapes translation inhibition through a unique mechanism,
while some proteins are even upregulated in response to
eIF2a phosphorylation (64). Transcripts that have one or
more upstream open reading frames (uORFs) are able to
escape eIF2a-dependent translation arrest. When the amount
of eIF2-GTP-Met-tRNAi
Met ternary complexes is limited by
eIF2a phosphorylation, ribosomes are more likely to scan
through the uORFs and initiate translation at a downstream
ORF to generate functional protein (61, 63, 64). In con-
trast, when eIF2-GTP-Met-tRNAi
Met ternary complexes are
abundant, the ribosomes initiate first at uORFs and are sub-
sequently less able to initiate at downstream ORFs encoding
the relevant protein.
Inhibiting cap-dependent translation in stress
Another way to inhibit translation is to limit formation of
the eIF4F complex, which is composed of the cap-binding
protein eIF4E, the RNA helicase eIF4A, and the adapter pro-
tein eIF4G (66). eIF4F is required for initiating translation
of cap-dependent transcripts, which are most mRNAs. The
mechanisms of eIF4F inhibition have been reviewed else-
where (61, 66, 67). Although eIF2a is a common target of
almost every stress, only some stresses interfere with eIF4F,
and they do so through a diversity of mechanisms (Table 1).
For example, the heat shock protein HSP27 binds directly to
eIF4G to inhibit eIF4F complex formation during HS, which
profoundly limits translation to produce very few proteins
(68). The best-studied regulators of eIF4F are the
eIF4E-binding proteins (4E-BPs), which inhibit eIF4E
binding to eIF4G. 4E-BP binding to eIF4E is regulated by
phosphorylation: hypophosphorylated 4E-BP binds eIF4E
with high affinity, but phosphorylated 4E-BP does not bind
(67). The 4E-BPs are phosphorylated by mTORC1, a kinase
complex that integrates signaling from multiple mitogenic
pathways (67). In the absence of eIF4F, selected mRNAs can
be translated through structured elements in their 5′UTRs
termed internal ribosomal entry sites (IRES). Ribosome entry
at IRESs requires IRES trans-acting factors (ITAFs). Numerous
apoptosis-associated transcripts (with both pro- and anti-
apoptotic functions) contain IRESs that allow them to be
translated during cell stress.
Recently, a new mechanism for inhibiting cap-dependent
translation has been described (69). tRNA fragments (tiR-
NAs) are generated during certain stresses by tRNA cleavage
at a single site in the anticodon loop by the RNase A family
member angiogenin, which is secreted by stressed cells and
acts in an autocrine or paracrine fashion. The 5′ fragment
tiRNA inhibits cap-dependent translation but not IRES-medi-
ated translation, possibly by binding directly to eIF4G and
eIF4E (69, 70).
Regulated translation and the commitment to
apoptosis
Whether cells adapt to stress or commit to cell death
depends on a delicate balance between the activation of dif-
ferent pathways during stress, which in turn depends on the
intensity and duration of the stress. At levels of osmotic
stress that induce apoptosis, translation is globally inhibited
both through eIF2a phosphorylation and hypophosphoryla-
tion of 4E-BP1. Translation inhibition in response to osmo-
tic stress is not rescued in MEFs expressing eIF2a lacking a
phosphorylation site at serine 51 (S51 A/A), indicating that
eIF2a phosphorylation is not required. Inhibition of the
eIF4F complex is probably more important for blocking
translation in this setting. In spite of this, S51 A/A MEFs are
significantly protected from osmotic stress-induced apoptosis
(71). Cytoplasmic relocalization of hnRNP A1 does not
occur in S51 A/A MEFs during osmotic stress (51, 72).
Cytosolic hnRNP A1 can act as an ITAF or an inhibitor of
cap-dependent translation, depending on the transcript. For
example, cytosolic hnRNP A1 activates cap-independent
translation of the proapoptotic factor APAF-1, but inhibits
expression of anti-apoptotic BCL-xL (71, 73). Overexpres-
sion of cytosolic hnRNP A1 in S51 A/A MEFs restores the
same level of apoptosis during osmotic stress as observed in
wildtype MEFs. This study and others suggest that some of
the same factors that regulate altered splicing in response to
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stress or cell death can also modulate translation inhibition
(41, 51, 71).
Translation of individual mRNAs in the setting of global
inhibition is important for balancing cell fate between
repair and apoptosis. During hypoxic stress and hepatotoxic
ER stress, phosphorylation of eIF2a by PERK protects
against apoptosis (74, 75). In contrast, MEFs treated with
ER stressors (such as tunicamycin and thapsigargin)
undergo apoptosis that relies on eIF2a phosphorylation-
dependent expression of the CHOP transcription factor,
which upregulates expression of proapoptotic genes, such
as BIM and DR5 (76–79). CHOP commits cells to apoptosis
during the stress response, as Chop!/! MEFs are resistant to
death in response to ER stress (78). During ER stress, CHOP
mRNA is transcriptionally upregulated by the stress tran-
scription factors ATF6 and ATF4, but protein expression
requires eIF2a phosphorylation. A single uORF in the CHOP
5′ UTR is used during ER stress (79). Prolonged stress leads
to apoptosis (6, 7, 80). The proapoptotic upregulation of
CHOP requires the coordinated action and sustained signal-
ing of several ER stress pathways. During stress, translation
of ATF4 is upregulated through uORFs in its 5′ UTR (81),
and then ATF4 protein transactivates CHOP mRNA expres-
sion (82). In turn, continued eIF2a phosphorylation is
required for CHOP mRNA translation, and then the protein
transactivates target gene expression to exert its proapoptot-
ic function. CHOP protein is therefore downstream in the
ER stress response, and the events that lead to its expression
require persistent ER stress at multiple points (6) (Fig. 3).
This built-in delay could allow a cell time to execute a pro-
tective response before committing to apoptosis. A similar
mechanism induces CHOP during oxidative stress or amino
acid starvation (81), suggesting that it is a common means
to push cells toward apoptosis in response to sustained
insults.
Unanswered questions in cell stress
Although much is known about well-characterized stress
response master regulators, such as ATF4, that are upregulat-
ed by eIF2a phosphorylation, for most stresses, the full
complement of transcripts that escape translation inhibition
or are induced by stress remains unknown. New methods of
Fig. 3. Proapoptotic posttranscriptional events in the ER stress response. In response to ER stress, the three major ER-localized effectors (ATF6,
IRE1, and PERK) all contribute to signaling that can ultimately lead to repair or apoptosis. The ATF6 transcription factor translocates to the Golgi
apparatus and is cleaved. The released DNA binding domain enters the nucleus to transactivate expression of repair genes (such as ATF4) and
proapoptotic genes (such as CHOP). PERK and IRE1 kinases become activated. PERK phosphorylates eIF2a, which blocks translation initiation.
However, key transcripts, such as ATF4 and CHOP, involved in the stress response escape this translation block through uORFs. The CHOP
transcription factor activates expression of the BH3-only protein BIM, the death receptor DR5, and other proapoptotic targets. Latent RNase
activity of IRE1 also becomes activated. IRE1 contributes to cell death by cleaving and inactivating multiple miRNAs that normally suppress
translation of caspase 2. Caspase 2 translation then increases. IRE1 also cleaves many ER-resident mRNAs to reduce ER stress.
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high-resolution comprehensive ribosome profiling (83)
could be used to identify differentially translated proteins in
stress. Although the translational responses to diverse stresses
share many features, differences between types of stress and
how changes in translation help a cell adapt to each type of
insult could be better understood.
Inhibited translation in cell death
Translation is drastically inhibited early in cell death (84–
86), and a number of mechanisms have been posited,
mostly involving alterations to the same initiation factors
that regulate the stress response. Although genotoxic stress
occurs late during apoptosis, the generation of ROS is an
early event that is likely to activate many of the same
responses as non-lethal oxidative stress. During apoptosis,
the eIF4F complex is disrupted by phosphorylation of 4E-
BPs (87) and caspase cleavage of eIF4G (84), whereas eIF2a
phosphorylation can be induced by caspase cleavage of the
eIF2a kinase PKR, which activates it (85, 88). It remains
still unclear which apoptotic alteration(s) are responsible for
inhibited translation in cell death. They may vary with the
apoptotic insult (62). For example, translation inhibition is
caspase dependent in cells treated with death receptor
ligands, but independent of the caspases in the same cells
treated with the genotoxic agent etoposide (62, 89). Here,
we discuss alterations that occur before and after ‘commit-
ment’ to cell death, which we define as effector caspase acti-
vation.
Translation inhibition before the commitment to
apoptosis
Stress signaling that occurs before the commitment to apop-
tosis could play a pivotal role in blocking translation. Jurkat
T cells deficient in caspase 8 are almost completely resistant
to death receptor-mediated apoptosis, whereas caspase 8-
sufficient Jurkat cells activate the effector caspases and die
under the same treatment conditions. eIF2a phosphorylation
modestly increases shortly after adding anti-Fas, regardless
of caspase 8 status (20). However, the impact of non-apoptotic
eIF2a phosphorylation is modest because global translation
inhibition only occurs in caspase 8-sufficient (dying) Jurkat
cells. In MCF-7 cells treated for 4 h with the death receptor
ligand TRAIL, global translation is reduced by approximately
50%, at a time when there is very little PARP1 cleavage and
little phosphatidylserine externalization on the cell mem-
brane (markers of apoptosis). However, at this early time
4E-BP1 hypophosphorylation and reduced binding of eIF4G
to eIF4E inhibits the eIF4F complex to block cap-dependent
translation (87). These alterations to 4E-BP1 are indepen-
dent of caspase 3 but sensitive to the pan-caspase inhibitor
zVAD-FMK, suggesting a role for the initiator caspase 8
(89). It remains unclear how 4E-BP1 becomes hypophosph-
orylated or whether this event is essential for translation
inhibition. MCF-7 cells treated with etoposide demonstrate
reduced translation even when caspase activity is inhibited.
Wildtype MEFs treated with etoposide have increased eIF2a
phosphorylation and association of 4E-BP1 with eIF4E
concurrent with translation inhibition. However, MEFs
deficient in the eIF2a kinase PKR have a comparable block
to translation in response to etoposide without any increase
in eIF2a phosphorylation or 4E-BP1–eIF4E interaction (89).
These results suggest that other unknown events besides
eIF2a phosphorylation and disruption of eIF4E binding to
eIF4G may be important for inhibiting translation in cell
death triggered by DNA damage.
Alterations to translation after commitment to cell
death
Once activated, the effector caspases directly cleave many
translation factors. Notably, caspase 3 cleaves eIF4G (84, 90,
91). It remains unclear, however, whether eIF4G cleavage
products still support translation (62) or how much eIF4G
cleavage contributes to translation inhibition, which is often
already well underway by the time eIF4G is cleaved. In
some studies, eIF4G cleavage correlates well with translation
inhibition (84, 91), whereas in others, translation inhibition
precedes eIF4G cleavage (85, 86). The relative impact of
eIF4G cleavage on translation may depend on the cell type
and death-inducing stimulus. eIF4G is not cleaved in cas-
pase-3 null MCF-7 cells treated with TRAIL, but translation
is still effectively inhibited (89). PKR is also cleaved by the
caspases during death receptor-mediated apoptosis in Jurkat
cells, but PKR cleavage and eIF2a phosphorylation are late
events that occur well after translation inhibition and are
probably not major contributors to translation inhibition in
cell death (85).
Although large alterations in translation factors have been
cataloged during initiation and execution of apoptosis, it
remains still unclear which modifications are responsible for
inhibiting translation. Alterations to translation factors have
only been studied in bulk cell populations undergoing asyn-
chronous cell death. Even genetically identical sister cells die
asynchronously in response to apoptotic stimuli (92),
making it difficult to dissect which alterations occur in the
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preapoptotic versus commitment phases. For example, it has
been argued that many IRES-containing mRNAs are
upregulated in apoptotic cells (87), but markers of the com-
mitment phase of apoptosis remain low at the time IRES-
dependent translation was analyzed, raising the possibility
that these translation alterations are actually preapoptotic.
Synchronous and rapid means of inducing cell death or sin-
gle-cell studies will be necessary for understanding which
processes are truly responsible for blocking translation dur-
ing apoptosis. New genetic models with key apoptosis effec-
tors ablated may help dissect the contribution of different
pathways. At a more fundamental level, although widely
assumed, it has not been proven that translation inhibition
is necessary for cell death.
MicroRNAs at the nexus of mRNA translation and
stability in stress
MicroRNAs (miRNAs), approximately 22-nt RNAs that rec-
ognize target mRNAs by partial base-pairing, interfere with
mRNA translation and stability when they are bound to
the RNA-induced silencing complex (RISC) (93). miRNAs
can affect the overall protein expression of many genes,
sometimes only by a subtle amount. The regulated targets
also vary with the particular cellular context. Recent studies
suggest that miRNAs first inhibit translation initiation, then
activate mRNA deadenylation and decay (94). Because
miRNAs require only limited complementary sequence over
a short sequence to recognize targets, target identification
remains a major challenge (95). Knockouts of many miR-
NAs in mice exhibit no overt phenotypes under normal
conditions, but phenotypes can emerge after stress. miR-
NAs can act as important mediators of the balance between
repair and apoptosis (96). The miR-15 family is upregulat-
ed in the heart following ischemia/reperfusion (IR) injury
and promotes apoptosis in response to this stress. In car-
diomyocytes subjected to hypoxia and reoxygenation,
antagonizing miR-15 increases expression of the antiapop-
totic miR-15 target BCL-2 and reduces apoptosis (97, 98).
miR-15 suppression in vivo significantly reduces the size of
the infarct following IR injury. In contrast, miR-214,
which is also upregulated in response to IR, protects
against apoptosis. The hearts of miR-214 knockout mice
resemble their wildtype counterparts under normal condi-
tions, but these mice are much more susceptible to IR,
with decreased survival and increased cardiac apoptosis
(99).
miRNAs also play a role in the TP53-dependent response
to genotoxic stress. miR-34a and other miRNAs are upregu-
lated by diverse genotoxic stresses (100–104). The promot-
ers of these miRNAs contain strong TP53 consensus sites
transactivated by TP53. Ectopic expression of miR-34a
induces potent cell cycle arrest and/or apoptosis in vitro. In
one study, knockdown of miR-34a also significantly reduced
apoptosis in response to etoposide (104). These and other
early studies suggested a central role for the miR-34 family
(and miR-34a especially) in promoting cell cycle arrest and
cell death following genotoxic stress in a TP53-dependent
manner. Multiple negative regulators of TP53 have also been
identified as direct targets of miR-34a, suggesting that miR-
34a and TP53 might form a positive feedback loop, with
each promoting the expression or activity of the other
(105) (Fig. 4). However, a recent study using miR-34 fam-
ily knockout mice and mouse embryonic fibroblasts (MEFs)
has called into question the importance of miR-34 in the
response to genotoxic stress. Wildtype and miR-34 family
knockouts tested under a variety of genotoxic stress condi-
tions showed no difference in cell survival in vitro or in vivo
(106). Indeed, the only differences observed were increased
proliferation and transformation propensity of miR-34
knockout MEFs compared with wildtype MEFs. This finding
agrees with work from our laboratory. We developed a
novel biochemical approach to identify miRNA targets with-
out bias by isolating mRNAs bound to a biotinylated miRNA
mimic transfected into cultured cells. Although miR-34a
pulldown significantly enriched both for genes in the TP53
network and genes involved in cell cycle progression, con-
firming earlier studies, the most significant enrichment was
in genes whose products participate in all aspects of growth
factor signaling (105). Cancer cell lines overexpressing miR-
34a were less responsive to stimulation by serum growth
factors, whereas miR-34a-deficient MEFs were less likely to
die after serum starvation. As in the knockout study, we also
found that knockdown of the miR-34 family did not affect
cell survival after genotoxic stress (authors’ unpublished
results). In line with its role in regulating growth factor sig-
naling, miR-34a transcription is also regulated by an alter-
nate promoter that is activated by growth factor signaling
(107). These new results suggest that the primary role of
the miR-34 family may be to suppress growth-stimulating
signaling and downstream cell cycle genes to temper the
potentially oncogenic response to growth factors (Fig. 4).
These studies also suggest that the integrated effect of mod-
ulating an individual miRNA during stress can be less
straightforward than predicted by overexpression studies.
Although the above examples demonstrate the potential
of miRNAs to play a central role in mediating cell fate in
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response to stress, these regulatory events may be fairly slow
because they require de novo transcription and processing of
the miRNA before they can downregulate their targets.
Intriguing new studies implicate a fast-acting role for miR-
NAs in IRE1-dependent cell death in response to ER stress
(Fig. 3). IRE1 is an ER kinase composed of an N-terminal
lumenal domain, and cytosolic kinase and RNase domains
(6). During ER stress, IRE1 aggregation drives its trans-phos-
phorylation, unmasking its RNase activity. IRE1 cleaves a
subset of miRNAs (miR-17, miR-34a, miR-96, and miR-
125b) that blocks their target-suppressing functions. Nor-
mally, miRNAs are extremely stable (108), so the rapid
decline in these miRNAs (by approximately 50% after 4 h
of ER stress) is quite striking. Caspase 2 (CASP2) is a com-
mon target of these miRNAs. Caspase 2 upregulation is an
important initiator of the mitochondrial pathway of cell
death in response to ER stress (109). Knockdown of these
miRNAs increases caspase 2 protein, while their overexpres-
sion prevents the accumulation of caspase 2 following ER
stress. Although most miRNAs reduce the stability, and thus
steady state levels, of their mRNA targets (110), CASP2
mRNA levels are unchanged by ER stress, while its transla-
tion rate, as measured by polyribosomal occupancy, signifi-
cantly increases. Unlike IRE1-driven mRNA decay, miRNA
targeting is dependent on the IRE1 RNase domain but not
its kinase domain. However, although kinase-inactive IRE1
induces CASP2 protein, it does not induce apoptosis. Thus,
IRE1-dependent mRNA decay (discussed below) appears to
be crucial for tripping the apoptotic switch in response to
irreparable ER stress (111, 112).
miRNA alteration of mRNA stability in ER stress also can
have an inflammatory effect. TXNIP (thioredoxin interacting
protein) is a mediator of oxidative stress that may promote
insulin resistance in type 2 diabetes induced by a high-fat
diet (113). TXNIP protein is upregulated in response to
diverse ER stresses in a PERK and IRE1-dependent manner.
Signaling downstream of PERK enhances TXNIP transcription
(114). Moreover, IRE1 cleavage of miR-17 also enhances
the stability of its target TXNIP. The physiological impact of
increased TXNIP following ER stress in vitro and in vivo is pro-
found. Pancreatic islets activate the inflammasome to cleave
the precursor of the proinflammatory cytokine IL-1b in
response to ER stress, which is linked to the development of
diabetes in this model (115). Inflammasome activation may
be secondary to increased ROS generation when TXNIP
increases, as pharmacological inhibition of IRE1 RNase activ-
ity or knockdown of TXNIP fully or partially inhibits, respec-
tively, the increase in IL-1b in response to ER stress (114,
116). In response to pharmacological inducers of ER stress,
fewer Txnip-null MEFs die than their wildtype counterparts,
while Txnip deletion partially reduces development of dia-
betes in a model driven by ER stress (116). Together, these
results suggest that miRNAs can play a central role in regu-
lating inflammation and apoptosis under stress conditions.
Two consistent themes emerge in the study of miRNAs
and stress. First, target identification is central to under-
standing a miRNA’s true biological function, and second,
that functions inferred from cell culture experiments must
be validated in vivo. Many miRNA studies have relied on
ectopic expression of miRNA mimics, which can suggest
Fig. 4. miR-34a regulates growth factor signaling and the DNA damage response. The miR-34 family participates in the TP53-dependent
response to DNA damage (indicated in red). The miR-34a promoter is strongly upregulated by TP53. miR-34a in turn downregulates many TP53
inhibitors, cell cycle genes, and apoptosis inhibitors. This positive feedback loop suppresses cell proliferation. miR-34a is also induced by growth
factor signaling (indicated in green) and dampens responsiveness to mitogenic signals by suppressing many growth factor signaling pathways.
Results from knockout mice suggest that regulating growth factor signaling is the major biological function of miR-34, as knockout mice have no
detectable difference in their response to genotoxic stress.
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functions that are not physiologically relevant. This is high-
lighted best by recent studies of miR-34a. miRNA levels
may change rapidly in response to stress to alter protein lev-
els that are critical to cell survival under stress. One mecha-
nism for this has been described (miRNA cleavage by
activated IRE1), but other unknown mechanisms may be at
play.
Changes in mRNA stability during cell stress
Little is known about how cell stress affects mRNA stability.
Most mRNAs are protected from decay by a 5′ 7-meG cap
and a 3′ poly(A) tail (117), and most basal mRNA turnover
is mediated by deadenylation followed by decapping and
exonucleolytic decay. However, mRNA decay can be initi-
ated by a variety of other mechanisms, including endonu-
cleolytic cleavage (118). Although many of the trans-acting
factors that regulate mRNA turnover are well characterized
(nucleases, RNA-binding proteins), little is known about
what signals initiate basal mRNA decay and how individual
mRNAs become tagged for decay. Recent work suggests an
intimate coupling between mRNA translation and stability.
However, although almost all stresses globally shut off trans-
lation, there is no evidence for a concomitant global decline
in mRNA stability, suggesting that somehow, stability and
translation are decoupled following cell stress.
Recent work suggests that altered mRNA stability could
play a key role in the commitment to cell death following
prolonged ER stress. IRE1 cleaves the XBP1 mRNA to activate
an unusual cytosolic splicing reaction, excising a 26-nt intron
from XBP1 to generate XBP1-s (7). This processed transcript
encodes a functional XBP1 transcription factor that transacti-
vates many genes that function to reduce the unfolded pro-
tein load in the ER and alleviate ER stress. Until recently, this
was the only known stress-dependent function of IRE1 (7).
However, it is now clear that IRE1 also directly degrades
many mRNAs during stress (111, 119, 120). Gene expres-
sion profiling of Drosophila S2 cells depleted of IRE1 or XBP1 by
RNAi demonstrated that a subset of transcripts is downregu-
lated in ER stress in an IRE1-dependent, XBP1-independent
fashion. Most of these degraded transcripts are normally
found at the ER, leading to the hypothesis that IRE1 cleaves
these mRNAs to reduce ER-localized translation. mRNA deg-
radation would collaborate with the PERK/eIF2a-dependent
inhibition of translation to reduce the protein load in the ER
(119). Follow-up studies have confirmed that the IRE1 RNase
directly targets some ER-localized mRNAs for decay (111,
120). This mRNA-targeted activity depends on both the
kinase and the RNase domains of IRE1, whereas XBP1 splicing
does not require IRE1 kinase activity. As only cells expressing
IRE1 protein with functional kinase and RNase domains
undergo apoptosis in response to prolonged ER stress, the
mRNA decay activities of IRE1 may be essential for commit-
ting to apoptosis (111). In support of this hypothesis,
expressing an IRE1-binding peptide that enhances XBP1 splic-
ing activity, but reduces IRE1-dependent mRNA decay, pro-
tects cells from ER stress-induced apoptosis (121).
Stress granules: mysterious mRNA-protein reservoirs
No review of mRNA stability in stress would be complete
without a discussion of stress granules (SGs) (122–125).
SGs, microscopically defined cytoplasmic structures that
aggregate in response to a diverse array of stresses, contain
the 40S ribosomal subunit, several translation initiation
factors and numerous RNA-binding proteins bound to large
amounts of mRNA. G3BP1, TIA1, and TIAR proteins are
important for SG formation, which is triggered by phos-
phorylation of eIF2a, a common feature of many stresses
(125). Despite intensive research on SGs, it is still not com-
pletely clear what role they play in mRNA stability. Some
transcripts translated during stress are excluded from SGs,
while housekeeping genes are contained in them (122).
This finding has led to the hypothesis that SGs ‘store’
mRNAs in a translationally inactive state during conditions
of cell stress. When stress is relieved, SGs disappear and the
stored mRNAs are available for translation. However, SGs
localize close to P bodies, sites of miRNA-dependent and
independent mRNA decay. Moreover, it is not possible to
separate SGs from P bodies, and they contain some of the
same proteins. SGs might protect mRNAs during transient
stress but could hand them over to P bodies for degrada-
tion when stress persists. Moreover, the fate of individual
mRNAs within SGs need not be uniform. Whether a
SG-resident mRNA is stabilized may depend on the cis-
regulatory sequences in the mRNA and the trans-acting
factors that bind it. There is circumstantial evidence that
localization to SGs can stabilize mRNAs. For example,
IGF2BP1 (also known as zipcode binding protein) localizes
to SGs in conditions of cell stress, and individual IGF2BP1
target mRNAs are stabilized by this protein during stress
(126). Future work will be required to determine if
mRNAs are indeed globally or partially stabilized by SGs
under stress conditions.
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mRNA stability during apoptosis
In contrast with the very well-characterized changes that occur
to proteins, lipids, and DNA during cell death (9), the fate of
mRNAs in apoptotic cells has not been extensively studied. In
some cells, the 28S rRNA is cleaved by an unknown nuclease to
generate distinct fragments (127). Because this occurs late in
cell death and is not universally seen, it is unlikely to be impor-
tant for cell death. Some intriguing studies that have assayed
individual mRNA transcripts in apoptotic cells by Northern
blotting suggest that mRNA decay may be an early feature of
apoptosis (86, 128).
Postmortem: answering old questions with new
techniques
Recently developed methods could be deployed to follow
the effects of stress and apoptosis on the cellular transcrip-
tome to better define the fate of newly transcribed RNAs.
Recent methods to label and capture new transcripts could
be paired with next-generation sequencing to track posttran-
scriptional changes in pre-mRNA processing and half-life
(1, 56, 57). These experimental approaches could be cou-
pled with genetic manipulation by knockout, knockdown,
or overexpression of mutant or wildtype candidate factors to
define the key pathways involved in controlling protein
expression in stressed cells. Although global inhibition of
translation in response to stress and cell death has been
known for decades, other posttranscriptional events need
further characterization. In particular, we lack an under-
standing of how the type, severity, and duration of stress
impact mRNA splicing, translation, and stability. Although
stress responses share some common features, the differ-
ences may prove important in determining how cells adapt
to diverse insults. Ultimately, we need to understand how
posttranscriptional changes during the stress response influ-
ence cell repair versus apoptosis.
Some of the basic mechanisms that regulate gene expres-
sion in the stress response remain unknown. Under normal
conditions, mRNA translation and stability are intimately
coupled, but generally mRNAs remain stable in stressed cells
despite blocked translation. It remains to be seen whether
the formation of SGs can explain this uncoupling. Similarly,
there are major open questions in the study of apoptosis.
The true cause(s) of translation inhibition during pro-
grammed cell death remain elusive. Is it secondary to the
stresses that accompany apoptosis, or do activated caspases
play a major role? Is blocking new protein expression neces-
sary for carrying the apoptotic program to completion?
More careful studies that separate preapoptotic cells from
cells committed to apoptosis will be crucial to answer these
questions.
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During immune-mediated death, death-inducing granzyme (Gzm)
proteases concentrate in the nucleus of cells targeted for immune
elimination, suggesting that nuclear processes are important tar-
gets. Here we used differential 2D proteomics of GzmA-treated
nuclei to identify potential GzmA substrates. Of 44 candidates,
33 were RNA-binding proteins important in posttranscriptional
RNA processing, including 14 heterogeneous nuclear ribonucleo-
proteins (hnRNP). Multiple hnRNPs were degraded in cells under-
going GzmA-, GzmB-, or caspase-mediated death. GzmA and
caspase activation impaired nuclear export of newly synthesized
RNA and disrupted pre-mRNA splicing. Expressing GzmA-resistant
hnRNP A1 inhibited GzmA-mediated cell death and rescued pre-
mRNA splicing, suggesting that hnRNP A1 is an important GzmA
substrate. Cellular stresses are known to inhibit initiation of cap-
dependent translation. Disrupting pre-mRNA processing should
block further new protein synthesis and promote death by inter-
fering with pathways induced to protect cells from death.
apoptosis | cytotoxic T lymphocyte
Killer lymphocytes deploy cytotoxic granule serine proteasesto activate programmed cell death in cells targeted for im-
mune elimination (1). Humans express ﬁve granzymes (Gzms),
of which GzmA and GzmB are the most abundant and best
characterized. GzmB activates the caspases and also directly
cleaves some caspase substrates (2). GzmA induces caspase-in-
dependent programmed cell death, characterized by ssDNA
damage and a unique pathway of mitochondrial damage without
mitochondrial outer membrane permeabilization (3). GzmA and
GzmB share few substrates. GzmA, a homodimer with tryptase
activity, binds its substrates through an extended exosite and
does not recognize a predictable cleavage site peptide (4). Thus,
in silico methods cannot predict its substrates.
A key mitochondrial substrate was identiﬁed by proteomics of
GzmA-treated mitochondria (5). This approach succeeded be-
cause a minimal Gzm concentration and incubation time were
used to treat intact organelles in which potential substrates are in
their native state. Although ∼300 mitochondrial proteins were
resolved, GzmA altered only a few. Thus, GzmA is a highly speciﬁc
protease. Although hundreds of potential substrates have been
identiﬁed by proteomics (6), only 14 GzmA substrates have been
veriﬁed in GzmA-mediated cell death. Both Gzms concentrate in
target-cell nuclei, suggesting that nuclear substrates are important.
In fact, all but two validated intracellular GzmA substrates either
are predominantly nuclear ormove to the nucleus during oxidative
stress [histones H1/H2B/H3, lamins A/B/C, PARP-1, Ku70,
nucleolin (NUCL), SET, HMGB2, and APE1] (3).
To understand GzmA’s nuclear function, we compared the
proteome of isolated nuclei before and after GzmA treatment.
Forty-four candidate substrates were identiﬁed, of which 33 are
RNA-binding proteins that regulate mRNA processing. These
RNA-binding proteins included 14 heterogeneous nuclear ribo-
nucleoproteins (hnRNP) that assemble on nascent transcripts and
participate in nearly all steps of mRNA maturation (7). Many
hnRNPs are both GzmA and caspase substrates, cleaved during
death by cytotoxic granules, death receptors, and cancer drugs.
Thus, inactivating hnRNPs is a shared feature of programmed
cell death. GzmA treatment or caspase activation, but not non-
lethal oxidative stress, disrupted splicing and export of newly
synthesized RNAs.
Results
Identiﬁcation of Candidate Nuclear GzmA Substrates. We compared
the proteome of isolated nuclei incubatedwithGzmAor buffer (Fig.
1 and Fig. S1). The GzmA concentration and incubation time used
were theminimumneeded to detect clearly cleavage of PARP-1 and
lamins A/C, known substrates. Approximately 1,554 spots were re-
solved. Because the nuclear proteome comprises ∼1,200–2,500
proteins, most nuclear proteins were resolved. Ninety-six spots were
reduced by≥10-fold in intensity byGzmA. Spots of similar apparent
mass that might represent posttranslational modiﬁcations were
grouped into 42 samples and analyzed by in gel digestion and mass
spectrometry. Forty-four nuclear proteins, identiﬁed by at least
three peptides, that had predicted molecular weight and isoelectric
point (pI) similar to theirmigrationwere selected as candidates (Fig.
1, Table S1, andDataset S1). The hits included previously described
GzmA substrates, lamins A/B/C, and NUCL.
Thirty-three of 44 candidate proteins—a signiﬁcant over-
representation—participate in posttranscriptional regulation of
RNA (P = 1.8 × 10−14; Ingenuity). These proteins included 14 of
24 hnRNP proteins (A0, A1, A2/B1, A3, C1/C2, C-like 1, D, G, L,
M,Q, andU). hnRNPs assemble on nascent transcripts to regulate
RNA processing and nuclear export. The list also included other
RNA-binding proteins, including the mRNA-splicing and -pro-
cessing protein SF2/ASF-1 (SFRS1), proteins involved in bio-
genesis of nucleoli and ribosomes, including nucleolin (NUCL)
and nucleophosmin (NPM1), and mRNA export proteins. A
protein interaction network of the candidate substrates was con-
structed, which conﬁrmed the enrichment for RNA-processing
proteins and suggested that GzmA may target multiple proteins
within some complexes (Fig. 1). Besides hnRNP complexes, mul-
tiple hits were in theDrosha complex (DDX5,DDX17, hnRNPM,
and hnRNP D) (8) and in NUCL complexes with hnRNP D or
NPM1. Thus, GzmA may interfere with RNA processing.
GzmA Cleaves Multiple hnRNPs. We veriﬁed that GzmA cleaves
multiple hnRNP family members. Nuclei treated with GzmA,
catalytically inactive GzmA (S-AGzmA), or GzmB were ana-
lyzed by immunoblot for some hnRNP proteins (Fig. 2 A and B).
hnRNP A1, A2/B1, C1/C2, and U were all cleaved by GzmA with
kinetics similar to those of PARP-1 in a dose- and time-dependent
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manner, as indicated by either a stable cleavage product or de-
creased intensity of the full-length protein. S-AGzmA had no
effect. hnRNPs C1/C2, and U, but not A1 and A2/B1, also were
cleaved by GzmB. Another proteomics hit, Nono/p54nrb, was
not a clear GzmA substrate; a slight mobility shift suggested it
might be cleaved near one end, but this possibility was not pur-
sued. GzmA also cleaved all analyzed hnRNPs within hnRNP
complexes immunopuriﬁed from HeLa nuclei using hnRNP C1/
C2 or A1 antibodies (Fig. S2A).
To determine whether hnRNPs are physiologically relevant
targets, we evaluated their cleavage in K562 cells treated with
perforin (PFN) and Gzms (Fig. 2C). hnRNPs A1 and A2/B1
were cleaved by GzmA in intact cells with dose and time de-
pendency similar to that of the known substrate SET. However,
the cleavage fragments were labile and were not detected in
whole cells. In contrast to treatment of isolated nuclei (Fig. 2B),
GzmB and PFN treatment of intact cells led to hnRNP A1 and
A2/B1 cleavage, conﬁrming previous proteomics studies (9–16)
suggesting that these hnRNPs might be caspase targets. When
cells were treated with PFN and GzmB in the presence of the
pan-caspase inhibitor zVAD-fmk, hnRNP A1 remained un-
changed, conﬁrming that hnRNP A1 is not a direct GzmB target
but is a caspase target (Fig. S2B). hnRNP A1 also was cleaved
when NK-92 natural killer (NK) cells attacked 721.221 B cells
(Fig. S2C). hnRNP A1 cleavage occurred, but was reduced, in
the presence of zVAD. Thus, hnRNP A1 is a shared substrate of
GzmA and activated caspases. In fact, all six validated hnRNPs
(A1, A2/B1, C1/C2, and U) were cleaved in GzmB-treated cells.
However, hnRNP C1/C2 and U were cleaved directly by GzmB
and the caspases, whereas hnRNP A1 and A2/B1 were cleaved
efﬁciently only via caspase activation (Fig. 2 B and C and
Fig. S2B).
hnRNPs Are Degraded During Caspase-Dependent Death. To in-
vestigate whether hnRNPs are degraded during caspase-mediated
death, Jurkat cells were treated with anti-Fas or doxorubicin, and
HeLa cells were treated with staurosporine (Fig. S3). A PARP-1
cleavage fragment was seen within 2 h after the addition of anti-
Fas. hnRNPA1, C1/C2, and U levels also declined within 2–4 h of
anti-Fas treatment. Cleavage was inhibited by zVAD-fmk.
HMGB2, an abundant DNA-binding protein, was an uncleaved
control. Doxorubicin, which induced apoptosis more slowly,
based on PARP-1 cleavage and procaspase-3 disappearance, also
led to caspase-dependent hnRNP A1 and C1/C2 cleavage and
a decrease in hnRNP U. hnRNP A1, C1/C2, and U also were
degraded in staurosporine-treated HeLa cells, roughly coincident
with caspase activation. Thus, hnRNP degradation occurs in
multiple apoptotic pathways.
GzmA Disrupts Export of Newly Synthesized RNA. Because cleavage
of hnRNPs and other RNA-binding proteins might disrupt
mRNA processing and nuclear export, we used immunoﬂuo-
rescence microscopy and a BrdU antibody that cross-reacts with
BrU to assess the localization of newly synthesized BrU-labeled
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Fig. 1. Identiﬁcation of candidate nuclear GzmA substrates. K562 nuclei
were treated with 1 μM GzmA or buffer for 30 min at 37 °C, and nuclear
proteins were resolved using 2D gel electrophoresis and visualized by silver
staining. Spots that changed in intensity at least 10-fold afterGzmA treatment
were grouped into 42 spots that migrated with similar apparent molecular
weight and were analyzed by mass spectrometry. Forty-four GzmA candidate
nuclear substrates (Table S1 and Dataset S1) were analyzed by Ingenuity
software for known protein–protein interactions. Proteins with similar func-
tions that are not annotated as interacting were added. Previously unknown
targets are in blue, previously validated substrates that scored as hits are in-
dicated in green, and those not scored as hits are in yellow.
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Fig. 2. GzmA cleaves multiple hnRNP proteins. (A) K562 nuclei were treated
with increasing GzmA concentrations or with 250 or 1,000 nM GzmA for
indicated times, and hnRNP cleavage was assessed by immunoblot. PARP-1 is
a known GzmA substrate; Ku-86 was a loading control. S-A, inactive GzmA.
(B) GzmA treatment of isolated K562 nuclei compared with GzmB. Treat-
ment was with 1 μM Gzm for 1 h. U, untreated control. (C) K562 cells were
treated with PFN and/or GzmA or GzmB at the indicated dose and time.
hnRNP cleavage was assessed by immunoblot. Control samples were treated
with buffer or with PFN only, GzmA only, or GzmB only for 1 h. SET is
a known GzmA substrate (29); β-actin was a loading control. Blots are rep-
resentative of at least three independent experiments.















Fig. 3. GzmA causes nuclear retention of newly synthesized RNA. HeLa cells
were labeled with BrU during treatment with PFN with or without 1 μM
GzmA. Cells were ﬁxed after 1 h and stained for BrdU, which also recognizes
BrU (green), and DAPI (blue). Most newly synthesized RNA was retained in
the nucleus after treatment with PFN and GzmA. Images are representative
of three independent experiments. (Scale bars, 10 μm.)









In untreated cells or in cells treated only with PFN, BrU-labeled
RNA was mostly cytoplasmic, suggesting efﬁcient processing and
export. However, in cells treated with GzmA and PFN newly
synthesized RNA was retained largely in the nucleus.
GzmA Disrupts Pre-mRNA Splicing. To investigate whether the RNA
export defect was caused by deﬁcient splicing and/or export, we
designed primers to amplify spliced (primer pairs in adjacent
exons), unspliced (primer pairs in adjacent exon and intron), and
total (primer pairs within an exon) transcripts. We selected
mRNAs (MYC, FOS, DUSP5, and E2F1) with short half-lives
(T1/2 ∼10–90 min) to weight the analysis toward newly synthe-
sized mRNAs. Nuclear and cytoplasmic RNA were isolated from
untreated cells and from cells treated for 1 h with PFN and/or
Gzms. Arsenite, which causes noncytotoxic oxidative stress, was
a control noncytotoxic cellular stress that induced FOS, DUSP5,
and E2F1. PFN- and GzmB-treated cells were analyzed with and
without zVAD-fmk. Subcellular fractionation was veriﬁed by
immunoblot for tubulin, which was not detected in the nuclear
fractions. The ratio of spliced/unspliced RNA in each compart-
ment was normalized to untreated cells. The ratios were not
altered signiﬁcantly by treatment with PFN alone or arsenite
(Fig. 4A). However, splicing was sharply reduced (up to ∼10-
fold) for all four genes after treatment with PFN and either Gzm.
The reduction in splicing after treatment with GzmA/PFN was
signiﬁcant forMYC, FOS, and DUSP5; a possible explanation for
the lack of a signiﬁcant reduction in E2F1 may be that E2F1
mRNA has the longest half-life. Caspase inhibition during GzmB
treatment largely restored splicing to control levels. Thus, both
GzmA and GzmB, the latter in a caspase-dependent manner,
disrupted splicing of newly synthesized mRNAs.
Nuclear export of intron-containing transcripts requires splic-
ing. The cytoplasm of untreated cells contained ∼10–20 times
more spliced mRNA for these genes than did the nuclear frac-
tions. Thus, once splicing occurs, nuclear export is efﬁcient. To
assess whether defective RNA export was caused mostly by in-
efﬁcient splicing and/or by inhibition of export, we next compared
the ratio of cytoplasmic:nuclear total and spliced RNA, normal-
ized to untreated cells, for MYC and FOS with the ratio for two
intronless genes, JUN and IFNA1. As expected, MYC and FOS
mRNA export was impaired severely in Gzm-treated cells, as
compared with untreated cells or cells treated only with PFN or
arsenite, but the export of JUN and IFNA1mRNAwas not altered
signiﬁcantly (Fig. 4B). However, nuclear export of spliced MYC,
FOS, DUSP5, and E2F1 mRNAs, assessed by the cytoplasmic:
nuclear spliced mRNA ratio, was unchanged (Fig. S4). Thus,
spliced mRNAs were exported efﬁciently, and nuclear retention
was caused by defective splicing.
FOS and JUN are induced by cellular stress. In fact, total FOS
and JUN RNA increased ∼eightfold within 1 h after the addition
of GzmA and PFN and >30-fold with GzmB and PFN (Fig. 4C).
FOS mRNA, which requires splicing, was not spliced or exported
after treatment with PFN and either Gzm, whereas the export of
intronless JUN mRNA was not impaired by the Gzms (Fig. 4B).
Thus, we expected that c-FOS up-regulation would be blunted in
cells undergoing programmed cell death but that c-JUN protein
could be induced. Arsenite induced both c-JUN and c-FOS
mRNA and protein (Fig. 4C). After treatment with Gzms and
PFN, c-FOS protein declined in 1 h, as compared with levels in
control cells, whereas c-JUN levels increased dramatically. Thus,
induction of early-response proteins that orchestrate the cellular
repair response probably is severely disrupted during pro-
grammed cell death only if their transcripts need splicing.
hnRNP A1 Cleavage Disrupts Its Nuclear Localization. We next fo-
cused on hnRNP A1, the best-studied hnRNP. An N-terminal
GST-hnRNP A1 fusion protein was generated to identify GzmA
cleavage sites. After puriﬁed GST-hnRNP A1 was treated with
GzmA for 10 min, three N-terminal cleavage products were seen
that increased with time as the full-length protein decreased (Fig.
5A). In-gel chymotryptic digestion and mass spectrometry iden-
tiﬁed R196, R232, and R284 as the cleavage sites. Site-directed
mutagenesis of the three putative cleavage sites (R196/232/284A)
protected mutant hnRNP fromGzmA cleavage in vitro (Fig. S5A)
and in transfected target cells treated with GzmA and PFN (Fig.
5B) or NK cells, provided zVAD-fmk was present (Fig. S2C).
Thus, these three arginines are functional GzmA cleavage
sites. hnRNP A1 has three RNA-binding domains, followed by
a C-terminal noncanonical nuclear localization sequence (Fig.
S5B). It shuttles between the nucleus and cytoplasm but is mostly
nuclear. Cleavage at these sites would separate or disrupt the
nuclear localization signal from the RNA-binding domains, likely
disrupting hnRNP A1 nuclear localization. In fact, immunoﬂuo-
rescence microscopy (Fig. 5C) and immunoblot of cell fractions
(Fig. 5D) showed that successive C-terminal truncations of N-
terminal HA-tagged hnRNPA1 that would be produced byGzmA
cleavage accumulated increasingly in the cytoplasm. Full-length
HA-hnRNP A1, like endogenous hnRNP A1, was mostly nuclear
(Fig. 5E).Moreover, endogenous hnRNPA1 redistributed toward
the cytoplasm after GzmA and PFN treatment for 1 h (Fig. 5E).
To verify that hnRNP A1 cleavage is responsible for its mis-
localization, HeLa cells expressing WT or GzmA-uncleavable
triple-mutant HA-hnRNP A1 were treated with PFN and GzmA
and examined by immunoﬂuorescence microscopy (Fig. S5C). In
untreated cells, HA staining for both WT and mutant hnRNP A1
was exclusively nuclear. WT hnRNP A1 partly stained in the
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zVAD   - -  -     -  +  - 
PFN   -    +    +    +    +  - 
Gzm   - -    A    B    B   - 
Ars    -     -    -     - - + 
Fig. 4. GzmA interferes with mRNA splicing. (A–C) HeLa cells were un-
treated or treated with PFN and/or 0.5 μM GzmA or GzmB (± zVAD-fmk) or
with arsenite (Ars) for 1 h before isolation of RNA from fractionated nuclei
and cytoplasm. PCR primers were chosen to amplify unspliced, spliced, or
total RNA. First, qRT-PCR results were normalized to GAPDH, and then the
ratios were normalized to their value in untreated cells (ratio = 1). (A) Ratio
of spliced:unspliced nuclear mRNA. (B) Ratio of cytoplasmic:nuclear total
RNA for spliced genes (MYC and FOS) compared with intronless genes (JUN
and IFNA1). Data are pooled from four independent experiments. Asterisks
indicate a signiﬁcant difference compared with untreated cells (P < 0.05). (C)
FOS and JUN RNA was isolated from fractionated nuclei, and protein was
extracted from whole-cell lysates. (Top) FOS and JUN transcripts (total RNA)
were ampliﬁed by qRT-PCR normalized to GAPDH and then to expression in
untreated cells. Both genes were signiﬁcantly induced under all conditions.
Data are mean ± SD of four independent experiments. (Middle) Protein
expression was assessed by immunoblot with β-actin as loading control.
(Bottom) Blots of four independent experiments were quantiﬁed by densi-
tometry showing the intensity of the c-Fos or c-Jun band relative to the
loading control (mean ± SEM percent of untreated cells; *P < 0.05).
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cytoplasm after treatment with GzmA and PFN, but the GzmA-
uncleavable mutant remained nuclear. Similar mislocalization of
endogenous hnRNP A1 occurred within 2 h after the addition of
staurosporine, increasing further after 3 h (Fig. S5D). Thus, both
GzmAand caspases interfere with hnRNPA1 nuclear localization.
GzmA-Resistant hnRNP A1 Inhibits Death and Rescues Splicing. To
determine whether hnRNP A1 cleavage is important during
GzmA-mediated death, HeLa cells overexpressingWT or GzmA-
resistant hnRNP A1 were treated with PFN and either Gzm and
were evaluated by 51Cr release assay (Fig. 6A) and annexin V/
propidium iodide staining (Fig. 6B). Expression of triple-mutant
hnRNP A1 rendered target cells more resistant to GzmA but
equally sensitive to GzmB as cells expressing WT protein. Fur-
thermore, GzmA-uncleavable hnRNP-A1 expression signiﬁcantly
restored MYC, DUSP5, and FOS splicing after GzmA treatment
but did not affect their splicing after GzmB treatment (Fig. 6C).
Thus, hnRNP A1 is an important GzmA substrate, because
blocking its cleavage inhibits GzmA-mediated death and
rescues splicing.
Discussion
The rapid concentration of Gzms in target cell nuclei motivated
us to analyze changes in the proteome of GzmA-treated nuclei.
Only 6% of protein spots changed after GzmA treatment, con-
ﬁrming GzmA’s speciﬁcity. Notably, some abundant nuclear
protein spots were unchanged. Treating proteins in intact nuclei
likely reduced background that might occur in treating cell
lysates. We identiﬁed 44 potential nuclear GzmA substrates,
which included four previously known GzmA substrates (lamins
and NUCL), but others (PARP-1, Ku70, Ape1, and histones)
were missed. By setting a stringent criterion (10-fold less pro-
tein), we biased our hits toward key substrates at the price of
reduced sensitivity. In fact, we were able to validate all the hits
we examined experimentally (with the possible exception of
Nono). Seventy-ﬁve percent of the candidate substrates, in-
cluding 14 hnRNPs, are RNA-binding proteins that orchestrate
posttranscriptional RNA processing. We veriﬁed that six of six
hnRNPs examined were cleaved during GzmA-mediated death
and also conﬁrmed previous proteomics studies that suggested
that these hnRNPs also are caspase targets (9–16).
Because RNA-binding proteins dominated our screen, we ex-
amined the effect of Gzms on RNA processing. A key common
and unrecognized feature of caspase-independent and caspase-
dependent programmed cell death is disruption of pre-mRNA
splicing and nuclear export of newly synthesized RNA. At least
11 of the 44 candidate GzmA substrates, including hnRNP A1
and ASF1, have important roles in pre-mRNA splicing. Pre-
mRNA levels of the early-response genes investigated in this
study (FOS, JUN, DUSP5, E2F1, MYC, and IFNA1) increased by
7–50 fold within 1 h of treatment with either Gzm. Thus, tran-
scription is unimpaired during the early stages of programmed
cell death. However, because of impaired splicing, early-response
proteins, whose mRNAs (like most mRNAs) require splicing, are
not up-regulated. Inhibiting synthesis of cellular stress-response
proteins, many of which have tightly regulated transcripts with
short half-lives, likely interferes with cellular repair.
Disruption of pre-RNA splicing and RNA export is not
a general feature of cellular stress, because, consistent with
previous reports, it did not occur during nonapoptotic oxidative
stress (17). Heat shock transiently interferes with pre-mRNA
splicing of at least some genes (18). However, global changes in






Fig. 5. GzmA cleaves hnRNP A1 after R196, R232, and R284, resulting in
cytoplasmic mislocalization. (A) Recombinant puriﬁed GST-hnRNP A1 was
treated with 0.4 μM GzmA or S-AGzmA and examined by Coomassie blue
(Upper) or GST immunoblot (Lower). The GST tag was at the N terminus.
Three N-terminal cleavage products (black asterisks) appear within 10 min.
Yellow asterisk indicates full-length GST-hnRNP A1; red asterisk indicates
a contaminating band. Mass spectrometry of excised bands indicated
cleavage after R196, R232, and R284. (B) HeLa cells, expressing WT (Left) or
GzmA-uncleavable mutant (Right) HA-hnRNP A1, were treated with PFN plus
GzmA or GzmB (0.5 and 0.16 μM, respectively) for 1 h. HA-hnRNP A1
cleavage was assessed by immunoblot probed for HA. α−Tubulin was the
loading control, and endogenous hnRNP U served as a cleavage control. WT
HA-hnRNP A1 and endogenous hnRNP U were cleaved by both Gzms; mu-
tant HA-hnRNP A1 was resistant to cleavage by GzmA but not by GzmB. (C)
HeLa cells expressing full-length (FL) HA-hnRNP A1 or indicated truncations
were stained with anti-HA (green) and DAPI (blue). (D) HeLa cells expressing
GzmA-generated HA-hnRNP A1 truncations were separated into cytoplasmic
(C) and nuclear (N) fractions, and HA-hnRNP A1 localization was assessed by
anti-HA immunoblot. Tubulin and hnRNP C1/C2 are fractionation controls
for the cytoplasm and nucleus, respectively. (E) Immunoﬂuorescence locali-
zation of endogenous hnRNP A1. Untransfected HeLa cells were treated
with buffer or PFN plus 1 μM GzmA for 1 h before staining for hnRNP A1
(green) and DAPI (blue). Blots and images are representative of at least three
independent experiments.









apoptosis have not been reported previously. Caspase activation,
and cellular stress more generally, disrupts translation initiation.
This disruption is accomplished by caspase cleavage of eIF4G,
eIF2α, and other initiation factors only during apoptosis and by
phosphorylation of eIF2α by a variety of stress-induced kinases
during both stress and apoptosis (19). Because translation uses
about half of the cell’s energy consumption, global inhibition of
translation husbands resources at times of stress. However, some
mRNAs, especially cap-independent transcripts whose products
may help the cell survive stress and apoptosis, overcome this
block. During stress there are shifts from cap-dependent to in-
ternal ribosome entry site (IRES)-dependent translation and
toward alternative splicing, especially of mRNAs for genes such
as bcl-XL, whose splice variants often play opposing roles in cell
survival (20). Alternative splicing is regulated by SFRS1/ASF1
and hnRNP A1 binding to exonic sites to enhance or inhibit,
respectively, binding of U2AF and the U2 small nucleotide ri-
bonucleoprotein to the 3′ splice site (21). Both ASF1 and
hnRNP A1 were hits in our screen for GzmA nuclear substrates,
although we did not conﬁrm that ASF1 is a bona ﬁde target, and
ASF1 is not a known caspase substrate. Alternative pre-mRNA
splicing occurs early in caspase-mediated death (22). Future
studies are needed to compare splice-site selection during cas-
pase-independent and -dependent programmed cell death and to
examine the role of hnRNP A1 and ASF1 cleavage in this pro-
cess. The relative efﬁciency of cleavage of hnRNP A1 and/or
ASF1 may inﬂuence the ratio of the splice variants that get
made. Changes in alternative splicing might play a more im-
portant role in more protracted forms of apoptosis (such as
following UV irradiation or chemotherapy) than in the relatively
rapid Gzm-induced cell death.
Impaired RNA processing should synergize with the inhibition
of translation to block de novo protein synthesis even of mRNAs
that bypass the stress-induced block in cap-dependent translation
initiation. If a target cell is unable to synthesize new proteins, it will
be crippled in repairing cellular damage instigated by death stim-
uli. In previous studies we signiﬁcantly reduced GzmA-mediated
death by overexpressing noncleavable forms of key substrates, in-
cluding Ape1, Ndufs3, PARP1, and Ku70 (3). These experiments
work—perhaps surprisingly—because inducing cell death is not an
all-or-none process: Programmed cell death disrupts multiple
cellular pathways that together overcome cellular repair. Indeed,
GzmA-noncleavable hnRNPA1, which rescued splicing, rendered
cells signiﬁcantly more resistant to GzmA-mediated death.
hnRNP A1, one of the most abundant nuclear proteins, binds to
nascent transcripts as soon as they are transcribed and remains
bound during their nuclear export (23). It regulates both cap-de-
pendent and IRES-mediated translation. It also is implicated in
ribosomal RNA (rRNA) processing, which potentially could in-
terfere with the translation of unspliced mRNAs and those intron-
containing mRNAs that succeed in getting spliced and exported.
Because of its central role in RNA processing, it is perhaps not
surprising that hnRNPA1 on its own is a physiologically important
GzmA target.
In some stresses, hnRNP A1 is phosphorylated by MAPK p38
and translocates to the cytoplasm (24). The cytoplasmic trans-
location of hnRNP A1 we observed following GzmA and staur-
osporine treatment could result from hnRNP A1 cleavage and/or
stress-induced phosphorylation. However, cleavage is likely the
dominant mechanism behind mislocalization, at least for GzmA,
because the noncleavable mutant retained its nuclear localization.
Expression of a phosphomimetic mutant of hnRNPA1 that local-
izes to the cytoplasm activates caspase 3. The proapoptotic effect of
hnRNP A1 cleavage may have been partly the result of its cyto-
plasmic mislocalization.
Although multiple proteins involved in mRNA export are
candidate GzmA targets (Fig. 1), mRNA export or protein ex-
pression of an unspliced immediate early gene product (c-JUN)
was not inhibited in Gzm-treated cells. Further study is needed to
assess if and when candidate proteins involved in RNA export are
cleaved during programmed cell death and whether their cleavage
affects export. Export may be impaired at times later than we
analyzed. The list of candidate GzmA substrates also included
RNA-binding proteins that affect synthesis and processing of
rRNAs (which make up ∼80% of cellular RNA) and microRNAs.
Because newly synthesized RNA overall was retained globally in
the nucleus after treatment with GzmA and PFN, the processing
of other classes of RNAs, especially abundant rRNAs and tRNAs,
is disturbed during apoptosis. Our identiﬁcation of four proteins
in the large Drosha complex as potential GzmA substrates sug-
gests that microRNA processing is impaired also. High-through-
put sequencing of nuclear and cytoplasmic RNAs or of newly
synthesized RNAs in cells undergoing programmed cell death
should help assess the effects of distinct programmed cell death
pathways on all steps of RNA processing.
The SET complex, which contains three GzmA substrates
(SET, HMGB2, and APE1) and is responsible for GzmA-medi-
ated DNA damage, was the ﬁrst recognized example of a pro-
grammed cell death protease targeting multiple substrates within
the same complex (3). However, cleavage of multiple components
of a multiprotein complex, as we found here for the hnRNPs, may
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Fig. 6. Uncleavable hnRNP A1 rescues splicing and inhibits cell death. (A–C)
HeLa cells stably expressing WT or GzmA-uncleavable mutant HA-hnRNP A1
were treated with PFN plus GzmA or GzmB. Death was monitored by a 4-h
51Cr release assay (A) and annexin V/propidium iodide staining 1 h later for
ﬂow cytometry (B). Data in A show mean ± SD of three independent
experiments of percent speciﬁc lysis after subtraction of percent speciﬁc lysis
of control cells treated with PFN alone. Data in B show mean ± SEM of
pooled data from six independent experiments. (C) RNA isolated from whole
cells 1 h after treatment was analyzed by qRT-PCR to compare spliced/
unspliced total cellular RNA. The ratio was normalized to untreated cells.
Data are mean ± SEM of ﬁve independent experiments. In all panels, sta-
tistical differences between WT and mutant hnRNP A1-expressing cells were
calculated using a paired Student’s t test.
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multiple proteins in the N-CoR/SMRT complex (13). GzmA and
the caspases may cleave multiple components of a complex, such
as the hnRNP complexes, because they are dimers: While one
monomer is attacking one component in the complex, the other
monomer may be well positioned to attack another.
Most previously identiﬁed GzmA substrates are unique to
caspase-independent death. The two substrates shared with the
caspases, PARP-1 and lamin B, illustrate processes that might
need to be disrupted for programmed cell death and for avoiding
necrosis. For example, failure to inactivate PARP-1 depletes
cellular ATP, needed for programmed death (25, 26). Lamin
cleavage may be needed to disrupt the nuclear envelope. In some
cases the same pathways are disrupted but by targeting different
proteins. For example, the repair of dsDNA breaks is inhibited
by GzmA by targeting Ku70 and by the caspases by cleaving
DNA-PKcs (27, 28). The identiﬁcation of multiple hnRNP pro-
teins as shared targets of both GzmA and the caspases suggests
that inhibiting mRNA processing is another critical feature of
programmed cell death. It will be of interest to identify how
many of the GzmA candidate targets are shared targets with
GzmB and/or the caspases and whether other posttranscriptional
RNA processing proteins are targeted during apoptosis.
Materials and Methods
Isolatednucleiwere treatedwithGzmAor buffer andwere analyzedby 2DSDS/
PAGE isoelectric focusing gels, and candidate GzmA substrates were identiﬁed
bymass spectrometry. Candidateswere validated by immunoblot and shown to
becleavedduring immune-mediateddeath.Changes inRNAsplicingandcellular
localizationwerefollowedby immunoﬂuorescencemicroscopyandquantitative
RT-PCR (qRT-PCR). Details are available in SI Materials and Methods.
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SI Materials and Methods
Cell Culture. HeLa, Jurkat, K562, 721.221, and NK-92(MI) cells
were obtained from ATCC. HeLa cells were maintained in
DMEM plus 10% (vol/vol) heat-inactivated FCS plus supple-
ment (100 U/mL penicillin G, 100 μg/mL streptomycin sulfate, 6
mM Hepes-free acid, 1.6 mM L-glutamine, 50 μM β-mercap-
toethanol) (D10). Jurkat, 721.221, and K562 cells were main-
tained in RPMI-1640 plus 10% (vol/vol) heat-inactivated FCS
with supplement (K10). NK-92(MI) cells were maintained in
RPMI-1640 plus 10% (vol/vol) heat-inactivated human AB se-
rum plus supplement.
Reagents/Antibodies. The following antibodies were used for im-
munoblotting and/or immunoﬂuorescence: mouse antibodies to
β-actin (JLA20; EMD Bioscience; 1/1,000), caspase 3 (3G2; Cell
Signaling Technology; 1/1,000), heterogeneous nuclear ribonu-
cleoprotein (hnRNP) A1 (4B10; Sigma; 1/5,000 for Western
blotting; 1/2,000 for immunoﬂuorescence), hnRNP A2/B1
(DP3B3; Sigma; 1/2,000), hnRNP C1/C2 (4F4; Sigma 1/5,000),
hnRNP U (3G6; Santa Cruz Biotechnology; 1/1,000), lamin A/C
(BD Biosciences; 1/1,000), tubulin-α (B5-1–2; Sigma; 1/5,000),
and c-Fos (2G9C3; Abcam; 1/2,000); rat antisera to HA (3F10;
Roche; 1/2,000) and BrdU (BU1/75; Abcam; 1/500); rabbit anti-
sera to PARP-1/2 (H-250; Santa Cruz Biotechnology; 1/1,000),
SET [Lieberman antibody (1); 1/1000], and c-Jun (Santa Cruz
Biotechnology; 1/1,000); goat antisera to GST (GE; 1/2,000) and
Ku80 (Santa Cruz Biotechnology; 1/1,000). Secondary antibodies
were sheep anti–mouse-HRP (GE; 1/2,000), donkey anti-rabbit-
HRP (GE, 1/2000), donkey anti-goat-HRP (Santa Cruz Bio-
technology, 1/1,000), donkey anti–rat-HRP (Zymed; 1/2,000),
donkey anti–mouse-488 (Invitrogen; 1/5,000), donkey anti-mouse-
647 (Invitrogen; 1/2,000), donkey anti–rat-488 (Invitrogen; 1/
5,000). Rabbit anti-mouse IgG (Jackson Immunoresearch),
mouse IgG (Jackson Immunoresearch), and protein A-agarose
beads (Roche) were used for immunoprecipitation. Mouse anti-
Fas (CH11; Immunotech) was used at 1 μg/mL ﬁnal concentra-
tion. Doxorubicin hydrochloride was from Fluka. zVAD-fmk was
from Calbiochem. Recombinant granzyme A (GzmA) and cata-
lytically inactive granzyme A (S-AGzmA) were puriﬁed from Es-
cherichia coli as previously described (1, 2). Native granzyme B
(GzmB) was puriﬁed from YT-Indy natural killer (NK) cells as
previously described (3). Native rat PFN was puriﬁed from ascites
ﬂuid as previously described (1). Recombinant granzymes (Gzms)
generated in a recently introduced mammalian expression system
for high-yield protein (4) were used in experiments in Fig. 5 and
Figs. S2C and S5. Brieﬂy, GzmA or GzmB cDNA was cloned into
pHLseq (kind gift of Yvonne Jones, University of Oxford, Oxford,
UK) at the AgeI and KpnI sites using the forward primers
5′GAAACCGGTGACGACGACGACAAGATTATTGGAGG-
AAATGAA for GzmA and 5′GAAACCGGTGACGACGACG-
ACAAGATCATCGGGGGACATGAG for GzmB (introducing
enterokinase sites before the N terminus of the active proteases)
and the reverse primers 5′GTGCTTGGTACCAACTGCTCCC-
TTGATAGTCATAAT for GzmA and 5′GTGCTTGGTACCG-
TAGCGTTTCATGGTTTTCTT for GzmB. The plasmid was
transfected into 293T cells by calcium phosphate precipitation.
The transfected cells were grown in serum-free medium (ExCell
293; Sigma) for 4 d. Recombinant protein in culture supernatants
was puriﬁed by immobilized metal afﬁnity chromatography using
Nickel-NTA (Qiagen) following the manufacturer’s instructions.
Eluted granzymes were treated with enterokinase (0.05 IU/mL
supernatant) (Sigma) for 16 h at room temperature. Active Gzms
were puriﬁed on an S column, concentrated, and quality tested as
previously described (5).
Cell Fractionation. K562 cells, maintained in exponential phase,
were harvested by centrifugation at 400 × g for 10 min. The cell
pellet was washed 3× in PBS, resuspended in 5× pellet volume of
Buffer A [10 mM Tris (pH 7.9), 1.5 mM MgCl2, 10 mM KCl,
0.2 mM EDTA], and incubated on ice for 30 min. Cells were dis-
rupted (as monitored by trypan blue staining) by three strokes of
a Dounce homogenizer on ice, and intact cells were pelleted by
centrifugation (100 × g, 30 s, 4 °C). The supernatant then was
centrifuged at 16,000 × g for 1 min at 4 °C. The nuclear pellet was
washed 3× with 5 mL cold Buffer A, centrifuged at 16,000 × g for
30 s, and resuspended in 0.5–1 mL PBS plus 1 mM MgCl2
(PBS+Mg). Cytosolic supernatant was clariﬁed further by cen-
trifugation at 16,000 × g for 10 min to remove organelles and
insoluble material. Protein content was determined using the
Pierce BCA Assay. HeLa cells, transfected 18 h earlier in six-well
tissue-culture plates using 2 μg DNA and 5 μL Lipofectamine
2000 (Invitrogen), were washed three times in PBS before frac-
tionation according to ref. 6. Two micrograms of total protein
were resolved per lane by SDS/PAGE. After Gzm and PFN
treatment, HeLa cells were harvested by centrifugation at 400 × g
for 3 min at 4 °C. The cell pellet was resuspended gently in 150 μL
RNase-free fractionation buffer (PARIS Kit; Ambion) and kept
on ice for 5 min. Nuclei were pelleted by spinning at 500 × g for 3
min at 4 °C. The nuclear pellet was resuspended in 125 μL frac-
tionation buffer and centrifuged immediately at 500 × g for 1 min
at 4 °C. After 25 μL was saved for SDS/PAGE analysis to conﬁrm
the fractionation, the pooled supernatant was mixed with 750 μL
TRIzol-LS (Invitrogen). The nuclear pellet was resuspended in
250 μL disruption buffer (PARIS Kit) and mixed with 750 μL
TRIzol-LS after samples were saved for protein analysis.
Two-Dimensional Electrophoresis Sample Preparation. Whole K562
nuclei (1–3 mg protein equivalents), suspended in PBS+Mg to
a ﬁnal concentration of 0.5 mg/mL, were left untreated or treated
with 1 μMGzmA for 30 min at 37 °C. Reactions were stopped by
adding 1 mM PMSF. Nuclei then were treated with 300 U/mL
Benzonase (Sigma) for 30 min at room temperature. Nuclease
activity was quenched by adding 10 mM EDTA for 5 min at room
temperature. Nuclei then were harvested by centrifugation at
16,000 × g for 30 s at 4 °C, solubilized in 200–400 μL of 2D sol-
ubilization buffer [4% (wt/vol) CHAPS, 7 M urea, 2 M thiourea],
and incubated on ice for 30 min before pulse sonication for 3 s
using a Misonix S-4000 sonicator set to 30% maximum. Insoluble
material was pelleted by Eppendorf microfuge Model 5415D at
top speed for 30 min at room temperature. The supernatant was
harvested, and protein was precipitated using the 2DClean-up Kit
(GE). Pellets were air dried before resuspension in 100 μL 2D
solubilization buffer followed by incubation at 37 °C overnight.
Protein concentration was determined using the RcDc Assay
(Bio-Rad).
Two-Dimensional Gel Electrophoresis. Two hundred ﬁfty micro-
grams of protein were diluted in 300 μL solubilization buffer
containing 40 mM DTT and 0.2% carrier ampholytes (pH 3–10)
(Bio-Rad). Samples were actively loaded under 50-μA current
onto pH 3–10 nonlinear 17-cm ReadyStrip immobilized pH
gradient strips (Bio-Rad) at 20 °C for 24 h. After 1 h hydration,
strips were overlaid with mineral oil. After hydration was com-
plete, strips were blotted with distilled water and placed in
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a clean focusing tray with water-wetted electrode wicks in place.
After mineral oil was layered on top of the strip, the focusing
program was initiated (step 1: 250 V, linear slope, 1 h; step 2:
500 V, rapid slope, 1 h; step 3: 8,000 V, rapid slope, 60,000 Vh;
50 μA limit/gel) using a Bio-Rad Protean isoelectric focusing
cell. After isoelectric focusing, strips were reduced in 2D
equilibration Buffer 1 [6 M urea, 375 mM Tris (pH 7.4), 2% (wt/
vol) SDS, 2% (vol/vol) glycerol, 10 mg/mL DTT] for 10 min at
room temperature. Buffer 1 was exchanged for Buffer 2 [6 M
urea, 375 mM Tris (pH 7.4), 2% (wt/vol) SDS, 2% (vol/vol)
glycerol, 25 mg/mL iodoacetamide] for 10 min at room tem-
perature. Strips were cleaned in 1× TGS [25 mM Tris (pH 8.6),
192 mM glycine, 0.1% SDS] before casting on top of a 17-cm
10% (wt/vol) PAGE gel with a 5% (wt/vol) polyacrylamide
stacking gel. Focusing strips and molecular-weight markers (Bio-
Rad) were cast in low-melt agarose with bromophenol blue (Bio-
Rad) and placed at 4 °C until set, about 5 min. Second-di-
mension electrophoresis was performed at 150 V until the dye
front was less than 0.5 cm from gel bottom. Gels were uncast and
were silver stained using the SilverQuest staining kit (Invitrogen)
using 200 mL solution per gel per staining step.
Two-Dimensional Gel Image Analysis and Mass Spectrometry. Silver-
stained gels were scanned, and imageswere analyzedusingRedFin
Image analysis software (Ludesi). Spots that decreased at least 10-
fold after GzmA treatment were chosen as hits if they matched
unambiguously, based on nearby spots, and had aminimal volume
of 100 in the untreated sample. Additional negatively stained spots
(negative volumebyRedFin)were addedmanually based on visual
analysis of decreased volume afterGzmA treatment. Chosen spots
were excised, trypsin-digested in gel, and then analyzed on
a nanoscale reverse-phase HPLC by electrospray ionization and
LTQ linear ion-trap mass spectrometry at the Taplin Biological
Mass Spectrometry Facility, Harvard Medical School.
GzmA Treatment of Intact Nuclei. Small-scale treatments were
performed as above using 0.5 mg/mL protein equivalents of nuclei
in PBS+Mg with the indicated dose of GzmA for the indicated
time at 37 °C. Reactions were stopped by adding 10 mM PMSF
and 5× SDS loading buffer and boiling for 5 min.
Gzm and Perforin Treatment.K562 cells (5 × 104) or HeLa cells (2 ×
105) in cell buffer (10 mM Hepes, 4 mM CaCl2, 0.4% BSA in
HBSS) were treated for the indicated time at 37 °C with a sublytic
concentration of rat perforin (PFN) (deﬁned as the concentration
that causes 5–15% cell death by propidium iodide staining in the
absence of Gzms) and the indicated GzmA or GzmB concentra-
tion [prediluted in PFN buffer (10 mM Hepes in HBSS)]. Re-
actions were stopped by boiling in 5× SDS loading buffer or by
transfer to 4 °C before nuclear/cytoplasmic fractionation. Samples
were resolved by SDS/PAGE and immunoblot. For caspase in-
hibition, cells were preincubated with 75 μM of zVAD-fmk in
loading buffer before Gzms and PFN were added. To assess cell
death, 2 × 104 cells were labeled with 51Cr, and 51Cr release was
assessed after 4 h or were stained with annexin V and propidium
iodide and analyzed 1 h after treatment by ﬂow cytometry as
previously described (5). Dead cells were deﬁned as annexin V-
positive and/or propidium iodide-positive.
Cytotoxicity Assay. 721.221 cells (5 × 104) were coincubated with
NK-92 cells at an effector:target ratio of 5:1 for 4 h at 37 °C. At
indicated times, cells were harvested by centrifugation (250 × g
for 3 min) before lysis on ice in RIPA buffer [50 mM Tris-HCl
(pH 7.4), 150 mM NaCl, 1% Triton X-100, 1% sodium deoxy-
cholate, 0.1% SDS, 1 mM EDTA]. After 5× SDS loading buffer
was added, samples were boiled for 1 min and analyzed by SDS/
PAGE and immunoblot.
Immunopuriﬁcation of hnRNP Complexes. hnRNP complexes were
puriﬁed as described (7). Immunoprecipitates were resuspended
in 40 μL of 2× SDS sample buffer and analyzed by immunoblot
or silver staining.
Caspase Activation. Jurkat cells (0.5 × 106/mL in K10) were treated
with 1 μg/mL anti-Fas (CH11 mAb) or 1 μM doxorubicin in the
presence or absence of 75 μM zVAD-fmk for the indicated time.
HeLa cells were treated with 1 mM staurosporine for the in-
dicated time. Cell death and caspase inhibition were veriﬁed by
annexin V/propidium iodide staining. Cells were harvested and
resuspended in RIPA buffer plus 5× sample loading buffer con-
taining β-mercaptoethanol.
Recombinant hnRNP. hnRNP genes were ampliﬁed from HeLa
cDNA using primers that added 5′-EcoRI and 3′-NotI restriction
sites for insertion into pGEX-4T1 (GE). Insertions were veriﬁed
by sequencing. GST-hnRNP fusion proteins were puriﬁed from
BL21(DE3) E. coli according to the supplier’s instructions.
Protein purity was assessed by Coomassie blue staining of SDS/
PAGE gels.
Cleavage Site Determination. GST-hnRNP A1 was treated with
increasing doses of GzmA and resolved on SDS/PAGE gels
stained with Coomassie blue. Bands corresponding to cleavage
fragments were excised, in-gel digested with chymotrypsin, and
analyzed by mass spectrometry to identify GzmA cleavage sites.
Construction of hnRNP A1 mutants. Site-directed mutagenesis in-
troduced point mutations of R196, R232, and R284 to alanine













Mutant sequences then were PCR ampliﬁed to substitute an
N-terminal HA epitope tag for GST. HA-hnRNP genes were
cloned into the EcoRI and XhoI sites of pcDNA4/V5-His
(Invitrogen) and pBABEpuro to obtain pBABEpuro-HA-hnRNP
A1 WT or mutant. Retrovirus-containing supernatant was
obtained by harvesting 293T cells 48 h after transfection with
pBABEpuro-HA-hnRNP A1 (WT or mutant), pgagpol, and
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To construct hnRNP A1 truncations from the pGEX4T1:hnRNP
A1WT template, an N-terminal HA tag, 5′ EcoRI restriction site,
and 3′ stop codon and XhoI restriction site were added using
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HA-hnRNP genes were cloned into the EcoRI and XhoI sites
of pcDNA4/V5-His (Invitrogen). Truncations were conﬁrmed by
sequencing.
Fluorescence Microscopy. HeLa cells were transfected on collagen-
coated coverslips with 1 μg DNA using 3 μL FuGene (Roche).
Cells were ﬁxed 18 h posttransfection with 2% paraformaldehyde
for 20 min at room temperature. Fixative was removed and re-
placed with 50 mM ammonium chloride in PBS for 20 min at
room temperature. Cells were washed 3× with wash buffer (0.05%
Triton X-100 in PBS) and then were permeabilized for 15 min at
room temperature with Perm buffer (0.2% Triton X-100 in PBS).
After blocking with 10% FCS in wash buffer for 30 min, slides
were stained with primary antibodies for 1 h at room temperature
in wash buffer. Cells were washed 3× before incubation with ﬂu-
orophore-conjugated secondary antibodies for 1 h at room tem-
perature in wash buffer. Cells were washed 3× before being
mounted on glass slides using VectaShield mounting medium
(Vector Laboratories) with DAPI. Image acquisition by epiﬂuor-
escence microscopy was performed using an Axiovert 200M mi-
croscope, equipped with a 63× lens (Pan Apochromat, 1.4 NA;
Carl Zeiss). Images were analyzed with SlideBook 4.2 (Intelligent
Imaging Innovations Inc.) to generate 3D stacks of optical sections
acquired 0.2 μm apart before nearest-neighbor deconvolution.
BrU Incorporation.HeLa cells grown overnight in D10 on collagen-
coated coverslips were washed 3× with HBSS and placed in 100 μL
cell buffer containing 2 mM bromouridine (Sigma) with 100 μL
PFN buffer containing PFN and GzmA (ﬁnal concentration,
1 μM). Cells were incubated for 30 min at room temperature
before 300 μL cell buffer was added and were incubated at room
temperature for an additional 30 min. Medium was aspirated, and
cells were ﬁxed with 2% paraformaldehyde and stained as above.
Quantitative RT-PCR. Total RNA was reverse transcribed using
random hexamers and superscript III reverse transcriptase
(Invitrogen). Quantitative RT-PCR (qRT-PCR) was performed
in duplicate samples using SYBR Green FastMix (Quanta) on
a BioRad CFX96. mRNA levels were normalized to GAPDH.
Primers to amplify spliced mRNAs were chosen at neighboring
exons separated by a large intron that would not be ampliﬁed
unless the intervening intron was removed by splicing. Primers to
amplify unspliced transcripts were chosen in an adjacent exon
and intron. Primers to amplify total RNA were chosen within
a single exon. The following primers were used:
MYC (spliced and unspliced) forward 5′GGAGGCTATTC-
TGCCCATTT
MYC (spliced) reverse 5′CACCGAGTCGTAGTCGAGGT
MYC (unspliced) reverse 5′GCATTCGACTCATCTCAGCA
MYC (total) forward 5′TTGCCGCATCCACGAAACTT
MYC (total) reverse 5′TGCAAGGAGAGCCTTTCAGA
FOS (spliced and unspliced) forward 5′TTGTGAAGACCAT-
GACAGGAGG
FOS (spliced) reverse 5′TCCTTTCCCTTCGGATTCTCCT
FOS (unspliced) reverse 5′TTCCCAGGAAGAGTACGC-
TAGA
FOS (total) forward 5′TCCAGTGCCAACTTCATTCCCA
FOS (total) reverse 5′TGTCATGGTCTTCACAACGCCA
DUSP5 (spliced and unspliced) forward 5′AATGTCAGCTA-
CAGGCCAGCTT
DUSP5 (spliced) reverse 5′AACTCGCACTTGGATGCAT-
GGT
DUSP5 (unspliced) reverse 5′AGCCCAGAATACCACTCA-
GGAT
DUSP5 (total) forward 5′ATCCTGAGTGTTGCGTGGA-
TGT
DUSP5 (total) reverse 5′AGCTGGCCTGTAGCTGACATTT
E2F1 (spliced and unspliced) forward 5′AGCTGGACCAC-
CTGATGAAT
E2F1 (spliced) reverse 5′TGCAATGCTACGAAGGTCC-
TGA
E2F1 (unspliced) reverse 5′AATCCAAGCCTCTCTAGTC-
CCA
E2F1 (total) forward 5′TTGACCCAGGACCTCCGACAG
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Fig. S1. Gels used to identify candidate nuclear GzmA substrates. K562 nuclei were treated with 1 μM GzmA or buffer for 30 min at 37 °C, and nuclear
proteins were resolved using 2D gel electrophoresis and visualized by silver staining. GzmA nuclear activity was veriﬁed by assessing cleavage of known GzmA
nuclear substrates, PARP-1, and lamin A/C, by immunoblot. Ku80, which is unaffected by GzmA, was used as a loading control. Most spots are unchanged by
GzmA treatment. Spots that changed in intensity at least 10-fold after GzmA treatment were grouped into 42 spots that migrated with similar apparent
molecular weight that were analyzed by mass spectrometry.
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Fig. S2. GzmA cleaves multiple hnRNP proteins. (A) hnRNP complexes immunopuriﬁed from HeLa nuclei using anti-hnRNP C1/C2 monoclonal antibody or IgG
control were mock treated or treated with 0.5 μM GzmA for 15 min at 37 °C, and protein degradation was monitored by immunoblot (Upper) or silver stain
(Lower). The presumed identity of hnRNP species, Ig heavy chain, and GzmA are denoted with asterisks. m, immunoprecipitations performed without adding
(“minus”) nuclear lysates. Most hnRNP protein is degraded under these conditions. (B) K562 cells were treated with PFN and/or GzmA or GzmB at the indicated
dose and time in the presence of zVAD-fmk to inhibit caspase activation. hnRNP A1 cleavage was assessed by immunoblot. Control samples were treated with
buffer, PFN only, or GzmA only for 1 h. Caspase inhibition does not affect GzmA cleavage of hnRNP A1 but largely abrogates the effect of GzmB shown in Fig.
2C. SET is a known GzmA substrate (1); β-actin served as loading control. (C) (Left) 721.221B cells, transfected to express HA-tagged WT (Upper) or triple-mutant
(Lower) hnRNP A1, were left untreated or treated with zVAD-fmk and coincubated with NK-92 cells at an effector cell:target cell (E:T) ratio of 5:1 for 1–4 h.
hnRNP A1 cleavage was monitored by HA-immunoblot. HLA-DR served as a loading control. A representative blot is shown. (Right) Quantiﬁcation by den-
sitometry (mean± SEM, normalized to HLA-DR and then relative to untreated cells) of three independent experiments. Statistical differences between WT and
mutant hnRNP A1-expressing cells were calculated using Student’s t test (*P < 0.05). In this experiment, which used an E:T ratio of 5:1, hnRNP A1 cleavage in the
target cell was assessed by HA-tag immunoblot of exogenously expressed HA-tagged hnRNP A1. HA-tagged hnRNP A1 became undetectable within 2 h of
natural killer cell incubation unless zVAD-fmk was added to inhibit caspase activation. HA-hnRNP A1 levels declined signiﬁcantly even in the presence of
caspase inhibition, suggesting that both caspase-dependent and -independent cleavage of hnRNP A1 occurred.
1. Beresford PJ, Kam CM, Powers JC, Lieberman J (1997) Recombinant human granzyme A binds to two putative HLA-associated proteins and cleaves one of them. Proc Natl Acad Sci USA
94:9285–9290.
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Fig. S3. Multiple hnRNPs are degraded during caspase-mediated apoptosis. Jurkat cells were treated with Fas antibody (A) or doxorubicin (B) for the indicated
time in the absence or presence of zVAD-fmk. (C) HeLa cells were treated with staurosporine (STS) for the time indicated. hnRNP degradation was monitored
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Fig. S4. Newly synthesized RNA that is spliced is exported from the nucleus efﬁciently during Gzm-mediated cell death. HeLa cells were left untreated or
treated with PFN and/or 0.5 μM GzmA or GzmB for 1 h before RNA isolation from fractionated nuclei and cytoplasm. PCR primers were chosen to amplify
unspliced, spliced, or total RNA. qRT-PCR results ﬁrst were normalized to GAPDH, and then the ratios were normalized to their value in untreated cells. The
ratio of cytoplasmic:nuclear spliced RNA is shown. The data shown are mean ± SD from four independent experiments. There was no signiﬁcant difference in
nuclear export of spliced RNA after Gzm treatment.
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Fig. S5. GzmA cleaves hnRNP A1 after R196, R232, and R284, resulting in mislocalization to the cytoplasm. (A) Recombinant puriﬁed GST-hnRNP A1 (GST was
added to the N terminus) was treated with 0.4 μM GzmA or S-AGzmA for 30 min at 37 °C and examined by Coomassie blue staining. Three N-terminal cleavage
products (black asterisks) appear within 10 min. Yellow asterisk indicates full-length GST-hnRNP A1; red asterisk indicates a contaminating band. Peptide
sequencing of these N-terminal fragments after in-gel chymotrypsin digestion identiﬁed cleavage after R196, R232, and R284. Single-point mutants (R196A,
R232A, or R284A) and a triple-point mutant (R196/232/284A) of GST-hnRNP A1 also were treated with GzmA or S-AGzmA. The triple mutant was resistant to
GzmA. (B) Domain structure of hnRNP A1 indicating GzmA cleavage sites. M9, nuclear localization signal; RGG, Arg-Gly-Gly–rich region; RRM, RNA recognition
motif. (C) (Left) HeLa cells transfected with WT (panels 1–3) or uncleavable mutant (panels 4–6) of HA-hnRNP A1 were treated with buffer, PFN, and/or 1 μM
GzmA for 1 h and stained for HA (green) and DAPI (blue). (Scale bars, 10 μm.) (Right) Quantitative analysis of proportion of cells without detectable cytoplasmic
HA-hnRNP A1. Data shown are mean ± SD for three independent experiments. (D) Immunoﬂuorescence localization of endogenous hnRNP A1 after staur-
osporine treatment. Untransfected HeLa cells were treated with 1 μM staurosporine for the indicated time and stained for hnRNP A1 (green) and DAPI (blue).
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Table S1. GzmA candidate nuclear substrates identiﬁed by 2D differential proteomics
Name Other names MW pI Spot Spot MW/pI Peptides % coverage
AURKB Aurora/IPL1-related kinase 2 39.3 9.4 11 37.8/9 9 24.1
DCJ11 DNAJ homolog subfamily c member 11 63.3 8.5 25 69.2/7.5 3 6.4
DDX17 p72 72.4 8.8 23 68.7/8 10 13.2
DDX21 GU 87.3 9.3 29 72.5/7 3 3.8
DDX41 69.8 6.8 33 81/6 5 9.5
DDX5 p68 69.1 9.1 27 73.1/8 23 37
DNL3 DNA ligase 3, LIG3 102.7 9.0 40 97/8 4 4.4
ELAV1 HuR 36.1 9.2 6 28.5/9 11 31.3
FIP1 Pre-mRNA 3′-end-processing factor FIP1 66.5 5.4 37 80.7/3.5 3 6.7
FUS 53.4 9.4 23 68.7/8 5 8.6
HNRCL hnRNP C-like 1 32.1 4.9 15 38.9/4.2 11 25.9
HNRPC hnRNP C1/C2 33.7 5.0 16 41.1/4.2 8 27.1
HNRPD hnRNP D0/hnRNP D 38.4 7.6 17 45.4/6 3 9
HNRPG hnRNP G 42.3 10.1 18 44/8.5 8 19.9
HNRPL hnRNP L 60.2 6.7 29 72.5/7 8 17.9
HNRPM hnRNP M 77.4 8.9 31 77.7/6.2 39 36.9
HNRPQ hnRNP Q 69.6 8.6 33 81/6 3 4.5
HNRPU hnRNP U 90.5 6.0 41 104/9.5 7 12.6
HS71L HSP70 like protein 1 70.4 6.0 35 74/4.8 3 5.1
IMB1 Importin beta-1 subunit (Importin 90) 97.2 4.7 38 82/3.5 4 7.5
LMNA Lamin A/C 74.1 6.6 33 81/6 47 57.8
LMNB1 Lamin B1 66.4 5.2 35 74/4.8 67 66
LMNB2 Lamin B2 67.7 5.4 35 74/4.8 7 12.7
NKRF NFκB-repressing factor 77.7 8.9 40 97/8 5 7
NOLC1 Nucleolar phosphoprotein p130, NOPP140 73.7 9.5 42 115/7 7 10
NONO p54nrb 54.2 9.0 22 60/8 10 23.8
NPM Nucleophosmin 32.6 4.6 13 33.2/5.5 6 24.5
NUCL Nucleolin 76.5 4.6 31 77.7/6.2 3 4.7
NUP37 Nucleoporin NUP37 36.7 5.6 13 33.2/5.5 3 11
NUPL2 Nucleoporin-like 2, NLP-1, HCG1 44.9 9.3 18 44/8.5 4 11.1
PHB2 Prohibitin-2 33.3 9.8 7 30/8 10 33.1
PININ 81.5 6.8 42 115/7 5 6.1
ROA1 hnRNP A1 38.7 9.3 6 28.5/9 13 36.9
ROA2 hnRNP A2/B1 37.4 9.0 7 30/8 22 54.5
ROA3 hnRNP A3 40 9.1 11 37.8/9 9 21.4
ROA0 hnRNP A0 30.8 9.3 8 31.7/8 3 16.7
SF3B4 Splicing factor 3b subunit 4 44.4 8.6 19 48.2/8.2 3 12.7
SFPQ H-splicing factor, PSF 76.1 9.5 40 97/8 17 17.3
SFRS1 SF2, ASF-1 27.6 10.4 5 23.7/8 5 20.2
THOC1 THO complex subunit 1, THO1 75.7 4.9 39 88.5/4 5 9.1
U5S1 116 kDa U5 small nuclear ribonucleoprotein
component
109.5 4.8 39 88.5/4 3 3.4
UTP18 U3 small nucleolar RNA-associated
protein 18
62 8.9 29 72.5/7 6 13.8
WDR18 WD repeat protein 18 47.4 6.2 17 45.4/6 8 21.8
ZN326 Zinc ﬁnger protein 326 65.7 5.1 34 80.7/5.2 6 11.2
The calculated molecular weight (MW) and isoelectric point (pI) are compared with their values from the GzmA-untreated 2D gel
(Fig. S1). The number of peptides identiﬁed by mass spectrometry and their coverage of the protein are given. Hits were required to
have at least three peptides, to be localized to the nucleus, and to be predicted to migrate roughly like the spot from which they were
retrieved. MW, molecular weight.
Dataset S1. Summary of mass spectrometry results
Dataset S1
All proteins recovered by at least three peptides are shown.
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Abstract
A simple biochemical method to isolate mRNAs pulled down with a transfected, biotinylated microRNA was used to identify
direct target genes of miR-34a, a tumor suppressor gene. The method reidentified most of the known miR-34a regulated
genes expressed in K562 and HCT116 cancer cell lines. Transcripts for 982 genes were enriched in the pull-down with miR-
34a in both cell lines. Despite this large number, validation experiments suggested that ,90% of the genes identified in
both cell lines can be directly regulated by miR-34a. Thus miR-34a is capable of regulating hundreds of genes. The
transcripts pulled down with miR-34a were highly enriched for their roles in growth factor signaling and cell cycle
progression. These genes form a dense network of interacting gene products that regulate multiple signal transduction
pathways that orchestrate the proliferative response to external growth stimuli. Multiple candidate miR-34a–regulated
genes participate in RAS-RAF-MAPK signaling. Ectopic miR-34a expression reduced basal ERK and AKT phosphorylation and
enhanced sensitivity to serum growth factor withdrawal, while cells genetically deficient in miR-34a were less sensitive.
Fourteen new direct targets of miR-34a were experimentally validated, including genes that participate in growth factor
signaling (ARAF and PIK3R2) as well as genes that regulate cell cycle progression at various phases of the cell cycle (cyclins
D3 and G2, MCM2 and MCM5, PLK1 and SMAD4). Thus miR-34a tempers the proliferative and pro-survival effect of growth
factor stimulation by interfering with growth factor signal transduction and downstream pathways required for cell division.
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Introduction
microRNAs (miRNAs) that promote cell differentiation, inhibit
cell proliferation, or enhance DNA damage or stress-induced cell
cycle arrest or death, and whose expression is reduced in some
cancers, are candidate tumor suppressor genes [1]. One of the most
well studied tumor suppressor miRNAs is miR-34a. Depending on
cellular context [2], ectopic over-expression of miR-34a induces cell
cycle arrest [3], senescence [4] or apoptosis [5]. miR-34a is up-
regulated by p53 in response to DNA damage [6–8], but can also be
transcriptionally activated independently of p53 [9,10]. miR-34a is
located on chromosome 1p36, a locus deleted in neuroblastoma,
breast, thyroid, and cervical cancer [11,12]. In other cancers, miR-
34a expression is epigenetically reduced by hypermethylation [13].
miR-34a administration can inhibit tumor outgrowth in mice [4].
Thus miR-34a satisfies the criteria for a tumor suppressor gene.
The best way to understand the function of a miRNA is to
identify the genes it regulates. In this study we sought to
understand how miR-34a acts as a tumor suppressor by identifying
its direct target genes. However, target gene identification is not
straightforward because of the partial complementarity of the
short ,22 nt miRNA sequence with the miRNA recognition
element (MRE) of the target gene [14]. MRE pairing to the
miRNA seed region (nt 2–7) contributes significantly to target gene
recognition and is the basis for the most successful target gene
prediction algorithms [15,16]. However, a perfect seed match is
not necessary [17,18] and does not guarantee targeting [19].
miRNA target prediction algorithms typically predict hundreds to
thousands of putative miRNA target genes, but most predicted
target genes are not bona fide targets and the best algorithms
sometimes miss key targets [17,19–21]. It is unclear how many
target genes are in fact regulated by a given miRNA in any
physiological context. Analysis of genes whose mRNA or protein
expression decreases when a miRNA is overexpressed or increases
when it is antagonized identifies genes that may be either direct
targets or indirectly regulated [22]. Biochemical methods to
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capture RNA-induced silencing complex (RISC)-bound mRNAs
potentially provide a more direct way to identify miRNA-
regulated target genes [23–25]. However, immunoprecipitation
has mostly been used to define the general features of miRNA-
regulated mRNAs and their MREs, rather than to identify the
targets of a particular miRNA.
Already 36 putative miR-34a targets have been validated by
luciferase reporter assays. These targets strongly support miR-
34a’s role as a tumor suppressor. They include genes that promote
cell cycle progression through the G1/S transition (CCND1,
CCNE2, CDK4, CDK6, MYC, MYCN and E2F3) [3,8,10,12,26],
enhance transcription (MYB, HNF4A and FOXP1) [9,27,28] or
growth factor signaling (MET, MEK1, AXL and RRAS) [8,29–32],
inhibit apoptosis (BCL2) [33] or p53 activity (YY1, MTA2, SIRT1
and MAGE-A) [5,32,34,35], and promote stem cell survival
(NOTCH1, NOTCH2, LEF1 WNT1, DLL1, JAG1 and CD44)
[32,36–40]. The diversity of direct miR-34a targets suggests that
miR-34a acts pleiotropically by regulating many genes.
To identify additional direct target genes of miR-34a without
bias and understand better how miR-34a functions, we optimized
a simple biochemical method to isolate mRNAs that bind to
transfected biotinylated (Bi-)miR-34a [41,42]. mRNAs significant-
ly enriched in the Bi-miRNA pull-down with streptavidin relative
to their cellular expression were candidate targets. The pull-down
was performed in two unrelated cancer cell lines, K562
erythroleukemia cells and HCT116 colon carcinoma cells. p53
activates transcription of miR-34a [8]. Under basal conditions,
p53-sufficient HCT116 cells highly express miR-34a, while p53-
null K562 cells do not express it above background (data not
shown). We selected disparate cell lines to identify genes that may
be regulated in multiple cell types or more specifically in a
particular context. Several thousand genes were significantly
enriched in the miR-34a pull-down in each cell line and 982
were significantly enriched in both cell lines. Most known miR-34a
target mRNAs expressed in these cells were pulled down with
miR-34a. Despite the large number of genes significantly enriched
in the miR-34a pull-down, 91% of a random list of 11 genes
enriched in both cell lines contained miR-34a-regulated 39UTR
sequences. These results suggest that the pull-down is quite specific
and that miR-34a potentially directly regulates hundreds of
genes. Bioinformatic analysis of the pulled down genes or of
genes down-regulated after miR-34a transfection suggested that
miR-34a regulates a dense network of genes that transduce
proliferative signals arising from growth factor stimulation.
Multiple candidate target genes participate in RAS-RAF-MAPK
signaling. In fact miR-34a knockout reduced sensitivity to growth
factor withdrawal by serum starvation, while miR-34a transfection
led to increased vulnerability. Fourteen novel miR-34a targets
identified by the pull-down in both cell lines were experimentally
verified, including ARAF and PIK3R2 in the RAS-RAF-MAPK
pathway, and additional target genes required for cell cycle
progression, including cyclins D3 and G2, MAD2L2, MCM2,
MCM5 and PLK1.
Results
Isolation of mRNAs bound to a transfected
biotinylated–miRNA
We modified a method [5] for capturing miRNA-mRNA
complexes using streptavidin-coated beads from cells transfected
with miR-34a biotinylated at the 39-end of the mature strand.
Control samples were transfected with a biotinylated C. elegans
miRNA (Bi-cel-miR-67) (Figure 1A). Biotinylation did not
interfere with miRNA-mediated gene suppression as measured
by luciferase reporter assay (Figure 1B). Over-expressing Bi-miR-
34a or miR-34a in K562 cells also similarly suppressed expression
of known miR-34a target genes (Figure 1C). Moreover, immuno-
precipitation of HA-tagged Ago1 or Ago2 in K562 cells
cotransfected with Bi-miR-34a specifically enriched for miR-34a
by ,4-fold and ,6-fold, respectively (Figure 1D). Thus the Bi-
miRNA is incorporated into the RISC and functions like the
unbiotinylated miRNA.
We next optimized conditions to capture known target gene
mRNAs. In the Bi-miR-34a pull-down of K562 cells, known miR-
34a target transcripts CDK4 and CDK6, but not UBC (a
housekeeping gene), were enriched 12 hr after transfection, and
their capture plateaued at 24–48 hr (Figure 1E). Therefore, 24 hr
was chosen for subsequent experiments. The specificity of the pull-
down and applicability to other cell types was verified since CDK4,
CDK6 and MYB mRNAs were consistently enriched by transfec-
tion of Bi-miR-34a, but not Bi-cel-miR-67, in K562 (Figure 1F)
and HCT116 (Figure S1A) cells. Streptavidin beads did not enrich
for non-target SDHA and UBC mRNAs, and the specific target
mRNAs were not pulled down in cells transfected with
unbiotinylated miR-34a (data not shown). miR-34a was specifi-
cally enriched .40-fold in the Bi-miR-34a pull-down compared to
the input lysate (Figure S1B). Modifications of the pull-down to
include formaldehyde cross-linking and/or pre-isolation of RNAs
in high molecular weight cellular fractions reduced the amount of
captured RNA, but did not improve the relative enrichment for
known target gene mRNAs (data not shown). To confirm that
association of Bi-miRNAs with target mRNAs was not a post-lysis
artifact, we performed streptavidin pull-downs after adding Bi-
miR-34a or Bi-cel-miR-67 to cytoplasmic extracts of untransfected
K562 cells. CDK4, CDK6 and MYB mRNAs were not enriched
when Bi-miR-34a was added post-lysis (Figure S1C). The general
applicability of the pull-downs to enrich for miRNA target genes
was also verified for another miRNA, miR-24 in HepG2 cells. Bi-
miR-24 capture enriched for 3 known miR-24 targets (H2AFX,
E2F2 and MYC [43]) by 2–5-fold (Figure 1G).
Sensitivity of the Bi-miR-34a pull-down
We next used gene expression microarrays to identify putative
miR-34a targets captured by Bi-miR-34a in duplicate experiments
from K562 (p53 deficient) and HCT116 cells (p53 proficient)
Author Summary
microRNAs (miRNAs) are small RNAs that regulate gene
expression by binding to mRNAs bearing a partially
complementary sequence. miRNAs decrease the stability
or translation of mRNA targets, leading to reduced protein
expression. Understanding the biological function of a
miRNA requires identifying its targets. Here we developed
a sensitive and specific biochemical method to identify
candidate microRNA targets that are enriched by pull-
down with a tagged, transfected microRNA mimic. The
method was applied to miR-34a, a miRNA that inhibits cell
proliferation. We found that miR-34a can potentially
regulate hundreds of genes. Computational analysis of
these genes suggested a novel function for miR-34a—
suppression of the pro-proliferative response to diverse
growth factors. This function complements the previously
known role of miR-34a in blocking cell cycle progression.
Thus, by reducing the expression of an extensive network
of genes, miR-34a dampens growth factor signaling as well
as its downstream consequences, promotion of cell
survival and proliferation.
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Figure 1. The Biotin-miRNA pulldown method. (A) Schematic of the Bi-miRNA pull-down (PD) assay. (B) Activity of 39-biotinylated miR-34a (Bi-
miR-34a) is similar to unbiotinylated miR-34a mimics by dual luciferase assay performed in HeLa cells cotransfected with psiCHECK-2 vector (black) or
psi-CHECK-2 bearing a perfectly complementary sequence to miR-34a (psiCHECK-2-AS-miR-34a, white). Transfection with cel-miR-67 is the control
(CTL). Luciferase expression was assayed after 24 hr; results are normalized to cells transfected with the luciferase vector and the CTL miRNA. (C) Bi-
miR-34a Inhibits Growth Factor Signaling
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(Table S1). mRNA abundance in the streptavidin pull-down and
input in Bi-miR-34a-transfected cells were separately normalized
to their levels in Bi-cel-miR-67-transfected cells. For each
biological replicate, the ratio of the abundance of the pull-down
mRNA compared to the input mRNA for cells transfected with Bi-
miR-34a versus Bi-cel-miR-67 was calculated, averaged and used
to define the enrichment ratio {Bi-miR-34a PD/Bi-cel-miR-67
PD}/{Bi-miR-34a input/Bi-cel-miR-67 input}. Normalizing to
the input improved identification of true targets in 2 ways – by
reducing the background caused by highly abundant mRNAs that
associate with streptavidin beads nonspecifically and by incorpo-
rating a measure of mRNA knockdown into the denominator of
the ratio.
The miR-34a pull-downs enriched for 2416 genes in HCT116
cells (by $1 standard deviation (SD), enrichment ratio $2.5) and
for 2816 genes in K562 cells ($1 SD, enrichment ratio $3.3)
(Figure 2A). The overlap of genes enriched $1 SD in both of these
unrelated cell lines was 982 genes. To determine the sensitivity of
the pull-down, we first looked at how many of the 36 published
targets of miR-34a were captured in the K562 or HCT116 pull-
downs (Figure 2B). Of the known expressed targets, 22 of 31
mRNAs (71%) were enriched in HCT116 cells and 14 of 29 (48%)
were enriched in K562 cells. It should be noted that the choice of
cut-off is somewhat arbitrary. Two additional known targets had
enrichment ratios of 2.5–3.2 in K562 cells. The enrichment ratio
ranged from 2.7–85. 12 genes were identified in both pull-downs.
The enrichment ratio for the shared hits was not significantly
different in K562 cells, which do not express miR-34a, compared
to HCT116 cells, which do, suggesting that the pull-downs
efficiently captured miR-34a targets even in cells that express
endogenous miR-34a.
Analysis of genes down-regulated by miR-34a
over-expression
To compare the mRNAs that associate with miR-34a to
mRNAs that decrease with miR-34a over-expression, we mea-
sured mRNA abundance in cells transfected with miR-34a or cel-
miR-67 by gene expression microarrays (Table S1). Genes whose
mean mRNA level ratio decreased by at least 20% after miR-34a
transfection were considered to be down-regulated either directly
or indirectly by miR-34a. With this arbitrary cut-off (,1 SD),
2087 genes were down-regulated in HCT116 cells and 945 genes
were down-regulated in K562 cells (Figure 2C). About a third of
these transcripts in both cell lines were also pulled down with Bi-
miR-34a (30% in HCT116, 36% in K562).
Down-regulated and pulled down mRNAs are enriched
for miR-34a seed sequences
Many miRNA targets contain a perfect match to the miRNA
seed region in their 39UTR. We examined the frequency of
39UTR matches to all hexamer sequences in miR-34a in the pull-
down and down-regulated gene sets relative to all genes probed on
the microarray (Figure S2A). Hexamer matches to nt 2–7 in the
miR-34a seed region were significantly enriched in the pull-down
(HCT116 p=1.8E-95; K562 p= 2.4E-11) and down-regulated
(HCT116 p= 1.7E-24; K562 p= 1.0E-11) datasets. There was also
significant enrichment in the HCT116 pull-down genes for nt 13–
19 exact matches, suggesting that base-pairing there enhances
miRNA binding, as has previously been shown [44]. In both cell
lines, seed enrichment was greater for the overlapping set of genes
that was both pulled down and down-regulated by miR-34a. For
genes in this overlap, exact matches to nt 2–7 were 1.8–2.0-fold
more frequent per kb of 39UTR than for all genes on the
microarray. These data suggest that genes in the overlap may be
more likely to be direct targets than genes identified by only one
method or that a perfect seed match might enhance miRNA-
mediated mRNA decay.
We next examined hexamer enrichment in the 982 genes
enriched$1 SD in pull-downs from both HCT116 and K562 cells
(Figure S2B). Seed matches were most enriched in the 39UTRs of
these genes, with the nt 2–7 match being the most abundant (1.7
fold more abundant than in all genes on the microarray (p = 8.4E-
39). The coding region (CDS) of these genes also contained a
highly significant enrichment for hexamer seed matches (p = 6.1E-
13). These results are consistent with recent cross-linked RISC
pull-downs that suggest that 25–50% of MREs may be in the CDS
[23,25]. There was also a modest enrichment of hexamers
matching the seed in the 59UTR (p= 0.005). Thus the pull-down
and down-regulated mRNAs were enriched for expected miRNA
target sequence features.
We next analyzed whether mRNA expression of the enriched
genes was reduced by miR-34a transfection in HCT116 cells
(Figure 2D). The mRNAs of the 982 genes enriched in the miR-
34a pull-down by $1 SD in both cell lines were significantly
down-regulated after miR-34a transfection compared to the set of
all genes expressed in the cell (p = 4.7E-80). The extent of down-
regulation was comparable to the set of 469 TargetScan-predicted,
evolutionarily conserved targets of miR-34a and significantly
greater than in the larger list of 2904 poorly conserved,
TargetScan-predicted genes (p = 1.6E-20). Increasing the cutoff
for the enrichment ratio in the pull-down led to a greater
proportion of highly down-regulated genes, indicating that a
higher enrichment ratio correlates with more effective mRNA
degradation and/or that highly enriched mRNAs are more likely
to be miR-34a targets. Thus, the Bi-miR-34a pull-down enriches
for known sequence and gene expression characteristics of bona fide
miRNA targets.
Genes enriched in the miR-34a pull-down of both cell
lines have a high probability of being direct miR-34a
targets
To determine the specificity of the pull-down, we generated a
random list (Table S2) of 11 genes enriched.2.5 fold in both pull-
downs (median enrichment 3.5-fold, range 2.5–17.3). The random
miR-34a efficiently silences known miR-34a targets CDK4, CDK6 and MYB. K562 cells were transfected with CTL miRNA, miR-34a, Bi-CTL or Bi-miR-34a
mimics for 48 hr. Expression was measured by qRT-PCR normalized to GAPDH. The housekeeping genes SDHA and UBC are negative controls. (D)
Cytoplasmic lysates from K562 cells were prepared 48 hr after cotransfection with Bi-CTL (black) miRNA or Bi-miR-34a (white) and a plasmid encoding
HA-Ago1, HA-Ago2, or empty vector. Enrichment of miR-34a by HA immunoprecipitation was measured by qRT-PCR normalized to U6. Enrichment of
Bi-miR-34a in the HA-immunoprecipitates suggests that Bi-miR-34a is incorporated into RISC. (E) Bi-miR-34a pull-downs optimally enrich targets 24 or
48 hr after transfection. K562 cells were transfected in duplicate with Bi-CTL (black) or Bi-miR-34a (white) mimics for the indicated times. Enrichment
of known miR-34a targets (CDK4 and CDK6) or control genes (GAPDH and UBC) was assessed by qRT-PCR relative to GAPDH. (F) The streptavidin pull-
down enriches for miR-34a target genes in K562 cells transfected with Bi-CTL (black) or Bi-miR-34a (white) mimics. (G) Known miR-24 target mRNAs
(H2AX, E2F2 and MYC) are also pulled down with Bi-miR-24 in HepG2 cells reverse transfected 48 hr earlier with Bi-CTL (black) or Bi-miR-24 (white).
Enrichment of target mRNAs in (F) and (G) was analyzed by qRT-PCR relative to SDHA. In all panels, data represent mean 6 SD of 3 independent
experiments. *, p,0.05, #, p,0.01, **, p,0.005, ##, p,0.001.
doi:10.1371/journal.pgen.1002363.g001
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list contained 3 known target genes (AXL, CDK4 and FOXP1; AXL
and FOXP1 were not known when the list was generated). First,
qRT-PCR analysis verified that the random gene mRNAs are
pulled down by Bi-miR-34a and not Bi-cel-miR-67. All 11
mRNAs were enriched (,4–10 fold) by Bi-miR-34a pull-down in
K562 cells, validating the microarray results (Figure 2E). miR-34a
over-expression significantly down-regulated mRNA levels of 9 of
11 genes by 25–90% (Figure 2F). PCYOX1L expression declined by
20%, but the change was not significant. To test whether the
39UTR of each gene could be regulated by miR-34a, the full 39
UTR of each gene was cloned into a dual luciferase reporter
plasmid. miR-34a repressed the 39UTRs of 10 of 11 genes by
,20–80% (Figure 2G). Thus, miR-34a could regulate the 39UTR
of 91% of a random set of genes enriched in both miR-34a pull-
downs. These results suggest that the Bi-miRNA pull-down is
highly specific for identifying direct miRNA targets. An important
implication of the large number of genes in the overlapping target
list and the low false positive rate is that miR-34a is capable of
regulating hundreds of genes.
miR-34a directly regulates growth factor signaling and
cell cycle progression
To understand miR-34a’s biological functions, we analyzed the
cellular pathways whose genes were most enriched in the Bi-miR-
34a pull-downs (Figure 3A). In both K562 and HCT116 cells, Bi-
miR-34a pull-downs enriched for genes in pathways related to
growth factor signaling and cell cycle control. Bi-miR-34a pull-
downs enriched significantly for genes in the EGFR, TGF-b,
interleukin, estrogen, and androgen receptor signaling pathways
(Figure 3A). Many of these pathways utilize common downstream
signaling molecules and have a well-established link to cancer.
Genes in the MAPK pathway, activated by most growth factors,
were highly enriched in the pull-downs for both cell lines. Growth
factor signaling also activates cell proliferation. Genes involved in
cell cycle regulation, especially the G1/S transition, and the p53
response were enriched in both pull-downs, consistent with
previously described targets and roles of miR-34a [3,4,7,8].
We performed a similar pathway enrichment analysis for genes
down-regulated by miR-34a (Figure 3B), which includes both
direct and indirect miR-34a targets. The downstream effects of
growth factor signaling on cell proliferation and p53 activation
were more prominent in the down-regulated genes than in the
pulled-down gene set, especially in p53-sufficient HCT116 cells.
Cell cycle and DNA repair pathways were enriched in genes
down-regulated by miR-34a in both K562 and HCT116 cells.
These results suggest that miR-34a directly inhibits growth factor
signal transduction and cell cycle progression pathways, culmi-
nating in reduced expression of genes needed for cell proliferation.
A pathway enrichment analysis of the TargetScan-predicted
targets of miR-34a (Figure S3) also highlighted the most
significantly enriched pathways in the experimental pull-down
and down-regulated gene sets, notably TGFb and MAPK
signaling and cell cycle and G1/S transition. However, the
significance of the enrichment was weaker and the strong role of
miR-34a in growth factor signaling was less obvious.
miR-34a regulates a dense network of genes involved in
signal transduction and cell cycle progression
To begin to understand regulation of growth factor signaling
and cell proliferation at the gene level by miR-34a, an interactome
of pulled down or down-regulated genes in HCT116 cells that
participate in the significantly enriched pathways was generated
(Figure 4). miR-34a potentially regulates the expression of critical
genes involved in virtually every step and branch of growth factor
signal transduction from ligand binding to downstream growth-
promoting transcription factors. The putative direct targets
included genes encoding multiple TGFb and FGF isoforms,
receptors for EGF, FGF, and insulin, and several oncogenic
receptor tyrosine kinases, including MET and AXL. Several genes
operating proximally in signal transduction, including SRC, PLCG1
and VAV2, were selectively pulled down. miR-34a targets also
included protein kinase subunits that activate downstream
signaling, including subunits of protein kinase A and C. In the
RAS-RAF-MAPK signal transduction pathway, putative directly
regulated genes included RRAS and RASA2, ARAF and BRAF,
JAK2, and 11 MAPK genes. Although knockdown of most of the
targets would be expected to inhibit cellular activation by diverse
growth factors, the genes also encode for some important
inhibitors, including the ubiquitin ligase CBLC, RASA2, and 5
DUSP genes (MAPK phosphatases). The pull-down also captured
76 transcripts of transcription factors, including some that
orchestrate the transcriptional response to signal transduction
(including STAT3, CREB1 and CREB3, SP1, ELK1 and SMAD4).
A major downstream effect of growth factor signaling and its
activated transcription factors is to stimulate cell proliferation.
miR-34a is already known to suppress E2F3 and some key cyclins
and cyclin-dependent kinases that regulate the G1/S transition.
The miR-34a pull-down enriched for additional cyclins (CCND3,
CCNG2), but also for transcripts of genes that inhibit the kinases
that promote exit from G1 (CDKN1C that encodes p57(KIP2),
CDKN2A (p14(ARF)). Other enriched transcripts include MCM5,
whose product is required to initiate DNA replication, and several
genes required for mitosis (PLK1, MAD2L2 and CDC23). Ectopic
miR-34a expression led to down-regulation of mRNAs for many
genes needed to replicate DNA, including 2 members of the
initiating complex that assembles at origins of DNA replication, 7
Figure 2. miR-34a pulls down transcripts of known and novel direct targets of miR-34a. (A) Overlap of genes enriched $1 SD in gene
expression microarray analysis of Bi-miR-34a pull-downs from HCT116 and K562 cells. (B) Enrichment of previously described miR-34a target gene
mRNAs in Bi-miR-34a pull-downs from HCT116 and K562 cells. Genes enriched $1 SD are indicated in bold. Abs =not expressed. (C) Genes down-
regulated by $20% after miR-34a over-expression. (D) mRNA expression of candidate miR-34a targets identified by Bi-miR-34a pull-down in both
HCT116 and K562 cells decreases after miR-34a over-expression. Cumulative distribution plots compare the extent of mRNA reduction of genes
enriched to varying degrees in the Bi-miR-34a pull-down with conserved (cons) or all TargetScan (TScan)-predicted targets. Genes whose mRNAs are
more highly enriched in the pull-down are progressively more likely to have reduced expression. (E) Pull-down of 11 mRNAs randomly selected from
the set of genes enriched$2.5-fold by microarray in both HCT116 and K562 Bi-miR-34a pull-downs is confirmed by qRT-PCR relative to SDHA in K562
cells transfected for 24 hr with Bi-CTL (black) or Bi-miR-34a (white). UBC is a negative control and E2F3 is a positive control. Three previously validated
miR-34a targets (AXL, CDK4 and FOXP1) in the random list of genes are indicated in bold. (F) miR-34a over-expression significantly decreases the
expression of 9 of 11 of the randomly chosen candidate target genes. K562 cells were transfected with CTL miRNA (black) or miR-34a (white) mimics
for 72 hr. Expression of random targets was measured by qRT-PCR normalized to GAPDH. Expression of 2 randomly selected genes (ACSM3 and
PCYOX1L) and the housekeeping mRNA UBC didn’t change significantly. (G) miR-34a targets the 39UTR of 10 of 11 randomly chosen targets. Luciferase
activity was measured 48 hr after HeLa cells were cotransfected with the luciferase reporter psiCHECK2 bearing the 39UTR of each gene and CTL
miRNA or miR-34a mimics. Results obtained after miR-34a transfection were normalized to CTL miRNA. In (E–G), data represent mean 6 SD of 3
independent experiments. *, p,0.05, #, p,0.01, **, p,0.005, ##, p,0.001.
doi:10.1371/journal.pgen.1002363.g002
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components of the MCM complex, 4 DNA polymerases, and 5
components of the RFC complex, a cofactor for DNA polymerase.
These results suggest that miR-34a not only interferes with the
signaling that transduces the growth factor response, but also
directly and indirectly suppresses the expression of numerous
genes needed for cell proliferation.
miR-34a regulates cellular responses to growth factor
signaling
The Ras–extracellular signal-regulated kinase (ERK) and
phosphoinositide 3-kinase (PI3K)–AKT pathways are key trans-
ducers of the cellular response to growth factors. Since many
candidate miR-34a target gene products act in pathways converging
on ERK and AKT activation, we analyzed the effect of miR-34a
over-expression on ERK and AKT phosphorylation. miR-34a
transfection reduced basal phosphorylation of ERK and AKT in
HCT116 and HeLa cells (Figure 5A, 5B), but not in A549 cells
(Figure S4A). miR-34a over-expression both reduced basal
proliferation in the absence of serum and blunted the ability of
HCT116 (Figure 5C), HeLa (Figure 5D) and A549 (Figure S4B)
cells to proliferate in response to serum growth factors. Conversely,
immortalized mouse embryonic fibroblasts (MEFs) genetically
deficient in miR-34a were more resistant to serum starvation than
WT MEFs (Figure 5E). Apoptosis measured by annexin V and
Figure 3. Genes in the Bi-miR-34a pull-down or down-regulated by miR-34a over-expression are enriched in growth factor
signaling, cell cycle progression, and DNA repair pathways. Network of canonical pathways (Wikipathways and KEGG) significantly enriched
for genes identified by Bi-miR-34a pull-down (A) or down-regulated following miR-34a over-expression (B) in HCT116 and K562 cells. Each pathway is
represented by a node in the network. The node size increases with the number of identified genes in the pathway and the node color represents the
p-value based on the hypergeometric distribution (see key). Pathways that are not significantly enriched in an experiment are still shown, but are in
gray. The number of genes shared between two pathways is represented by an edge whose thickness increases with the number of shared genes.
The pull-down enriched pathways (A) suggest that miR-34a extensively targets growth factor, signal transduction and cell cycle control pathways.
The integrated outcome of both direct and indirect effects of miR-34a on gene expression in (B) is suppression of expression of genes participating in
downstream signaling, cell cycle and DNA repair pathways.
doi:10.1371/journal.pgen.1002363.g003
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propidium iodide staining was also significantly reduced in miR-
34a2/2 MEFs compared to wild-type MEFs after 24 hours of
serum starvation (Figure 5F). Despite the strong difference in cell
survival in cells deficient in miR-34a, expression of several known
miR-34a targets did not differ significantly between wild-type and
miR-34a2/2 MEFs (data not shown). The lack of a notable
difference may be due in part to compensatory up-regulation of
miR-34b and miR-34c in miR-34a2/2 MEFs (Figure 5G). These
data suggest that miR-34a dampens the basal state of activation of
proliferative and pro-survival pathways mediated by AKT and
ERK by down-modulating multiple genes whose products contrib-
ute to their phosphorylation.
miR-34a directly targets genes that regulate ERK and AKT
phosphorylation
To determine whether some of the candidate miR-34a target
genes identified in the pull-down that participate in growth factor
signaling are bona fide targets, we next tested miR-34a targeting of
selected receptor-proximal (AXL, MET and PIK3R2) and more
downstream (ARAF and MEK1) components of ERK and AKT
signal transduction pathways. These 5 genes were both pulled
down with Bi-miR-34a and down-regulated by miR-34a in
HCT116 cells. ARAF is a serine/threonine protein kinase that
phosphorylates and activates MEK1, which in turn phosphorylates
ERK [45]. AXL is a receptor tyrosine kinase that stimulates cell
Figure 4. Interactome of genes in the enriched canonical pathways pulled down with Bi-miR-34a and/or down-regulated by miR-
34a over-expression. Interactome of products of genes identified by Bi-miR-34a pull-down (red) or down-regulated by miR-34a over-expression
(blue) in significantly enriched pathways (Figure 3) in HCT116 cells. Edges represent physical interactions. A dense network of genes involved in
growth factor signaling and downstream effects on cell cycle progression and DNA repair is implicated.
doi:10.1371/journal.pgen.1002363.g004
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proliferation and also promotes metastasis [46,47]. PIK3R2 is a
regulatory subunit of PI3K [48] and MET is a tyrosine kinase
receptor that activates both PI3K and RAS [49]. AXL, MET and
MEK1 are described miR-34a targets [8,29,31], although AXL and
MEK1 were not known when these studies were performed.
The transcripts of all 5 genes were enriched 3–15-fold in the Bi-
miR-34a pull-down by qRT-PCR, validating the microarray
results (Figure 6A). Furthermore, over-expression of miR-34a
down-regulated both the mRNA and protein levels of all 5 genes
(Figure 6B, 6C). All but ARAF are also predicted miR-34a targets
by TargetScan. To determine whether these genes are direct miR-
34a targets, we tested the 39UTRs for 4 of the genes (ARAF, AXL,
MEK1 and MET) by luciferase assay. miR-34a reduced reporter
activity of these 39UTRs by ,40–75% (Figure 6D). Using the
PITA algorithm [50] to identify potential MREs in their 39UTRs,
we found 1 potential MRE in AXL, 2 in ARAF, 3 in MEK1, 4 in
PIK3R2 and 5 in MET (Figure S4). We tested repression of these
MREs by miR-34a using luciferase assays. All 5 genes contained at
least one miR-34a-responsive MRE (Figure 6E). Point mutations
that disrupt the MRE-miR-34a interaction restored luciferase
Figure 5. miR-34a expression suppresses cellular activation in response to serum growth factors. (A,B) miR-34a over-expression reduces
basal phosphorylation of AKT and ERK as measured by immunoblot 48 hr after transfection of HCT116 (A) and HeLa (B) cells with control (CTL) miRNA
or miR-34a mimics. Abundance of total ERK and AKT doesn’t change. (C,D) miR-34a over-expression reduces cell proliferation in the absence of serum
and suppresses the proliferative response of HCT116 (C) and HeLa (D) cells 24 hr after adding serum. (E) Total numbers of miR-34a+/+ or miR-34a2/2
MEFs after 24 hr of culture in 10% serum (10%) or 24 hr in 10% serum followed by 24 hr in 0.1% serum (0.1%). MEFs sufficient for miR-34a were more
sensitive to serum starvation. (F) miR-34a+/+ MEFs were more prone to apoptosis than miR-34a2/2 MEFs after 24 hr of culture in reduced serum. (G)
Expression of miR-34 family members in miR-34+/+ (WT) and miR-342/2 MEFs assessed by qRT-PCR. miR-34a2/2 MEFs expressed higher levels of miR-
34b and miR-34c. In C,D,F, and G, data represent mean 6 SD of 3 independent experiments. *, p,0.05, #, p,0.01, **, p,0.005, ##, p,0.001.
doi:10.1371/journal.pgen.1002363.g005
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activity, validating their regulation by miR-34a. Therefore, these 5
important genes in PI3K and MAPK signaling are all directly
regulated by miR-34a.
miR-34a pull-downs identify new miR-34a targets that
regulate cell cycle progression
Ectopic expression of miR-34a reduces expression of multiple
direct target genes whose products facilitate the G1/S transition
(CDK4, CDK6, CCND1, CCNE2 and E2F3). The pull-down
identified novel genes acting at the G1/S transition and genes
involved in DNA replication and mitosis. Two cell cycle-regulating
genes enriched in the miR-34a pull-down are in the random gene
list and were already shown (Figure 2C–2E) to be miR-34a-
regulated - CCNG2, which is most highly expressed in late S phase,
and MAD2L2, a component of the mitotic spindle assembly
checkpoint complex. To examine whether some of the other
putative targets that participate in cell cycle progression are direct
miR-34a targets, we focused on genes that were both pulled down
and down-regulated by miR-34a in HCT116 cells (Table S2).
Fourteen cell cycle-regulating genes (CDK4, CDK6, CCNE2, E2F2,
E2F3, E2F5, HDAC1, CDKN2A, MCM5, PKMYT1, PLK1, SMAD4,
MAD2L2 and CCND3) met these criteria. Four of these (CDK4,
CDK6, CCNE2 and E2F3) are known miR-34a targets. We
experimentally tested 5 of the 9 putative novel targets. These
genes were CCND3, a cyclin that binds to CDK4 or CDK6 and
regulates Rb phosphorylation; MCM5, a mini-chromosome
maintenance (MCM) protein involved in initiating DNA replica-
tion, MYT1, a serine/threonine protein kinase that phosphorylates
and inactivates CDC2, thereby negatively regulating cell cycle
progression at the G2/M transition; PLK1, a serine/threonine
protein kinase required for mitotic spindle maturation; and
SMAD4, a TGFb-activated transcription factor that induces G1
arrest and apoptosis. To determine whether these miR-34a pull-
down genes are bona fidemiR-34a target genes, we first verified that
their transcripts associate with Bi-miR-34a (Figure 7A). After miR-
34a over-expression, 3 of the 5 genes (MCM5, PLK1 and MYT1)
had reduced mRNA by at least 2-fold (Figure 7B) and all 5 had
significantly reduced protein (Figure 7C). Two other MCM genes,
MCM2 and MCM4, also demonstrated a significant miR-34a-
dependent reduction in mRNA, and their protein levels became
undetectable in miR-34a-transfected cells.
To investigate whether these 5 genes are directly regulated, we
measured changes in luciferase activity in HeLa cells after miR-
34a co-transfection with reporters containing their 39UTRs. The
39UTRs of 4 of 5 of these genes (CCND3, MCM5, PLK1 and
SMAD4) were significantly repressed 30–60% by miR-34a
(Figure 7D). The 39UTR of MYT1, which bound to Bi-miR-34a
and was down-regulated by miR-34a over-expression (Figure 7A,
7B), was not regulated by miR-34a. MYT1 expression could be
regulated by MREs outside the 39UTR or indirectly. PITA and
TargetScan were used to identify miR-34a MREs in the 39UTRs
of CCND3, SMAD4, MCM5, and PLK1 (Figure 7E, Figure S5).
CCND3 MRE1, SMAD4 MRE1 and MCM5 MRE5 were
significantly suppressed by miR-34a (Figure 7E, Figure S5). The
CCND3 and SMAD4 MREs were predicted by TargetScan, while
MCM5 MRE5 contains a miR-34a hexamer seed match.
Mutations that disrupt base pairing with miR-34a rescued
luciferase expression, further confirming that these genes are
direct miR-34a targets. Because the enrichment ratios for MCM2
and MCM4 in the pull-down (,2.3) were close to our cut-off, we
also evaluated whether MCM2 and MCM4 might be direct targets.
MCM2 is a direct target as verified by mRNA enrichment in the
pull-down, decrease in mRNA and protein following miR-34 over-
expression, miR-34a regulation of its 39UTR by luciferase activity
and MRE identification (Figure 7A–7E). However, the MCM4
39UTR was not active in luciferase assays. Collectively, these
findings suggest that miR-34a acts as a master regulator of cell
proliferation, directly suppressing many key genes that control cell
cycle progression.
Discussion
Despite improvements in bioinformatic and experimental tools,
distinguishing the direct targets of a miRNA from indirectly
regulated genes remains challenging [14]. Here we describe a
simple biochemical method to isolate candidate miRNA targets by
streptavidin pull-down of mRNAs that associate with a transfected
Bi-miRNA, and apply it to study miR-34a. Comparison of the set
of mRNAs that directly associate with the Bi-miRNA with
mRNAs down-regulated by miRNA over-expression makes it
possible to distinguish the direct and indirect effects of a miRNA.
Candidates identified by Bi-miR-34a pull-down have properties of
validated miRNA targets: they are enriched for sequences
complementary to the miR-34a seed and tend to decrease in
expression with miR-34a over-expression. Genes that both
decrease in mRNA abundance after over-expression and are
isolated by Bi-miR-34a pull-down are further enriched for seed
matches, indicating that either they are more likely true miR-34a
targets or that a perfect seed match might enhance target mRNA
degradation.
In our analysis we defined candidate direct targets using an
arbitrary enrichment ratio cut-off of 1 SD, which corresponded to
an enrichment of $2.5-fold for HCT116 cells and $3.3-fold for
K562 cells. As the enrichment ratio cut-off was increased, mRNA
suppression after ectopic miR-34a expression increased in tandem
(Figure 2D). A more stringent cut-off would reduce the already low
false positive rate, but also reduce the sensitivity to detect direct
targets (Figure 2B). With this cut-off, we identify 71% of the known
miR-34a targets expressed in HCT116 cells as ‘‘hits’’, but only
48% of the known expressed targets in K562 cells. If we had also
chosen a 2.5-fold cut-off for K562 cells, our sensitivity for picking
targets would have increased to 55%, while a 2-fold cut-off would
have increased it to 69%. Since 10 of 11 genes in the random list
of genes enriched by $2.5 fold by Bi-miR-34a pull-downs in both
cells have 39UTRs regulated directly by miR-34a by luciferase
assay, a lower cut-off for the enrichment ratio might have
increased sensitivity without an unacceptable false discovery rate.
Some bona fide target genes are only enriched in the pull-down by
,2-fold; one of the novel genes we validated by identifying its
MRE (MCM2) was only enriched by 2.3-fold in the pull-down of
both cell lines. The low false positive rate of target identification
demonstrated with the random gene list was also supported by the
high degree of experimental validation of the growth factor
signaling and cell cycle regulatory genes we chose to examine
experimentally (Table S2). In all, we provided experimental
evidence for 14 novel direct targets of miR-34a and identified 14
miR-34a MREs, of which 11 had a perfect hexamer seed match
and the 3 others had perfect matches if G:U wobbles were allowed.
Thus, the majority of genes we identified as regulated by miR-34a
contain canonical 39UTR MREs with good seed pairing. In the
setting of over-expression by transfection, protein levels of all 11
genes we analyzed by immunoblot declined substantially. The few
target genes that we tested for which we did not find miR-34a
regulation of the 39UTR might be false positives or might be direct
targets, regulated by sequences in the 59UTR or CDS. In fact we
found enrichment for hexamer seed matches in these regions in
the mRNAs pulled down with miR-34a, consistent with MRE
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Figure 6. miR-34a directly inhibits growth factor signaling and signal transduction pathways by regulating novel genes. (A) Five
genes involved in growth factor signaling or signal transduction are pulled down by Bi-miR-34a. HCT116 cells were transfected with Bi-cel-miR67 (CTL
miRNA, black) or Bi-miR-34a (white) mimics for 24 hr and mRNA capture was measured by qRT-PCR normalized to GAPDH. Five of 5 (ARAF, AXL, MEK1,
MET and PIK3R2) genes identified by microarrays, but not housekeeping mRNAs SDHA and UBC, are significantly enriched in the Bi-miR-34a pull-
down. (B) miR-34a decreases ARAF, AXL, MEK1, MET and PIK3R2 mRNAs, measured by qRT-PCR relative to GAPDH, in HCT116 cells transfected with CTL
(black) or miR-34a (white) for 48 hr. UBC is a negative control gene. Relative mRNA levels were normalized to levels in CTL miRNA-transfected cells. (C)
ARAF, AXL, MEK1, MET and PIK3R2 protein levels decline by immunoblot after miR-34a over-expression in HCT116 cells harvested 48 hrs after
transfection with CTL miRNA or miR-34a mimic. Because of the low signal for AXL, an additional experiment probed for AXL with a longer exposure is
shown at right. (D) miR-34a significantly regulates the 39UTR of ARAF, AXL, MEK1 and MET in HeLa cells co-transfected with a dual luciferase reporter
bearing the 39UTR of each gene and CTL miRNA or miR-34a for 48 hr. Insertion of a sequence fully complementary to miR-34a into the Renilla
luciferase 39UTR (AS-34a) is the positive control. Luciferase activity was normalized to results obtained with the empty vector (V). (E) Luciferase
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properties in recent cross-linking-RISC immunoprecipitation
experiments [23,25].
Known targets may not have been identified by the pull-down
for a variety of reasons. First, not all of the targets in the literature
may be correctly assigned. Second, some known targets, such as
CD44, are only modestly regulated by miR-34a [40]. The ratio
that defines a ‘‘hit’’ is arbitrary. We set a relatively high threshold
for identifying ‘‘hits’’ to maximize the specificity of the method
(especially given the large numbers of enriched mRNAs in the
pull-down), which came at the cost of sensitivity. Some known
targets, which we did not designate hits with our 1 S.D. threshold
of the enrichment ratio (which corresponded to .3.3 in K562
cells) had enrichment ratios of 2.5–3.2 in K562 cells. Other bona
fide targets may have low, but detectable expression levels, and
could have been missed due to the low sensitivity and inter-assay
variability of microarray experiments. In addition to cellular
variation in endogenous miRNA expression and RISC abun-
dance, other context-dependent biological factors, such as target
site accessibility, might vary due to the expression of RNA binding
proteins, which could influence the efficiency of miRNA target site
binding and the mechanism of targeting [51,52]. Cell-type specific
expression of other MRE-containing genes that compete for
miRNA binding could also influence the pull-down enrichment
ratio [53]. Finally, some missed targets are likely to be false
negatives.
Normalizing the pulled down mRNAs to their abundance in the
input cellular mRNA was critical to eliminate from consideration
highly abundant housekeeping mRNAs. Our pull-down method
modified a previously developed protocol [41,42], which did not
normalize the pull-down mRNAs to the input RNA. Many of the
‘‘hits’’ pulled down with Bi-miR-10a included ribosomal mRNAs,
which may represent background binding of very abundant
transcripts. Moreover, the miR-10a ‘‘hits’’ were not enriched for
mRNAs containing miR-10a 39UTR seed matches and were not
down-regulated by miR-10a over-expression. In other work to be
presented elsewhere, the pull-down method was used to identify
genome-wide targets of miR-200c and miR-21. Importantly, the
miR-200c and miR-21 pulled down mRNAs are also enriched for
known targets and for 39UTR seed sequences.
An advantage to the Bi-miRNA pull-down method described
here is its simplicity. In contrast to mRNA expression-based target
identification methods, Bi-miRNA pull-downs should identify only
direct targets, excluding genes whose expression is indirectly
modulated by changes in miRNA expression. Because the degree
of mRNA suppression mediated by miRNAs is often small relative
to changes in protein, methods that rely on changes in mRNA
expression in response to manipulation of miRNA levels will
necessarily miss some direct targets. Although the enrichment ratio
takes into account a reduction in target gene mRNA in its
denominator, the pull-down should not only identify target genes
whose mRNA levels decline, but also those that are regulated
primarily by inhibiting translation. Unlike approaches based on
Ago pull-downs, the Bi-miRNA pull-down identifies the mRNAs
directly associated with a specific miRNA, simplifying analysis of
biological processes regulated by the miRNA.
The method described here without cross-linking does not
directly identify MREs. The streptavidin pull-down method might,
however, readily be modified to include cross-linking, RNase
digestion of unbound mRNA segments and sequencing, similar to
the HITS-CLIP protocol [23,24], to capture not only direct
targets, but also identify MREs of an individual Bi-miRNA.
Isolating RNAs associated with an individual miRNA rather than
all RISC-associated RNAs in cells over-expressing the miRNA of
interest might be a more direct way to define specific target
sequences. Future bioinformatic studies of Bi-miRNA pull-down
datasets could be used to better define in an unbiased manner the
sequence features that dictate miRNA targeting, and could reveal
non-canonical modes of targeting, such as those that contain only
partial seed complementarity [17] or pairing to the central region
of the miRNA [18] or that lie outside the 39UTR. Indeed, in this
work, we enriched for mRNAs with 59UTR and CDS seed
matches, indicating that some direct miR-34a targets may be
regulated outside of their 39UTR.
Only 29% of the 2416 enriched genes in the HCT116 pull-
down had down-regulated mRNA levels by mRNA microarray
analysis after over-expressing miR-34a for one day, while 10 of 11
randomly chosen genes in the pull-down had significantly
decreased mRNA by qRT-PCR analyzed 72 hr after transfection.
Thus although miRNAs may commonly lead to mRNA
degradation, the degree of mRNA down-regulation of most genes
is slight if cells are harvested within a day of transfection. mRNA
microarrays may be too noisy to detect subtle changes in
expression, unless the analysis is performed on many replicates.
Our data also suggest that the kinetics of mRNA degradation may
be slow. The early 24 hr time point used for the assay may have
fortuitously enhanced our ability to capture miRNA-bound
transcripts before too many had been degraded. Indirect effects
of the miRNA are also likely to increase over time. The set of
genes enriched in the miR-34a pull-down of both HCT116 and
K562 cells contains 76 transcription factors or co-factors, whose
suppression would reduce many mRNAs.
One important corollary of our results is that miR-34a likely
directly regulates hundreds of genes. However, further experi-
mental work is needed to assess how many of the hundreds to
thousands of genes whose mRNAs associated with ectopic miR-
34a are actually directly regulated by endogenous miR-34a.
Possibly only a minority of potential targets is indeed directly
regulated in an individual cell at any time. Based on our analysis
(Figure 2D), the genes whose transcripts are most enriched in the
pull-down may be the most significant targets in a given context.
Additional experiments are needed to probe the functional
consequences of miR-34a regulation of the genes we identified
as targets. The directly regulated genes might vary considerably
from cell type to cell type or even in the same cell lineage
depending on differentiation state or environmental conditions.
For this study we focused on the shared targets identified in two
very different types of cells, rather than the ones that were unique
to each cell-type. The pull-down method could be used in the
future to compare miRNA target genes in different cellular
contexts. Notably, the effect of miR-34a on cell signaling differed
in the cancer cells we examined. Basal phosphorylation of AKT
and ERK was reduced by miR-34a over-expression in HCT116
and HeLa cells (Figure 5), but not in A549 cells (Figure S4).
Constitutively active RAS in A549 cells may override the effect of
miR-34a in that context. Our results suggest that a dense network
of genes that participate in common pathways, sometimes with
opposing functions, is capable of being regulated by one miRNA.
Although we observed a clear effect of genetic loss of miR-34a on
the ability to cells to survive growth factor withdrawal, we did not
see reduced expression in miR-34a2/2 compared to wild-type
reporters bearing PITA-predicted wild-type (WT) MREs from each target gene are significantly repressed in HeLa cells cotransfected with miR-34a.
Point mutations (MT) that disrupt base pairing with miR-34a rescue reporter expression. MRE sequences are provided in Figure S4.
doi:10.1371/journal.pgen.1002363.g006
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Figure 7. miR-34a pull-downs identify novel miR-34a targets involved in cell cycle progression. (A) Bi-miR-34a pull-down captures
transcripts of cell cycle genes. Enrichment of candidate mRNAs in HCT116 cells transfected with Bi-cel-miR-67 miRNA (CTL, black) or Bi-miR-34a
(white) for 24 hr was assessed by qRT-PCR analysis normalized to GAPDH. SDHA and UBC mRNAs are housekeeping genes not enriched in the pull-
downs. (B) miR-34a over-expression significantly suppresses mRNA levels of 5 of 7 cell cycle genes tested. mRNA expression was analyzed by qRT-PCR
relative to GAPDH performed on total RNA harvested from HCT116 cells transfected with CTL miRNA (black) or miR-34a (white) mimics for 48 hr. Two
candidate target genes (CCND3 and SMAD4) and the housekeeping genes SDHA and UBC are not significantly altered. (C) Protein levels of 6 of 6 cell
cycle genes examined decrease with miR-34a over-expression. HCT116 cells were transfected with CTL miRNA or miR-34a mimics for 48 hr before
immunoblot. b-Actin is a loading control. (D) miR-34a represses the 39UTR of CCND3, MCM2, MCM5, PLK1 and SMAD4, but not MCM4 and MYT1. HeLa
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cells of some of the key miR-34a target genes we identified. Since
growth factor signaling is so central to cell survival and
proliferation, the permanent loss of miR-34a expression likely
led to myriad compensatory changes. This seeming paradox
supports the conclusions of our study – namely that a single
miRNA may exert its biological effect by regulating expression of
hundreds of genes. The capacity of miR-34a to potentially regulate
so many genes that affect growth factor signaling may enable it to
exert an effect in diverse contexts.
The numbers of genes that are actually regulated by miR-34a in
any setting will likely depend on how strongly miR-34a is
expressed. In our pull-down, we greatly over-expressed miR-34a.
However, the level of over-expression throughout this study was
not greater than endogenous miR-34a expression in some
physiological settings, i.e. in K562 cells stimulated with phorbol
ester where miR-34a increases 1000-fold [9]. There may be a
target gene hierarchy – some genes regulated by low levels of miR-
34a, others regulated only by high levels.
The dense network of cell signaling genes captured in the pull-
downs suggests that an important function of miR-34a is to
regulate the proliferative and activation responses to extracellular
growth factors. Despite its function in regulating growth factor
signaling and cell proliferation, we did not find a significant
variation in miR-34a expression after serum starvation or when
cells were synchronized in different phases of the cell cycle (data
not shown). In this study we experimentally verified as direct miR-
34a targets 5 growth factor signaling genes (ARAF, AXL, MEK1,
MET and PIK3R2). miR-34a was previously shown to inhibit the
G1/S transition [3,8]. Here we identified 7 novel cell cycle-
regulating direct targets that included genes also required for DNA
replication and mitosis. The ultimate anti-proliferative effect of
miR-34a integrates both direct consequences of suppressing
expression of genes required for progression through the G1/S
transition and at other steps of the cell cycle as well as indirect anti-
proliferative effects from repressing the growth factor signaling
pathways that activate cell cycle progression. Consistent with our
genome-wide target gene analysis, miR-34a expression resets the
basal state of ERK and AKT phosphorylation in several cell lines,
rendering cells less responsive to growth factor signaling (Figure 5).
This was shown both by miR-34a overexpression as well as by
genetic deletion. miR-34a may reduce cellular sensitivity to growth
factor signaling by suppressing many genes in multiple signal
transduction pathways. miR-34a candidate targets include genes
that are universally involved in transmitting growth factor
activation signals as well as some that participate in specific
pathways. The particular signaling genes that are suppressed in a
given cell line will likely vary from cell to cell, depending on the
growth factors to which the cell responds. These types of
differences likely contribute to the incomplete overlap between
the enriched pathways captured in the two hematopoietic and
colon cancer cell lines examined here.
Materials and Methods
Cell lines
HCT116, K562, A549 and HeLa cells were from ATCC. miR-
34a+/+ and miR-34a2/2 MEFs were generated from E14.5
littermate embryos. A full description of the mice will be published
elsewhere. MEFs were transformed by infecting the cells with
retroviruses encoding H-RAS-V12 and E1A and by selection with
puromycin (1 mg/ml) and hygromycin (50 mg/ml). The plasmids
for expression of H-RAS-V12 (plasmid 9051) and E1A (plasmid
18748) were obtained from Addgene. The VSV-G pseudotyped
viruses were produced in 293T cells using the standard protocol.
MEFs, HCT116, A549 and HeLa cells were grown in DMEM
with 10% fetal bovine serum and supplemented with penicillin,
streptomycin, HEPES, L-glutamine and b-mercaptoethanol,
K562 cells were grown in RPMI containing 10% fetal bovine
serum and the same supplements.
Transfection of miRNA mimics and plasmid DNA
For most experiments, 26106 HCT116 or K562 cells were
transfected with 200 pmol hsa-miR-34a or cel-miR-67 miRNA
mimics (Dharmacon), using Amaxa nucleofection according to the
manufacturer’s protocol. Biotin was attached to the 39-end of the
active strand. HeLa and A549 cells were transfected with
Lipofectamine 2000 and miRNA mimics at a final concentration
of 50 nM (Invitrogen). To study the association of Bi-miRNAs
with HA-Ago1 or HA-Ago2, pIRESNeo (Clontech) or pIRESNeo-
HA-Ago1 or pIRESNeo-HA-Ago2 (Addgene) plasmids were co-
transfected in six-well plates (2 mg/well, 16106 cells/well) with
200 pmol Bi-miR-34a or Bi-cel-miR-67 using Amaxa as per the
manufacturer’s instructions.
RNA isolation and quantitative RT–PCR
Total RNA was isolated using Trizol reagent (Invitrogen), treated
with DNase I (Ambion) and reverse transcribed using random
hexamers and superscript III reverse transcriptase (Invitrogen).
qRT-PCR was performed in triplicate samples using SYBR Green
FastMix (Quanta) on a BioRad CFX96. mRNA levels were
normalized to housekeeping genes GAPDH, UBC or SDHA. miRNA
was quantified in triplicate using the TaqMan MicroRNA Assay
(Applied Biosystems) as per the manufacturer’s instructions and
normalized to U6. Primer sequences are listed in Table S3.
Immunoblot
Whole cell lysates from transfected K562 or HCT116 cells were
prepared using RIPA buffer. Proteins were analyzed by SDS-
PAGE, transferred to nitrocellulose membranes and probed with
the following antibodies: AXL [4566], ARAF [4432], MEK1
[9124], CDK4 [2906], MCM2 [3619], PKMYT1 [4282], PLK1
[4513], SMAD4 [9515], FOXP1 [2005], RBBP4 [4633], AKT
[9272], pAKT ser-473 [4051], ERK [4370], pERK [9107] from
Cell Signaling; MET [sc-161], MCM5 [sc-165995], E2F1 [sc-
251], E2F3 [sc-879], CHEK1 [sc-8408] from Santa Cruz;
ACSM3 [SAB1400253], MAD2L2 [SAB1400387], AGBL5
[AV53752], CCNG2 [AV03032], PSMD5 [WH0005711M1]
from Sigma; MCM4 [06-1296] from Millipore; and PI3KR
[610045], BD Biosciences. Western Blots were quantified by
densitometry.
Biotin pull-down
HCT116 or K562 cells (16106) were transfected in triplicate
with Bi-miR-34a or Bi-cel-miR-67 (Dharmacon) as described
cells were cotransfected for 48 hr with CTL miRNA or miR-34a mimics and psiCHECK-2 empty vector (V) or psiCHECK-2 containing the 39UTR of each
gene in the Renilla luciferase 39UTR. The positive control reporter contained a perfectly complementary sequence to miR-34a (AS-34a). Relative
luciferase activity in miR-34a-transfected cells is normalized to CTL miRNA-transfected cells. (E) Dual luciferase reporter plasmids bearing wild-type
(WT) MREs from CCND3, MCM2, MCM5 and SMAD4 are significantly repressed by co-transfection with miR-34a in HeLa cells. Mutation of the seed
region of each MRE (MT) rescues reporter expression. MRE sequences are provided in Figure S5. *, p,0.05, #, p,0.01, **, p,0.005, ##, p,0.001.
doi:10.1371/journal.pgen.1002363.g007
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above and then cultured in six-well plates. Twenty-four hours
later, the cells from 3 wells were pelleted at 5006g. After washing
twice with PBS, cell pellets were resuspended in 0.7 ml lysis
buffer (20 mM Tris (pH 7.5), 100 mM KCl, 5 mM MgCl2, 0.3%
NP-40, 50 U of RNase OUT (Invitrogen), complete mini-
protease inhibitor cocktail (Roche Applied Science)), and
incubated on ice for 5 min. The cytoplasmic lysate was isolated
by centrifugation at 10,0006g for 10 min. Streptavidin-coated
magnetic beads (Invitrogen) were blocked for 2 hr at 4uC in lysis
buffer containing 1 mg/ml yeast tRNA and 1 mg/ml BSA
(Ambion) and washed twice with 1 ml lysis buffer. Cytoplasmic
lysate was added to the beads and incubated for 4 h at 4uC before
the beads were washed five times with 1 ml lysis buffer. RNA
bound to the beads (pull-down RNA) or from 10% of the extract
(input RNA), was isolated using Trizol LS reagent (Invitrogen).
The level of mRNA in the Bi-miR-34a or Bi-cel-miR-67 control
pull-down was quantified by qRT-PCR or mRNA microarray.
For qRT-PCR, mRNA levels were normalized to a housekeeping
gene (GAPDH, SDHA or UBC). The enrichment ratio of the
control-normalized pull-down RNA to the control-normalized
input levels was then calculated.
Microarray analysis
Total RNA (independently in two experiments) was amplified,
labeled and hybridized to Affymetrix U133 plus 2.0 mRNA
microarrays. The quality of the RNA was assessed before
performing the microarray and the quality of the microarray data
was assessed using affyPLM and Affy software. The replicate data
sets for the 4 sets of samples (pull-down and input for miR-34a and
cel-miR-67) were compared using an unsupervised hierarchical
clustering algorithm, which verified the similarity of the duplicates.
The microarray data were normalized using RMA [7] to reduce
interarray variation. The enrichment ratio {Bi-miR-34a PD/Bi-
cel-miR-67 PD}/{Bi-miR-34a input/Bi-cel-miR-67 input} was
calculated for each probe. For genes represented by multiple
probes, the mean ratio for all the probes was calculated. Genes for
which none of the probe hybridization signals exceeded the
background were considered not expressed and were disregarded
in the analysis. For informatic analysis of the PD data, genes whose
enrichment ratio were $1 SD above background based on a log-
normal distribution were considered ‘‘hits’’.
Gene down-regulation after miR-34a over-expression
HCT116 or K562 cells were transfected in independent
duplicate experiments as above with unbiotinylated miR-34a or
cel-miR-67 (Dharmacon) and total RNA was harvested 24 hr later
and analyzed as above by gene expression microarrays. After
normalization, fold changes for each probe were calculated as the
ratio of input RNA from miR-34a-transfected cells to the ratio of
input RNA from cel-miR-67-transfected cells. Genes were
considered down-regulated if the ratio decreased by at least
20%, which corresponded to ,1 SD. To test the expression levels
of putative target sets, each gene list was plotted in a cumulative
distribution function (CDF) plot, and the Kolmogorov-Smirnov
[KS] test was used for statistical comparisons between gene sets.
Analysis of miR-34a target genes by target prediction
algorithms
To determine whether a gene was also a predicted target of
miR-34a, the presence of miR-34a binding sites was analyzed




The mature hsa-miR-34a sequence was obtained from miRBase
(http://mirbase.org/). All RefSeq human mRNA sequences were
downloaded from NCBI in July 2009 (http://ftp.ncbi.nih.gov/).
mRNAs were indexed by Entrez Gene ID; in cases where multiple
sequences matched a gene ID, the sequence with the longest
39UTR was selected. For each test gene list and miR-34a
hexamer, the miR-34a hexamer frequency (hexamer matches
per kb of sequence) was calculated. The frequency of hexamer
matches for all genes on the microarray (the background set) was
also determined. Gene IDs with no corresponding sequence in the
database were excluded from analysis. Monte Carlo simulations of
equally sized random gene sets (without replacement) were used to
generate an empirical 2-tailed p-value for each gene set/hexamer
combination. When p,1E-4, the p-value was calculated from
curve fitting relative to the random background distribution.
Pathway enrichment analysis and network visualization
For each of the lists of down-regulated and pull-down-enriched
genes, the p-value of over-representation in a suite of canonical
pathways (KEGG [56] and Wikipathways [57]) was determined
using the hypergeometric distribution. A visualization of the
relationship between the enriched pathways (p,0.001) based on
the number of overlapping genes was rendered using Cytoscape
[58]. The network of gene-gene interactions underlying these
relationships was constructed based on interactions supplied by
MetaCore (GeneGo Inc). Physical, predicted and genetic interac-
tions were used to connect the down-regulated and pull-down
enriched genes within the significant signaling, cell cycle or DNA
repair pathways. Signaling pathway genes with no connection to
any other node were removed and the network was arranged
according to predicted sub-cellular localization.
Luciferase assay
HeLa cells were cotransfected in 24 well plates using
Lipofectamine 2000 (Invitrogen) with 50 nM miR-34a mimic or
control miRNA mimic and 50 ng of psiCHECK2 (Promega)
vector containing the MRE or 39UTR of indicated genes cloned
into the multiple cloning site of Renilla luciferase. After 48 hr of
transfection (unless otherwise indicated) luciferase activities were
measured using the Dual Luciferase Assay System (Promega) and
Top count NXT microplate reader (Perkin Elmer) per manufac-
turer’s instructions. All experiments were performed at least in
triplicate. Results were normalized to those obtained in cells
transfected with an empty vector. For some experiments, a
perfectly complementary antisense sequence to the active strand of
miR-34a was inserted into the multiple cloning site for use as a
positive control. Data were normalized to Firefly luciferase and
results from 3 independent experiments were compared. Sequence
of primers used for cloning 39UTRs for miR-34a target genes are
listed in Table S4. MREs sequences were cloned into psiCHECK-
2 by annealing complementary oligomers matching each MRE
sequence (Figures S4, S5) with overhanging ends complementary
to the XhoI and NotI sites of psiCHECK-2.
Cell growth experiments
HCT116, HeLa and A549 cells were transfected as described
above. One day after transfection, cells were placed in serum-free
medium or medium containing 10% fetal calf serum. 48 hours
after the medium was changed, total cell numbers were counted.
MEFs were plated at a density of 2.56105 or 56105 cells per well
of a 6-well plate. The medium was changed to vary serum
concentration 24 hr after plating. The MEFs were harvested 24 hr
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later and counted using Trypan blue staining or stained in
PBS+0.4% BSA with annexinV-APC (Invitrogen) at a 1:30
dilution, then washed once and stained with propidium iodide
(4 mg/ml) (Sigma-Aldrich).
Supporting Information
Figure S1 (A) HCT116 cells were transfected with Bi-miR-34a
or Bi-cel-miR-67 (CTL) and after 24 hr, abundance of known
miR-34a target mRNAs (CDK4, CDK6 andMYB) was measured by
qRT-PCR analysis of pull-down RNA. CDK4, CDK6 and MYB
and not UBC (a housekeeping mRNA) were significantly enriched
in the Bi-miR-34a pull-downs (white) and not the control pull-
down (black). (B) K562 cells were transfected with Bi-miR-34a
(white) or Bi-CTL (black), and RNA isolated from the streptavidin
pull-down was analyzed by qRT-PCR for miR-34a and miR-24 (a
control miRNA) after normalization to U6. miR-34a was,50-fold
higher in miR-34a pull-down as compared to control pull-down.
miR-24 was not enriched and its levels were similar in each pull-
down. (C) Addition of Bi-miR-34a (white) or Bi-CTL (black) to
cytoplasmic extracts prepared from untransfected K562 cells does
not enrich for known miR-34a target mRNAs, suggesting that the
specific association of these mRNAs with Bi-miR-34a occurs in
live cells and not post-lysis. Data in (B) are from 3 independent
experiments and in (A) and (C) are from duplicate experiments.
(TIF)
Figure S2 Sequence characteristics of Bi-miR-34a pull-down
targets. (A) Enrichment of hexamers matching each position of the
mature miR-34a sequence in the HCT116 and K562 pull-down
(red), down-regulated genes (blue), and genes down-regulated by
miR-34a and pulled-down (yellow). Genes both enriched by Bi-
miR-34a pull-down and down-regulated by miR-34a are the most
enriched for miR-34a seed matches (B) Hexamer enrichment
analysis for genes enriched in both HCT116 and K562 Bi-miR-
34a pull-downs. Bi-miR-34a pull-down enriched for sequences
matching two miRNA regions: the seed (positions 1–8) and a
possible 39 compensatory region (positions 13–19). Bi-miR-34a
pull-down mRNAs are also enriched for CDS and 59UTR
matches to these sequences (*p#0.0001).
(TIF)
Figure S3 Pathway networks representing the significant
canonical pathways enriched for TargetScan conserved (A) and
TargetScan non-conserved (B) target predictions.
(TIF)
Figure S4 miR-34a regulation of growth factor signaling. (A)
Western blots of A549 cells transfected with miR-34a or CTL
mimics. No reproducible change in pERK or pAKT was observed
in these cells. (B) A549 cells were transfected with miR-34a or cel-
miR-67 (CTL) mimics, and placed in normal growth medium with
10% serum (+) or growth medium lacking serum (2). Cells
transfected with miR-34a did not proliferate in response to serum.
Candidate miR-34a microRNA recognition elements (MRE) in
the 39UTR of AXL, ARAF, MEK1, MET and PIK3R2 mRNAs
predicted by PITA (see Materials and Methods). Numbers in
parenthesis represent the location of the MRE in the 39UTR.
Wild-type MREs in (C) were repressed by miR-34a (see Figure 5F)
whereas MREs that were not responsive to miR-34a are shown in
(D). Point mutations that disrupt the base-pairing with miR-34a
are shown in red in the mutant MREs.
(TIF)
Figure S5 Candidate miR-34a microRNA recognition elements
(MRE) in the 39UTR of CCND3, MCM2, MCM5, PLK1 and
SMAD4 mRNAs predicted by PITA or TargetScan (see Materials
and Methods). Numbers in parenthesis represent the location of
the MRE in the 39UTR (PLK1 MRE2 spans the stop codon of
PLK1). Wild-type MREs in (A) were repressed by miR-34a (see
Figure 6E), whereas MREs that were not responsive to miR-34a
are shown in (B). Point mutations that disrupt the base-pairing
with miR-34a are shown in red in the mutant MREs.
(TIF)
Table S1 Genes enriched in Bi-miR-34a pull-downs or down-
regulated by miR-34a over-expression in HCT116 and K562 cells.
(XLS)
Table S2 Experimental validation of miR-34a target genes.
(XLS)
Table S3 Sequence of primers used for qRT-PCR.
(XLS)
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genes5,8–14. However, these algorithms typically predict hundreds to 
thousands of target genes for each miRNA, and most predicted genes 
are not bona fide targets15. Moreover, the algorithms sometimes 
fail to predict the most biologically important miRNA targets, such 
as the oncogenes KRAS and HRAS for the miRNA let-7 (ref. 16) or 
the transcription factor E2F2 and the oncogene MYC for miR-24 
(ref. 17). Recent studies provide examples of MREs located outside of 
the 3a UTR (especially in the coding sequence (CDS)) or that lack exact 
seed pairing, but compensate by downstream complementarity17–20.
Experimental methods for identifying miRNA targets identify mRNAs 
or proteins that are downregulated when a miRNA is overexpressed or 
that are upregulated when a miRNA is antagonized17,21–25, or mRNAs 
that precipitate with miRISC-associated proteins26–31. High-throughput 
sequencing of Ago-immunoprecipitated RNAs after crosslinking now 
provides a way to identify miRNA-MRE pairings32–34. These methods 
confirm that current target prediction algorithms miss many genes. Both 
prediction algorithms and experimental methods generate large lists of 
candidate miRNA targets. However, choosing the important targets from 
these long lists is daunting. Gene ontology and interactome analyses of 
candidate target gene lists can be useful tools for this task17. Here, we 
review methods for identifying biologically relevant miRNA targets.
Computational prediction of miRNA targets
Bioinformatics captures the sequence and location characteristics of MREs 
to predict miRNA targets5,14,35. Commonly used algorithms place variable 
weight on: (i) complementarity to the miRNA seed region; (ii)  evolutionary 
conservation of the MRE; (iii) free energy of the miRNA-mRNA hetero-
duplex; and (iv) mRNA sequence features  outside the target site17,36–38 
(Table 1). Early algorithms, such as TargetScan and PicTar8,9, focus on the 
seed region in miRNA targeting (Table 1). TargetScan8,10,11 requires an 
exact match to r7 bases of the seed sequence, but PicTar9 doesn’t, instead 
imposing a stringent free energy cutoff for imperfect matches. (TargetScan 
includes a special class of seed matches with a hexamer match in 
positions 2–7, plus an adenosine at position 1). Both TargetScan and 
PicTar improve their predictions by taking into account evolutionary 
conservation. TargetScan also adds a ‘context score’, which considers features 
in the surrounding mRNA, including local A-U content and location 
(near either end of the 3a UTR is preferred) and improves predictions for 
nonconserved sequences39. Messenger RNAs that have a high context 
score or multiple predicted MREs are more likely to be true targets.
The miRanda algorithm12 aligns a miRNA to the target mRNA to 
identify highly complementary sequences. Seed pairing is weighed 
more strongly than pairing elsewhere40, but seed GvU wobbles and 
mismatches (Table 1) are allowed. High-scoring targets are then  filtered 
on a secondary criterion of heteroduplex free energy ($G). Finally, 
only conserved predictions are considered. Because miRanda does not 
MicroRNAs (miRNAs) suppress gene expression by 
inhibiting translation, promoting mRNA decay or both. Each 
miRNA may regulate hundreds of genes to control the cell’s 
response to developmental and other environmental cues. 
The best way to understand the function of a miRNA is to 
identify the genes that it regulates. Target gene identification 
is challenging because miRNAs bind to their target 
mRNAs by partial complementarity over a short sequence, 
suppression of an individual target gene is often small, and 
the rules of targeting are not completely understood. Here 
we review computational and experimental approaches 
to the identification of miRNA-regulated genes. The 
examination of changes in gene expression that occur when 
miRNA expression is altered and biochemical isolation of 
miRNA-associated transcripts complement target prediction 
algorithms. Bioinformatic analysis of over-represented 
pathways and nodes in protein-DNA interactomes formed 
from experimental candidate miRNA gene target lists can 
focus attention on biologically significant target genes.
MicroRNAs regulate virtually every aspect of biology, including 
 developmental timing, differentiation, proliferation, antiviral defense 
and metabolism. MicroRNAs are ~22-nucleotide-long RNAs that are 
generated by sequential processing from longer transcripts that  contain 
a stem-loop1–4. One strand is loaded into the miRNA-induced  silencing 
complex (miRISC), which contains the proteins argonaute (Ago) and 
Tnrc6 (trinucleotide repeat–containing 6; GW182). The other strand is 
usually degraded. The mature miRNA guides the miRISC to  partially 
complementary sequences, termed miRNA recognition  elements 
(MREs), in target mRNAs to repress mRNA translation,  promote 
 transcript decay or both1,5–7. MicroRNAs probably regulate the 
 expression of most coding genes8.
Most metazoan miRNAs pair imperfectly with their cognate 
mRNAs, and it is difficult to identify their biologically important 
 targets. Bioinformatic analysis of the first known miRNA-regulated 
genes showed that pairing of miRNA nucleotides 2–8, called the seed 
region, to the 3a untranslated region (UTR) of the target mRNA is 
often  important5. Algorithms based on seed pairing and evolutionary 
 conservation became a powerful tool for identifying miRNA-regulated 
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MREs lack a perfect seed match to expressed miRNAs32,33. An increasing 
list of  validated MREs lack a canonical seed17,18,24,41. Therefore, filtering 
gene lists by requiring an exact seed match will eliminate true targets.
All bioinformatic analyses need to consider variations in the annotated 
sequence databases used to generate predictions. The same algorithm 
run on two databases (UCSC and Ensembl) generated target  predictions 
that overlapped by less than 50%46. Current  databases do not take into 
account cell type–specific mRNA isoforms. Some mRNAs are alternatively 
 polyadenylated in cellular proliferation47,  cancer48 and  differentiation49, 
generating transcripts with unique 3a UTRs. It is  important to know 
whether the expressed isoforms in a cell under study contain the predicted 
MREs. High-throughput mRNA  sequencing of  tissue-, development- or 
disease-specific gene expression50 can be  combined with miRNA profiling 
to identify candidate miRNA  targets32.
Genetic approaches to miRNA target identification
Forward genetics involves screening for mutants with interesting 
 phenotypes, whereas reverse genetics is used to  examine the  functional 
effect of manipulating a  specific gene51. The  founding miRNA lin-4 and 
its target lin-14, which were identified in  forward genetic screens for  larval 
defects in C. elegans, led to the discovery of miRNAs51–53. Other miRNAs 
and a few of their targets were  identified by screens for mutant  phenotypes 
in C. elegans and Drosophila melanogaster51. These targets were generally 
deduced from  epistatic  relationships and the  complementary phenotypes 
that sometimes occur when a miRNA and a key target are mutated51,53.
Reverse genetics has been especially useful for identifying the 
 biological function of miRNAs, and a few examples are described here. 
Conditional overexpression of each of the six miRNAs in the oncogenic 
miR-17–92 cluster pinpointed a prominent role for miR-19, which largely 
 recapitulated the oncogenic properties of the cluster, in  hematological 
cancers in vitro and in vivo54–56. Furthermore, when combined with 
 computational, expression or functional analyses, these studies all 
 identified the tumor suppressor Pten as an important target of miR-19. 
The function of the miR-143–145 cluster, which is highly expressed in 
smooth muscle cells, was elucidated by knocking it out in mice. Knockout 
mice lacked gross developmental defects,  indicating that the cluster is 
not essential for development57,58. However, smooth muscle cells from 
the knockout mice were less differentiated than those from wild-type 
 animals, and were impaired in responding to vascular injury. Targets 
of the cluster were then identified by manually  selecting  interesting 
candidate genes from computational predictions57. Combining reverse 
genetics with computational and other molecular methods is a powerful 
method for dissecting miRNA function21,27,32.
require exact seed pairing, it predicts sites such as the two let-7 sites in 
the Caenorhabditis elegans gene lin-41, which contain either a bulge or 
a GvU wobble in the seed region40,41.
Other algorithms account for target site accessibility42,43. Instead 
of considering only the $G of the miRNA-mRNA duplex12,13, these 
 algorithms estimate the free energy cost to unfold the mRNA secondary 
structure that surrounds the target site. The PITA algorithm42 combines 
this free energy cost with the $G of miRNA-target pairing to measure 
$$G. The algorithm finds seed matches (allowing a user-specified 
 number of mismatches), and calculates $$G for each match,  irrespective 
of conservation. Although designed and tested for 3a UTRs, PITA can 
predict MREs outside the 3a UTR. The algorithm mirWIP43 is based on 
sequence features of mRNAs isolated by immunoprecipitation of the 
C. elegans miRISC26. The mirWIP program scores targets on the basis 
of: (i) perfect and imperfect seed matches; (ii) site accessibility from 
predicted mRNA secondary structure; and (iii) $Gtotal, an analog of 
$$G. The sensitivity and specificity of mirWIP are high relative to those 
of other algorithms for the miRISC dataset that was used to develop it. 
However, it was not tested against other high-throughput datasets.
The rna22 algorithm differs radically from other algorithms13. It relies on 
recognition of shared miRNA sequence patterns. Briefly, the  training  dataset 
considered all known mature miRNA sequences to identify  statistically 
over-represented sequence patterns. Potential MREs were identified as 
complementary patterns. Predictions are made by ‘folding’ each known 
miRNA in silico into a heteroduplex with the  predicted target sequence 
and identifying miRNAs with the lowest $G. The rna22  algorithm does not 
consider conservation, its  predictions are not restricted to the 3a UTR, and 
the user can allow seed mismatches. This algorithm has been used to locate 
‘seedless’ and CDS MREs (Table 1). The developers of rna22 reported a low 
false-positive rate13. However, rna22 did not perform as well as seed-biased 
algorithms on high-throughput proteomic data21,22, and only some rna22-
predicted MREs were validated in low-throughput studies17,44.
Robust comparisons of prediction algorithms are lacking. However, a few 
reviews have compared predictions against a ‘benchmark’ of  experimentally 
validated or refuted miRNA targets14,45. In these  comparisons seed-based 
predictions that require stringent pairing have the highest specificity and 
sensitivity45. Proteomics studies by the  developers of TargetScan and 
PicTar suggest that their seed-based  algorithms have superior  predictive 
power15,21,22. Many experimental studies have found that miRNA 
 targets are enriched for exact miRNA seed matches. Moreover, many 
experimentally validated targets were chosen on the basis of  seed-based 
algorithms. However, recent high-throughput experimental analyses of 
Ago-bound miRNA-mRNA  pairings suggest that around 25%–45% of 
Table 1  miRNA target prediction algorithms differ in their ability to identify unconventional miRNA recognition elements (MREs)
Target prediction algorithma
MRE feature Example TargetScan PicTar miRanda PITA rna22
Perfect  
seed Ref. 36
G:U wobble  
seed Ref. 37 –
Imperfect  
seed/seedless Ref. 17 –
Outside the  
3a UTR Ref. 38 – – – + +
aThe algorithms are listed in the rough order by which they weigh perfect seed pairing and location within the 3a UTR. The algorithms that allow identification of noncanonical recognition sites 
generally are more inclusive, but have much higher false prediction rates. +, algorithm predicts targets of this class; –, algorithm does not predict targets of this class.



























NATURE STRUCTURAL & MOLECULAR BIOLOGY   VOLUME 17   NUMBER 10   OCTOBER 2010 1171
Loss of function has also been used to identify miRNA targets (Fig. 1). 
In vivo knockdown of the liver-specific miR-122 modestly  upregulated 
hundreds of mRNAs60. The most enriched 3a UTR hexamer motif of 
these genes matched the miR-122 seed and the upregulated genes were 
enriched in genes for cholesterol biosynthesis pathways. An  analysis of 
changes in gene expression after knockdown of miR-15 and -16 was 
 performed at the same time as the overexpression study described above59. 
The increase in mRNA expression after knockdown was small  compared 
to the  downregulation that occurred after ectopic  overexpression, 
 suggesting that ectopic miRNA expression might be more useful than 
miRNA  antagonism for identifying targets. However, the  relative 
 benefits of  overexpression and knockdown depend on  biological context. 
Overexpression may result in supraphysiological miRNA  levels, leading 
to artifacts. In particular, transfection of miRNA  mimics can increase 
the expression of endogenous miRNA targets,  probably because it  limits 
the  available miRISC61. Conversely,  repression of an underexpressed 
miRNA is unlikely to have a substantial effect on target genes. It can also 
be  difficult to suppress a highly expressed  endogenous miRNA.
Proteomics
Proteomic analysis can also identify miRNA targets. Stable isotope  labeling 
with amino acids in cell culture (SILAC) followed by mass spectrometry 
can assess the effect of the loss or overexpression of  miRNAs on global 
 protein expression21,22 (Fig. 1). In one study, the nuclear proteome was 
analyzed after overexpression of miR-124, miR-1 and miR-181 in HeLa 
cells21. The results support the  importance of the seed region. For miR-124 
and miR-1, the most enriched  heptanucleotide motif in the transcripts of 
the most downregulated proteins matched the miRNA seed sequence, and 
for miR-181, the second most enriched motif matched the seed. SILAC was 
also used to compare the  expression of  cytoplasmic and nuclear  proteins in 
neutrophils from wild-type and  miR-223  knockout mice. The mRNAs of 
proteins that were  overexpressed in miR-223  knockout  neutrophils were 
most highly enriched for  miR-223 seed matches. Although algorithms that 
Forward genetics can also be used to  identify 
miRNA targets without bias. In one study, 
candidate miR-19 targets were  identified by 
a genome-wide short hairpin RNA screen to 
 discover genes whose  knockdown ‘ phenocopied’ 
overexpression of miR-19 (ref. 54). The screen 
identified eight candidate miR-19–regulated 
genes, of which four were  validated. An 
 important benefit of forward genetic methods 
is that they might identify the most biologically 
meaningful targets.
Microarray analysis after miRNA 
overexpression or knockdown
Because miRNAs reduce the steady-state transcript levels of most target 
genes6,21–23, identifying mRNAs that are downregulated after ectopic 
miRNA expression or upregulated after miRNA antagonism provides 
a useful way to identify putative miRNA-regulated genes (Fig. 1). 
Although this method cannot distinguish direct from indirect targets, 
harvesting cells soon after transfection might enhance the proportion 
of direct targets24,59. This strategy can also pinpoint miRNA function 
by bioinformatic analysis of the effect of miRNA manipulation on 
global gene expression17,23,59 (Fig. 1). This approach was first used to 
 investigate changes in mRNA after overexpression of muscle-specific 
miR-1 and brain-specific miR-124 (ref. 23). Remarkably, transfection of 
miR-1 into HeLa cells shifted their gene expression profile toward that of 
muscle cells, whereas transfection of miR-124 shifted the profile toward 
that of brain cells. For miR-1, 88% of downregulated genes contained a 
3a UTR hexamer seed match, and 76% of genes that were downregulated 
by miR-124 had a similar match. CDS seed matches were also somewhat 
enriched. When miR-124 with mutations in seed region bases 5 and 6 
was transfected into cells, the downregulated genes no longer overlapped 
with genes downregulated by wild-type miR-124. However, when bases 
9 and 10 were altered, 89% of downregulated genes overlapped. Recently, 
similar transcriptome analysis identified a class of functional ‘seedless’ 
targets that pair with 11 central bases of the miRNA18.
Overexpression of miRNAs has also been used to study the  biological 
effects and targets of cancer-related miRNAs. Overexpression of let-7 
decreased the proliferation of liver and lung cancer cells, and more than 
200 transcripts were downregulated in both cell types24. Gene ontology 
analysis of the downregulated genes indicated that they were enriched in 
genes for DNA replication and cell cycle pathways. Similarly,  transfection of 
miR-15a and miR-16 into colon cancer cell lines increased the  proportion 
of cells in cell cycle phase G0/G1 and genes that were downregulated were 
enriched in cell cycle–related genes59. Paradoxically, these downregulated 
cell cycle genes were not enriched in miR-15a or miR-16 seed matches, 
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Figure 1  Methods for identifying miRNA 
targets. Putative target genes can be identified 
by expression profiling of cells in which the 
miRNA is overexpressed or antagonized, by 
biochemical isolation of the miRISC or by target 
prediction algorithms. These methods generally 
identify hundreds of candidate genes or more. 
Bioinformatic analysis of these large candidate 
gene lists for over-represented Gene Ontology 
(GO) terms, enriched biological pathways 
or gene interaction networks can then help 
researchers to select candidate genes to evaluate 
experimentally.
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that immunoprecipitated with endogenous Ago1 and Ago2 (ref. 31). Five 
out of six randomly chosen genes that were sequenced more than once 
were experimentally validated as miRNA targets. However, most of the 
clones were recovered only once, suggesting that the depth of sequencing 
may have been a limiting factor.
The biochemical approach to target identification has mostly been 
used to describe the general features of MREs, rather than to  identify 
specific  targets. Pulldown of Ago-associated mRNAs  usually enriches 
transcripts containing seed matches. Experimental  validation of putative 
miRNA  targets  identified by  immunoprecipitation is high, supporting the 
 usefulness of the method29,30. Immunoprecipitation studies have  identified 
targets whose mRNAs do not decrease after  overexpression of miRNAs29 
as well as unanticipated CDS MREs27,30. However, some  questions remain 
about the utility of Ago  immunoprecipitation for  identifying miRNA 
targets. The miRNAs and mRNAs that are pulled down with Ago1 or 
Ago2 might not be  identical to those found in miRISCs that contain other 
Agos64. Moreover, epitope-tagged Ago has some  drawbacks. Epitope-
tagged Ago proteins can associate with transfer RNAs65,  potentially 
introducing experimental artifacts27. Overexpression of Ago globally 
increases endogenous miRNA  production66,67, which could skew the 
profile of endogenous miRNA-mRNA interactions. As Ago proteins in 
cell extracts can associate with cognate mRNAs after lysis29 some Ago-
immunoprecipitated mRNAs might not be true targets. Finally, the Ago 
pulldowns have the limitation that they identify mRNAs rather than 
 specific MREs and are usually not specific for an individual miRNA.
Pulldowns using miRISC components enrich for all miRNA targets, 
but don’t directly identify mRNAs associated with a specific miRNA. 
To circumvent this problem, a recent study sought to identify mRNAs 
directly bound to transfected biotinylated miR-10a (refs. 68,69). 
However, the results are controversial because the pulled down mRNAs 
were not enriched for known targets or for miR-10a seed matches. 
Moreover, they were mostly abundant ribosomal mRNAs, suggesting 
they might have associated with biotinylated miR-10a nonspecifically. 
Most identified genes were translationally upregulated, rather than being 
 downregulated, by miR-10a. The authors attributed this unexpected 
result to the  presence of weak miR-10a binding sites in the 5a UTR.
Identifying miRISC-bound MREs
An important recent development, called Ago HITS-CLIP (high 
 throughput sequencing by crosslinking and  immunoprecipitation), 
directly  identifies miRNA-bound MREs32–34. Nucleic acids are  crosslinked 
by  ultraviolet radiation to miRISC proteins and then  immunoprecipitated 
with an antibody to a miRISC component. Unbound RNA is digested 
to leave miRISC-protected RNA fragments, which are then analyzed 
by high-throughput RNA sequencing to identify both Ago-associated 
 miRNAs and their target MREs. In the first study, protected transcript 
fragments associated with native Ago complexes in mouse brain or 
HeLa cells were most enriched for motifs that matched the seeds of the 
most abundant miRNAs. Fragments of mRNAs were also enriched for 
sequences just after the stop codon or before the polyadenylation site, 
consistent with studies indicating that MREs in the middle of 3a UTRs 
contribute less to  silencing than those at the ends39. Both the false- positive 
and false- negative rates of the MRE predictions were low in this study. 
Notably, detection of  previously validated miRNA targets  correlated with 
their expression; highly expressed targets were more readily identified. 
Of the enriched sequences, 25% mapped to the CDS and 27% lacked 
a  perfect seed match to the 20 most highly expressed miRNAs. These 
results  support recent findings that miRNAs regulate many genes by 
‘seedless’ or CDS  interactions17,18,20,38,41,70,71.
A HITS-CLIP study in C. elegans32 also found enrichment for 3a UTR 
seed matches to isolated miRNAs. However, 37% of sequences lacked 
require stringent seed  pairing had the greatest power to predict changes 
in  protein levels, only 33% of the  targets predicted by such algorithms 
showed a change in  protein  expression, suggesting that the  algorithms 
have a high false-positive rate21.
SILAC was also used to analyze the proteome of HeLa cells that 
 overexpressed one of five different miRNAs22. The 3a UTR hexamer 
motifs that most correlated with changes in protein expression were 
complementary to the miRNA seed for each miRNA. To assess whether 
depletion and overexpression of miRNAs influenced the expression of 
the same proteins, the authors knocked down let-7b. The protein changes 
in cells that overexpressed let-7b and cells in which it was knocked down 
were negatively correlated. However, the effect of knockdown was only 
about one-third as great as that of overexpression. Therefore, miRNA 
overexpression has more of an effect than miRNA antagonism on both 
protein and mRNA expression.
Changes in mRNA expression correlated well with protein changes 
in both studies. Proteomics, like mRNA expression studies,  cannot 
 distinguish between direct and indirect miRNA targets. SILAC 
 experiments are time-consuming, expensive and not accessible to most 
laboratories. Moreover, current methods can resolve only a fraction of the 
proteome at a time. Given these practical challenges, and because mRNA 
and protein  expression changes are highly correlated, microarray analysis 
might be preferred for its simplicity.
Identification of miRISC-associated miRNA targets
The mammalian miRISC contains a mature miRNA and several proteins, 
including an Ago protein and Tnrc6 (refs. 62,63). Several studies have 
identified miRNA targets by their association with miRISC proteins, 
using immunoprecipitation of epitope-tagged miRISC  components27–30 
or native miRISC31, often while manipulating a  specific miRNA to 
 identify its targets27,29,30 (Fig. 1). The Cohen  laboratory used  microarrays 
to identify mRNAs that immunoprecipitated with  hemagglutinin (HA)-
tagged Ago1 in D. melanogaster S2 cells27. The 89 reproducibly isolated 
mRNAs were enriched for 3a UTR seed matches, and some contained 
CDS seed matches. When introduced into the luciferase open  reading 
frame, CDS MREs were moderately active in reporter assays. The 
HA-Ago1 immunoprecipitation was performed in transgenic flies with 
mutant or wild-type miR-1, and 108 transcripts were selectively depleted 
in embryos with mutated miR-1. The 11  transcripts that  contained 
miR-1 heptamer seed matches all had some activity by luciferase assay. 
This study highlighted the potential  utility of  biochemical pulldown 
to identify miRNA targets. However, it  captured only 10% of the 
expected number of miR-1 target genes28. A more  sensitive protocol 
was later developed by optimizing  immunoprecipitation conditions and 
 increasing amplification of the mRNAs that were pulled down28.
Several other studies immunoprecipitated tagged miRISC  components 
to identify targets. The Hannon laboratory identified 294 mRNAs that 
bound specifically to myc-tagged Ago2 in cells that  overexpressed 
miR-124a (ref. 29). Of these mRNAs, 67% contained 3a UTR  heptamer 
miR-124a seed matches. Notably, many mRNAs that were enriched 
in the immunoprecipitation were not  downregulated in the cells that 
 overexpressed miR-124a. However, when their 3a UTRs were tested by 
luciferase assay, 21 out of 30 were  suppressed. A  similar Ago2 pulldown 
to identify miR-124a and miR-1 targets30  isolated 49% of the  putative 
 miR-124a targets identified by the Hannon  laboratory. Many  putative 
targets had seed matches in the CDS, but not the 3a UTR. Expression of 
mRNAs with CDS seed matches decreased after  transfection with miRNA, 
but genes with 3a UTR matches were more strongly  suppressed, consistent 
with  earlier studies27,30. Immunoprecipitation with Tnrc6 has also been 
used to  isolate targets in mammalian cells62 and C. elegans26. Another 
approach to target  identification has been to clone and sequence mRNAs 
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could vary amongst miRNAs. This example of a miRNA that suppresses 
key transcription factors and also directly suppresses their transcriptional 
target genes suggests that some miRNAs function as master regulators by 
downregulating a dense network of genes in the same pathway. Applying 
unbiased systems biology approaches to experimental datasets may help 
to define miRNA function and pinpoint important target genes.
Validation of putative target genes
The identification of putative miRNA targets is only the first step. To 
 validate candidate genes, the effect of manipulating the miRNA (by 
 overexpression, knockdown or genetic ablation) on protein and mRNA 
levels of the candidate gene needs to be assessed. An inverse  relationship 
between the gene product (at least the protein) and the miRNA is expected. 
Direct regulation of gene expression by an miRNA is then tested by reporter 
assays that use expression plasmids  incorporating the entire 3a UTR or 
CDS in cells that have been transfected to  overexpress the miRNA mimic. 
Showing that the entire 3a UTR of a gene is  regulated by a miRNA adds 
confidence that the transcript is recognized in its native context. Further 
confirmation is provided by identifying the MRE. Candidate MREs can be 
identified using seed-based algorithms or algorithms that do not require 
an exact seed match, such as rna22 or PITA13,42. Direct regulation by the 
miRNA is then confirmed by  mutating or deleting binding residues in 
the reporter and testing for restored expression. Most studies test direct 
regulation by miRNA  overexpression using reporters driven by a strong 
promoter. Showing that a gene can be regulated by physiologically relevant 
levels of the miRNA provides additional evidence that regulation of the 
gene by the miRNA is biologically important.
Some genes that have been identified by experimental approaches 
have candidate CDS MREs. As CDS MREs have a weaker effect on gene 
expression than 3a UTR MREs, it is important to determine whether 
these potential CDS MREs are functional. To do this, CDS MREs and 
(potentially) their surrounding sequences should be cloned in-frame 
into the CDS of an appropriate reporter27,71. The presence of rare codons 
upstream of a CDS MRE may slow down translation, permitting  miRNAs 
to bind to CDS MREs and effectively to repress gene expression74. This 
fact needs to be considered in designing CDS MRE reporters.
Concluding remarks
Genome-wide miRNA target identification methods are constantly 
 improving. Ectopic miRNA expression followed by microarray analysis may 
be the simplest way to identify the biological function and candidate targets 
of a miRNA. This approach is supported by proteomics studies, which have 
provided evidence that changes in the expression of mRNA and  proteins 
 correlate well21,22. However, this strategy has limitations. First,  targets that are 
translationally repressed will be missed. Second,  overexpression of a miRNA 
does not distinguish direct from indirect targets and supraphysiological 
overexpression can introduce artifacts. Knockdown of a miRNA may 
therefore be better than overexpression for identifying miRNA targets in 
a physiological context, although it is less sensitive. Biochemical  pulldown 
methods are continuing to improve and will ultimately provide a more 
specific and sensitive method for identifying miRNA targets.
Although the importance of the miRNA seed region in miRNA  target 
recognition is clear, a subset of biologically relevant MREs lack a  canonical 
seed or are located in the CDS. Filtering miRNA  overexpression or 
 pulldown gene lists by requiring an exact 3a UTR seed match will  eliminate 
potentially important target genes from  consideration. Therefore, we 
favor an unbiased selection of candidate targets. Gene ontology and 
 interactome analysis or forward genetics can help to pinpoint biologically 
 interesting targets from the hundreds of genes identified by any method. 
The  identification of biologically important targets will be crucial for 
 understanding miRNA function.
a conserved seed match, even after allowing one GvU wobble. CDS 
sequences were significantly enriched for matches to the central region 
of the miRNA, but not for seed matches. The identified MREs were 
found in more accessible regions (lacking secondary structure).
An improved method for isolating protein-associated RNAs, termed 
PAR-CLIP (photoactivatable-ribonucleoside-enhanced crosslinking 
and immunoprecipitation), has also been used to identify miRNA 
 targets34. Cells are cultured with photoreactive 4-thiouridine, which 
can substitute for uridine during transcription, before cross-linking 
and  immunoprecipitation. Protein-bound miRNAs and mRNAs are 
then analyzed by high-throughput sequencing. The incorporation 
of 4- thiouridine substantially improves RNA yields. Because reverse 
 transcription of 4-thiouridine leads to T-C transitions, the  MRE-miRISC 
interaction site can be accurately mapped. PAR-CLIP of Flag- or 
HA-tagged AGO1–4 identified almost 20,000 enriched sequences. Nine 
out of ten of the most enriched heptamers matched the seed sequence 
of highly expressed miRNAs. Fifty percent of the crosslinked candidate 
MREs mapped to the CDS, whereas 46% matched a 3a UTR. Target site 
identification was tested by antisense inhibition of the 25 most highly 
expressed miRNAs followed by expression profiling. Targets with 
seed matches were more frequently upregulated than targets without 
seed matches. Similarly, mRNAs that were sequenced exclusively in 
the 3a UTR were more frequently upregulated after the miRNA was 
 antagonized than those with CDS-only sequence clusters.
Although these methods provide an elegant way to identify miRNA 
targets, they involve a technically challenging, multistep protocol. The 
challenges of the procedure need to be weighed against the benefit of 
genome-wide direct identification of miRNA target sites.
Gene network analysis of miRNA targets
Given the potential of a miRNA to regulate a large number of genes, 
it can be challenging to identify key miRNA targets and functions 
from the long lists of putative target genes generated by the methods 
described above. Gene ontology and interactome analysis can be used to 
probe the features of lists of candidate genes17 (Fig. 1). We applied this 
approach to investigating the biological function of miR-24, a miRNA 
that is  consistently upregulated during cellular differentiation72,73. 
Candidate miR-24 targets were identified by their downregulation after 
 overexpression of miR-24. We found that 248 mRNAs had significantly 
reduced expression, of which 40% were predicted by TargetScan and 
51% had a 3a UTR miR-24 hexamer seed, suggesting that a significant 
proportion of the downregulated mRNAs were direct targets of miR-24. 
The cellular pathways that were enriched in the downregulated genes 
suggested that miR-24 regulates cell cycle progression and DNA repair. 
Consistent with this hypothesis, overexpression of miR-24 inhibits 
 cellular proliferation and sensitizes cells to DNA damage17,72.
We used the Ingenuity Pathways software to examine the interactome 
formed by the  downregulated genes. The network of genes that were 
 downregulated by miR-24 was enriched for proteins that have key roles 
in cell cycle  progression. E2F2 and MYC formed highly connected nodes 
of this interactome, and the effects of miR-24 on cell cycle progression 
could be reproduced by manipulating E2F2 (a direct target that was not 
 predicted by any algorithm and that lacks a 3a UTR miR-24 seed match). We 
 suggested, on the basis of these results, that the genes at nodes of a miRNA 
target interactome might be biologically important targets. This idea 
needs to be tested in other experimental systems. Many of the genes in the 
 interactome that are downregulated by miR-24 are key elements of cell cycle 
regulation, including genes that are  transcriptionally regulated by E2F2 
and MYC. These were also validated as direct targets. Most of those also 
lacked a seed match, which is consistent with the Ago HITS-CLIP  findings 
noted above. The importance of seed pairing for target mRNA selection 
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